Appendix S1

Results of searches on clinicaltrials.gov – 17 September 2021

All results from clinicaltrials.gov were completely assessed for eligibility after removal of duplicates.

Other terms	**Condition/disease**
Vismodegib	basal cell nevus syndrome → 7 results
Vismodegib	multiple basal cell carcinomas → 7 results, 7 duplicates
Vismodegib	basal cell carcinoma → 28 results, 6 duplicates
GDC-0449	basal cell nevus syndrome → 6 results, 6 duplicates
GDC-0449	multiple basal cell carcinomas → 6 results, 6 duplicates
GDC-0449	basal cell carcinoma → 23 results, 23 duplicates

n = 29 unique results, n=2 inclusions

Study	**Inclusion or exclusion**	**Reason**
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome	Exclusion	- Study was withdrawn - Combination therapy
Trial Comparing the Effects of Intermittent Vismodegib vs. PDT in Patients With Multiple Basal Cell Carcinomas	Exclusion	- Completion in 2015 but no available results
To Determine The Efficacy and Safety of GDC-0449 in Patients With Basal Cell Nevus Syndrome (BCNS)	Inclusion	Randomized controlled trial comparing vismodegib 150mg daily to placebo in patients with BCNS
Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas	Exclusion	- Completion in 2017 but no results available - Combination therapy
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas	Inclusion	Randomized controlled trial comparing two vismodegib dosing regimens in patients with BCNS or multiple BCCs.
Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor	Exclusion	- Still recruiting - Combination therapy
Levocarnitine in Treating Patients With **Vismodegib-**Associated Muscle Spasms	Exclusion	- Completion in 2017 but no results available - Does not provide answers to our research questions
Vismodegib for Treatment of **Basal Cell Carcinoma**	Exclusion	- Completion in 2013, only 3 patients enrolled, no results - Vismodegib as neoadjuvant therapy
Neoadjuvant **Vismodegib** in Patients With Large and/or Recurrent Resectable **Basal Cell Carcinoma**	Exclusion	- Study status unknown - Vismodegib as neoadjuvant therapy

Study Evaluating the Interest of **Vismodegib** as Neo-adjuvant Treatment of **Basal Cell Carcinoma** (BCC)	Exclusion	- Vismodegib as neoadjuvant therapy *results available
A Study Evaluating the Efficacy and Safety of **Vismodegib** (**GDC-0449**, Hedgehog Pathway Inhibitor) in Patients With Advanced **Basal Cell Carcinoma**	Exclusion	- Outcomes focused on response of advanced basal cell carcinoma *Results available, ERIVANCE trial
A Study Evaluating the Efficacy and Safety of **Vismodegib** (**GDC-0449**) in Operable **Basal Cell Carcinoma**	Exclusion	- Outcomes focused on efficacy of vismodegib on one, new, operable, nodular BCC - BCNS patients were excluded *Results available
A Study to Assess the Effectiveness and Safety of **Vismodegib** (**Erivedge®**) in Participants With Advanced **Basal Cell Carcinoma** (BCC)	Exclusion	- Completed in 2020, no results - Outcomes focused on response of advanced basal cell carcinoma but did include BCNS patients
A Study of **Vismodegib** With Surgery in Participants With Previously Untreated **Basal Cell Carcinoma**	Exclusion	- Outcomes focused on change in BCC and surgical defect area at Mohs micrographic surgery after treatment of one BCC *Results available
Vismodegib on Locally Advanced **Basal Cell Carcinoma** Under Real World Conditions	Exclusion	- Study focuses on prospective data of vismodegib for laBCC (inappropriate for surgery or radiotherapy) in Germany *Results available
STEVIE: A Study of **Vismodegib** in Patients With Locally Advanced or Metastatic **Basal Cell Carcinoma**	Exclusion	- Study focuses on outcomes laBCC and mBCC. *Results available, STEVIE trial
Vismodegib in **Basal Cell Carcinomas** (BCC) Chemoprevention	Exclusion	- Study focuses on vismodegib as chemoprevention for development of new BCCs in high risk subjects - Study was terminated due to low enrolment
Pembrolizumab With or Without **Vismodegib** in Treating Metastatic or Unresectable **Basal Cell Skin Cancer**	Exclusion	- Combination therapy for aBCC - Compared pembrolizumab to pembrolizumab+vismodegib *Results available
Vismodegib in Treating Patients With **Basal Cell Carcinoma** (BCC)	Exclusion	- Outcomes focused on change in BCC and surgical defect area at Mohs micrographic surgery after treatment of one BCC *Results available
Study Evaluating the Efficacy of Oral **Vismodegib** in Various Histologic Subtypes	Exclusion	- Included maximum of 4 BCCs per patient - Outcomes focuses on efficacy of different histological

		subtypes *Results available
Relationship Between Pharmacokinetics and Safety of **Vismodegib** - OPTIVISMO-1	Exclusion	- Still recruiting - Outcomes focuses on relationship between plasma concentration of vismodegib and occurrence of adverse effects
Phase II Study of Radiation Therapy and **Vismodegib** for Advanced Head/Neck **Basal Cell Carcinoma**	Exclusion	- Combination therapy for laBCC of the head and neck, BCNS patients are excluded *Results available
To Assess The Efficacy And Safety Of **Vismodegib** And Radiotherapy In Advanced **Basal Cell Carcinoma**	Exclusion	- Terminated due to low recruitment rate - Combination therapy for patients with high risk of relapse BCC in technically difficult areas for surgery, BCNS patients are excluded
VISmodegib for ORbital and Periocular **Basal Cell Carcinoma**	Exclusion	- Outcome focuses on efficacy of one orbital/periocular aBCC after vismodegib and with or without surgery *results available
Observational Study to Determine the Effectiveness and Safety of **Vismodegib** (**Erivedge®**) in Participants With Locally Advanced **Basal Cell Carcinoma** (laBCC	Exclusion	- No results available *Study focuses on prospective data of vismodegib for laBCC (inappropriate for surgery or radiotherapy) in Germany
Observational Study of **Vismodegib** (**Erivedge**) in Patients Treated in Argentina	Exclusion	- Study focuses on prospective data of vismodegib for aBCC (inappropriate for surgery or radiotherapy) in Argentina *Results available
A Study of **Vismodegib** (**GDC-0449**) in Patients Treated With **Vismodegib** in a Previous Genentech-sponsored Phase I or II Cancer Study	Exclusion	- Outcomes focuses on adverse events in patients treated with vismodegib regardless for what tumour *Results available
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ **Basal Cell Carcinomas**	Exclusion	- Outcomes focuses on tumor biomarkers in patients with one BCC >4mm diameter that would get surgically removed
A Study of Hedgehog Pathway Inhibitor **GDC-0449** in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists	Exclusion	- Outcomes focuses on plasma concentrations of vismodegib in patients treated with vismodegib regardless for what tumour *Results available

BCNS = basal cell nevus syndrome BCC = basal cell carcinoma laBCC = locally advanced basal cell carcinoma aBCC = advanced basal cell carcinoma

Other terms	Condition/disease
Sonidegib	basal cell nevus syndrome → 4 results
Sonidegib	multiple basal cell carcinomas → 6 results, 4 duplicates
Sonidegib	basal cell carcinoma → 14 results, 7 duplicates
LDE225	basal cell nevus syndrome → 4 results, 4 duplicates
LDE225	multiple basal cell carcinomas → 6 results, 6 duplicates
LDE225	basal cell carcinoma → 14 results, 14 duplicates

n=13 unique results, n=2 inclusions

Study	Inclusion or exclusion	Reason
A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of **LDE225** on Skin **Basal Cell** Carcinomas in **Gorlin Syndrome** Patients	Inclusion	Randomized vehicle-controlled trial to evaluate safety, tolerability, pharmacokinetics- and dynamics of topical LDE225 in patients with multiple BCCs and BCNS
Efficacy, Safety and Pharmacokinetics of Oral **LDE225** in Treatment of Patients With Nevoid **Basal Cell Carcinoma Syndrome** (NBCCS)	Inclusion	Randomized proof-of-concept dose-ranging trial to evaluate efficacy, safety and pharmacokinetics of oral LDE225 in patients with BCNS and multiple basal cell carcinomas.
Efficacy, Safety and Tolerability of Topically Applied **LDE225** Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid **Basal Cell Carcinoma Syndrome** (NBCCS)	Exclusion	- Withdrawn before participants were enrolled - Randomized vehicle-controlled trial of topical LDE225 in patients with multiple BCCs and BCNS
Pilot Study of **Sonidegib** and Buparlisib in Treating Patients With Advanced or Metastatic **Basal Cell** Carcinoma	Exclusion	- Combination therapy for patients with laBCC or mBCC - Terminated (business decision) with 10 enrollments *Results available
To Evaluate the Safety, Local Tolerability, PK and PD of **LDE225** on Sporadic Superficial and Nodular Skin **Basal Cell Carcinomas** (sBCC)	Exclusion	- Randomized vehicle-controlled trial of topical LDE225 in one sporadic superficial or nodular BCC - Terminated due to insufficient efficacy in superficial BCC with the formulation and treatment conditions, results available
Post-authorization Safety Study on the Long Term Safety of **Sonidegib** in Patients With Locally Advanced **Cell Carcinoma**	Exclusion	- Still recruiting - Observational study to assess safety of sonidegib for laBCC
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic **Basal Cell Carcinoma**	Exclusion	- Results focuses on outcomes for laBCC and mBCC patients *Results available, BOLT study

Pilot **LDE225** in Locally Advanced or Metastatic BCC + Previously Tx Non-LDE225 Smoothened Inhibitors	Exclusion	- Results focuses on outcomes for laBCC and mBCC patients *Results available
Tailored **Sonidegib** Schedule After Complete Response in BCC	Exclusion	- Still recruiting - Open-label Study Improving Compliance and Time of Treatment After Obtaining Complete Response Through a Tailored Schedule of Sonidegib in Locally Advanced Basal Cell Carcinomas
A Study to Evaluate Neoadjuvant **Sonidegib** Followed by Surgery or Imiquimod in the Management of **Basal Cell Carcinoma**	Exclusion	- Still recruiting - Sonidegib as neodjuvant therapy followed by surgery or imiquimod in aBCC
Anti-PD1-antibody and Pulsed HHI for Advanced BCC	Exclusion	- Still recruiting - Prospective single-arm trial with anti-PD1 antibody and pulsed hedgehog pathway inhibitor therapy in aBCC
An East Asian Study of **LDE225**	Exclusion	- Open-label dose-ecalation study of sonidegib in advanced solid tumors *Results available
Dose Finding and Safety of Oral **LDE225** in Patients With Advanced Solid Tumors	Exclusion	- Open-label dose-ecalation study of sonidegib in advanced solid tumors - Completion in 2013, no results available

BCNS = basal cell nevus syndrome BCC = basal cell carcinoma laBCC = locally advanced basal cell carcinoma aBCC = advanced basal cell carcinoma mBCC = metastatic basal cell carcinoma

Other terms	Condition/disease
Saridegib	basal cell nevus syndrome → 5 results
Saridegib	multiple basal cell carcinomas → 5 results, 5 duplicates
Saridegib	basal cell carcinoma → 6 results, 5 duplicates
Patidegib	basal cell nevus syndrome → 5 results, 5 duplicates
Patidegib	multiple basal cell carcinomas → 5 results, 5 duplicates
Patidegib	basal cell carcinoma → 6 results, 6 duplicates
IPI-926	basal cell nevus syndrome → 5 results, 5 duplicates
IPI-926	multiple basal cell carcinomas → 5 results, 5 duplicates
IPI-926	basal cell carcinoma → 6 results, 6 duplicates

n=6 unique results, n= 1 inclusions

Study	Inclusion or exclusion	Reason
Extension Study of **Patidegib** Topical Gel, 2% in Subjects With **Gorlin Syndrome** (**Basal Cell Nevus Syndrome**)	Exclusion	- Terminated due to low blinded event rate and not related to safety of the drug - No results available
Study of **Patidegib** Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing **Basal Cell** Carcinomas (BCCs) in Subjects With **Basal Cell Nevus Syndrome** (**Gorlin Syndrome**)	Exclusion	- Completion in 2020, results not available - Randomized vehicle-controlled trial of patidegib topical gel for multiple BCC in BCNS patients
Trial of **Patidegib** Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible **Basal Cell** Carcinomas in **Gorlin Syndrome** Patients	Inclusion	Randomized vehicle-controlled trial that evaluates efficacy and safety of patidegib 2% and 4% for multiple BCC in BCNS patients
Clinical Trial of **Patidegib** Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular **Basal Cell** Carcinomas	Exclusion	- Outcomes focuses on a maximum of one or two nodular BCCs in patients without BCNS
An Study of **Patidegib** Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing **Basal Cell** Carcinomas in Patients With Non-Gorlin High Frequency BCC	Exclusion	- Terminated due to low blinded event rate - No results available
IPI-926 Extension Protocol for Continuation of Treatment With **IPI-926**	Exclusion	- Oral IPI-926 extension study for patients experiencing clinical benefit from oral IPI-926 for chondrosarcoma or basal cell carcinoma - No results available

Other terms	Condition/disease
Itraconazole	basal cell nevus syndrome → 1 result
Itraconazole	multiple basal cell carcinomas → 1 results, 1 duplicate
Itraconazole	basal cell carcinoma → 6 results, 2 duplicates

n=5 unique results, n= 1 inclusions

Study	Inclusion or exclusion	Reason
Open-label Trial of SUBA™-**Itraconazole** (SUBA-Cap) in Subjects With **Basal Cell** Carcinoma **Nevus Syndrome** (BCCNS)	Exclusion	- Results submitted in 2020 but not posted on clinical trials, pending after review - Open-label study evaluating oral SUBA-cap in patients with at least one BCC and BCNS
Topical **Itraconazole** in the Treatment of **Basal Cell Carcinoma**	Exclusion	- Completion 2019, no results available - Studies molecular effects of topical itraconazole on growth of BCCs
Topical **Itraconazole** in Treating Patients With **Basal Cell Cancer**	Inclusion	Randomized vehicle-controlled trial on topical itraconazole in patients with at least 4 BCCs
Arsenic Trioxide and **Itraconazole** in Treating Patients With Advanced **Basal Cell Cancer**	Exclusion	- Withdrawn due to logistics, no results available - Combination therapy for aBCC
Use Of Oral **Itraconazole** In Patients With Locally Limited Basocellular **Carcinoma** Of Skin.	Exclusion	- Study status unknown - Open label trial on oral itraconazole prior to curative surgery for at least one localized BCC <10mm

Other terms	Condition/disease
BMS-833923	basal cell nevus syndrome → 1 result
BMS-833923	multiple basal cell carcinomas → 2 results, 1 duplicate
BMS-833923	basal cell carcinoma → 1 result, 1 duplicate

n=2 unique results, n= 0 inclusions

Study	Inclusion or exclusion	Reason
Study of **BMS-833923** in Two Specific Patients With **Basal Cell Nevus Syndrome**	Exclusion	- Completion 2017, no results available - Two patients with BCNS who continue to receive BMS-833923 because of clinical benefit
A Phase 1 Study of **BMS-833923** (**XL139**) in Subjects With Advanced or Metastatic Cancer	Exclusion	- Completion 2014, no results available - Outcomes focuses on patients with advanced or metastatic solid tumours

Other terms	Condition/disease
LEQ506	basal cell nevus syndrome → 0 result
LEQ506	multiple basal cell carcinomas → 1 result
LEQ506	basal cell carcinoma → 1 result, 1 duplicate

n=1 unique result, n= 0 inclusions

Study	Inclusion or exclusion	Reason
A Dose Finding and Safety Study of Oral **LEQ506** in Patients With Advanced Solid Tumors	Exclusion	- Completion 2015, no results available - Outcomes focuses on patients with advanced or metastatic solid tumours

Other terms	Condition/disease
TAK-441	basal cell nevus syndrome → 0 result
TAK-441	multiple basal cell carcinomas → 0 result
TAK-441	basal cell carcinoma → 1 result

n=1 unique result, n= 0 inclusions

Study	Inclusion or exclusion	Reason
A Study of **TAK-441** in Adult Patients With Advanced Nonhematologic Malignancies	Exclusion	- Completion 2012, no results available - Outcomes focuses on patients with advanced or metastatic solid tumours

Results of searches on PubMed – 17 September 2021

("HhAntag691" [Supplementary Concept]) AND "Carcinoma, Basal Cell"[Mesh] → 312 results

N=11 duplicates, N=301 unique results, n=258 excluded after screening, n=

N= inclusions

1: Stratigos AJ, Sekulic A, Peris K, Bechter O, Prey S, Kaatz M, Lewis KD, Basset-Seguin N, Chang ALS, Dalle S, Orland AF, Licitra L, Robert C, Ulrich C, Hauschild A, Migden MR, Dummer R, Li S, Yoo SY, Mohan K, Coates E, Jankovic V, Fiaschi N, Okoye E, Bassukas ID, Loquai C, De Giorgi V, Eroglu Z, Gutzmer R, Ulrich J, Puig S, Seebach F, Thurston G, Weinreich DM, Yancopoulos GD, Lowy I, Bowler T, Fury MG. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):848-857. doi: 10.1016/S1470-2045(21)00126-1. Epub 2021 May 14. PMID: 34000246.

- → Excluded after screening, research concerns cemiplimab (anti-PD1) treatment instead of hedgehog pathway inhibitor treatment

2: Kahana A, Unsworth SP, Andrews CA, Chan MP, Bresler SC, Bichakjian CK, Durham AB, Demirci H, Elner VM, Nelson CC, Kim DS, Joseph SS, Swiecicki PL, Worden FP. Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial. Oncologist. 2021 Jul;26(7):e1240-e1249. doi: 10.1002/onco.13820. Epub 2021 May 31. PMID: 33988881; PMCID: PMC8265335.

- → Duplicate (clinicaltrials.gov)

3: Angnardo L, Humeda Y, Alexandraki I, Wolfe CM, Cognetta AB Jr. Vismodegib as Eye-Sparing Neoadjuvant Treatment for Locally Advanced Periocular Basal Cell Carcinoma. J Drugs Dermatol. 2021 May 1;20(5):552-554. doi: 10.36849/JDD.5661. PMID: 33938701.

- → Excluded after screening, article concerns vismodegib as neoadjuvant treatment

4: Gutzmer R, Schulze HJ, Hauschild A, Leiter U, Meier F, Haferkamp S, Ulrich C, Wahl RU, Berking C, Herbst R, Häckl M, Schadendorf D. Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-

world conditions in Germany - The non-interventional study NIELS. J Eur Acad Dermatol Venereol. 2021 Aug;35(8):1678-1685. doi: 10.1111/jdv.17332. Epub 2021 May 27. PMID: 33931910.

➔ Duplicate (clinicaltrials.gov)

5: Migden M, Farberg AS, Dummer R, Squittieri N, Hanke CW. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma. J Drugs Dermatol. 2021 Feb 1;20(2):156-165. doi: 10.36849/JDD.5657. PMID: 33538567.

➔ Excluded after screening, review

6: Passarelli A, Galdo G, Aieta M, Fabrizio T, Villonio A, Conca R. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature. Int J Mol Sci. 2020 Nov 14;21(22):8596. doi: 10.3390/ijms21228596. PMID: 33202689; PMCID: PMC7696523.

➔ Excluded after eligibility assessment, 2 case reports concerned treatment of laBCC

7: Mansour KP, O'Duffy F, Webb A, Goh M, Morrison E. About face: can Vismodegib change the treatment paradigm of locally advanced basal cell carcinoma? ANZ J Surg. 2021 Jun;91(6):1304-1306. doi: 10.1111/ans.16399. Epub 2020 Oct 22. PMID: 33091207.

➔ Excluded after screening, article concerns treatment of laBCC

8: Villani A, Cinelli E, Fabbrocini G, Lallas A, Scalvenzi M. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits. Expert Opin Drug Saf. 2020 Dec;19(12):1585-1594. doi: 10.1080/14740338.2020.1837773. Epub 2020 Oct 22. PMID: 33054455.

➔ Excluded after screening, opinion

9: Nasifoglu S, Srour J, Lill D, Seegräber M, Sattler E, Schlaak M. Vismodegib-Therapie bei großem Basalzellkarzinom des Mittelgesichts mit Orbitabeteiligung [Vismodegib therapy for a large basal cell carcinoma on the midface with orbital involvement]. Hautarzt. 2020 Jul;71(Suppl 1):57-59. German. doi: 10.1007/s00105-020-04626-y. PMID: 32974719.

➔ Excluded after screening, article concerns treatment of laBCC

10: Campione E, Di Prete M, Lozzi F, Lanna C, Spallone G, Mazzeo M, Cosio T, Rapanotti C, Dika E, Gaziano R, Orlandi A, Bianchi L. High-Risk Recurrence Basal Cell Carcinoma: Focus on Hedgehog Pathway Inhibitors and Review of the Literature. Chemotherapy. 2020;65(1-2):2-10. doi: 10.1159/000509156. Epub 2020 Aug 10. PMID: 32777789.

➔ Excluded after screening, review

11: Dika E, Scarfì F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, Campione E, Riefolo M, Ricci C, Lambertini M. Basal Cell Carcinoma: A Comprehensive Review. Int J Mol Sci. 2020 Aug 4;21(15):5572. doi: 10.3390/ijms21155572. PMID: 32759706; PMCID: PMC7432343.

➔ Excluded after screening, review

12: Susanto E, Marin Navarro A, Zhou L, Sundström A, van Bree N, Stantic M, Moslem M, Tailor J, Rietdijk J, Zubillaga V, Hübner JM, Weishaupt H, Wolfsberger J, Alafuzoff I, Nordgren A, Magnaldo T, Siesjö P, Johnsen JI, Kool M, Tammimies K, Darabi A, Swartling FJ, Falk A, Wilhelm M. Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells. Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):20127-20138. doi: 10.1073/pnas.1920521117. Epub 2020 Aug 3. PMID: 32747535; PMCID: PMC7443968.

➔ Excluded after screening, research on cell models

13: Di Raimondo C, Mazzeo M, Di Prete M, Lombardo P, Silvaggio D, Del Duca E, Bianchi L, Spallone G. Efficacy of Vismodegib in pigmented basal cell carcinoma: Appearances are deceiving. Dermatol Ther. 2020 Nov;33(6):e14057. doi: 10.1111/dth.14057. Epub 2020 Aug 18. PMID: 32713089.

→ Excluded after eligibility assessment

14: Wang H, Meng Q, Ding Y, Xiong M, Zhu M, Yang Y, Su H, Gu L, Xu Y, Shi L, Zhou H, Zhang N. USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines. FEBS J. 2021 Feb;288(4):1325-1342. doi:

10.1111/febs.15461. Epub 2020 Jul 20. PMID: 32578360.

➔ Excluded after screening, research on cell models

15: Villani A, Costa C, Fabbrocini G, Scalvenzi M. Drug holiday regimen for vismodegib treatment in patients with multiple primary basal cell carcinomas. Dermatol Ther. 2020 Jul;33(4):e13707. doi: 10.1111/dth.13707. Epub 2020 Jun 19. PMID: 32472574.

→ Included after eligibility assessment

16: Villani A, Cappello M, Costa C, Fabbrocini G, Scalvenzi M. Advanced basal cell carcinoma treated with vismodegib: impact on the lives of patients and their families. Clin Exp Dermatol. 2020 Dec;45(8):1044-1046. doi: 10.1111/ced.14287. Epub 2020 Aug 26. PMID: 32415864.

➔ Excluded after screening, article concerns treatment of laBCC

17: Ben Ishai M, Tiosano A, Fenig E, Ben Simon G, Yassur I. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial. JAMA Ophthalmol. 2020 Jul 1;138(7):749-755. doi: 10.1001/jamaophthalmol.2020.1539. PMID: 32407451; PMCID: PMC7226292.

➔ Excluded after screening, article concerns treatment of laBCC

18: Cengiz FP, Kelahmetoglu O, Yildiz P, Yenigun A, Emiroglu N, Akarslan TC, Shbair A, Seker M, Tekce E, Onsun N. A case of multiple familial trichoepitelioma with malignant transformation successfully treated with Vismodegib. Dermatol Ther. 2020 Jul;33(4):e13569. doi: 10.1111/dth.13569. Epub 2020 May 22. PMID: 32401420.

➔ Excluded after screening, article concerns treatment of trichoepithelioma

19: Valenzuela-Oñate CA, Magdaleno-Tapial J, Garcia-Legaz Martínez M, Perez-Pastor G, Sanchez Carazo JL. Drug holiday approach for Vismodegib treatment in patients with nevoid basal cell carcinoma syndrome: Three cases from real clinical practice. Dermatol Ther. 2020 Jul;33(4):e13540. doi: 10.1111/dth.13540. Epub 2020 May 27. PMID: 32385947.

➔ Included after elgibility assessment

20: Russo F, Provvidenziale L, Mancini V, Lazzeri L, Flori ML, Taddeucci P, Rubegni P. Amenorrhea secondary to vismodegib: An adverse event to consider especially in female patients with Gorlin-Goltz syndrome. Dermatol Ther. 2020 Jul;33(4):e13527. doi: 10.1111/dth.13527. Epub 2020 May 26. PMID: 32383228.

➔ Excluded after elgibility assessment, does not report on reoccurence/resistance/dosing regiment/QoL

21: Villani A, Costa C, Fabbrocini G, Cappello M, Scalvenzi M. Reply to: "Comparison of daily dosing vs. Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma (laBCC) and basal cell nevus syndrome: A retrospective case series". J Am Acad Dermatol. 2020 Sep;83(3):e201-e202. doi: 10.1016/j.jaad.2020.03.124. Epub 2020 May 4. PMID: 32376431.

➔ Excluded after elgibility assessment, does not discuss outcomes in multiple BCC patients

22: Bossi P, Peris K, Calzavara-Pinton P, Queirolo P, Alfieri S, Palla M, Rossi MT, Spagnolo F, Tambone S, Astolfi C, Ascierto PA. Cohort analysis of safety and efficacy of vismodegib in Italian patients from the Phase II, multicenter STEVIE study. Future Oncol. 2020 Jun;16(16):1091-1100. doi: 10.2217/fon-2019-0664. Epub 2020 May 6. PMID: 32374193.

➔ Excluded after eligibility assessment, only discusses vismodegib for la & mBCC

23: Ren J, Ma X, Tu C, Li Z. Lentivirus-mediated CD44s expression increases human basal cell carcinoma cell resistance against vismodegib. Oncol Rep. 2020 May;43(5):1650-1658. doi: 10.3892/or.2020.7534. Epub 2020 Mar 6. PMID: 32323842.

➔ Excluded after screening, , research on cell models

24: Schadendorf D, Hauschild A, Fosko S, Zloty D, Labeille B, Grob JJ, Puig S, Makrutzki M, Gilberg F, Hong A, Dréno B, Rogers G, Kunstfeld R. Quality-of-life analysis with intermittent vismodegib regimens in patients with multiple basal cell carcinomas: patient-reported outcomes from the MIKIE study. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e526-e529. doi: 10.1111/jdv.16446. Epub 2020

May 19. PMID: 32277508.

- ➔ **Included after eligibility assessment, research on quality of life during a randomized controlled trial of two vismodegib regimens in patients with multiple BCC or BCNS.**

25: Villani A, Fabbrocini G, Costa C, Scalvenzi M. Patients with advanced basal cell carcinomas in treatment with sonic hedgehog inhibitors during the coronavirus disease 2019 (COVID-19) period: Management and adherence to treatment. J Am Acad Dermatol. 2020 Jun;82(6):e205. doi: 10.1016/j.jaad.2020.03.057. Epub 2020 Mar 31. PMID: 32244017; PMCID: PMC7270927.

- ➔ Excluded after screening, article concerns treatment of laBCC

26: Sun Q, Atzmony L, Zaki T, Peng A, Sugarman J, Choate KA. Clues to primary vismodegib resistance lie in histology and genetics. J Clin Pathol. 2020 Oct;73(10):678-680. doi: 10.1136/jclinpath-2020-206448. Epub 2020 Mar 26. PMID: 32217615; PMCID: PMC7513245.

- ➔ Excluded after screening, article concerns treatment of laBCC

27: Glen P, Farrugia D, Farrier J. Complete remission of advanced, locally invasive basal cell carcinoma with vismodegib. Int J Oral Maxillofac Surg. 2020 Sep;49(9):1149-1152. doi: 10.1016/j.ijom.2020.03.006. Epub 2020 Mar 20. PMID: 32204965.

- ➔ Excluded after screening, article concerns treatment of laBCC

28: Wong C, Poblete-Lopez C, Vidimos A. Comparison of daily dosing versus Monday through Friday dosing of vismodegib for locally advanced basal cell carcinoma and basal cell nevus syndrome: A retrospective case series. J Am Acad Dermatol. 2020 Jun;82(6):1539-1542. doi: 10.1016/j.jaad.2020.02.050. Epub 2020 Feb 21. PMID: 32092372.

- ➔ Excluded after eligibility assessment

29: Cozzani R, Del Aguila R, Carrizo M, Sanchez S, Gonzalez A; ML29740 Investigators. Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina. Int J

Dermatol. 2020 May;59(5):627-632. doi: 10.1111/ijd.14780. Epub 2020 Feb 7. PMID: 32034775.

➔ Excluded after screening, article concerns treatment of laBCC

30: Oliphant H, Laybourne J, Chan K, Haridas A, Edmunds MR, Morris D, Clarke L, Althaus M, Norris P, Cranstoun M, Sullivan TJ, Rajak SN. Vismodegib for periocular basal cell carcinoma: an international multicentre case series. Eye (Lond). 2020 Nov;34(11):2076-2081. doi: 10.1038/s41433-020-0778-3. Epub 2020 Jan 29. PMID: 31996838; PMCID: PMC7784971.

➔ Excluded after screening, article concerns treatment of laBCC

31: Dummer R, Ascierto PA, Basset-Seguin N, Dréno B, Garbe C, Gutzmer R, Hauschild A, Krattinger R, Lear JT, Malvehy J, Schadendorf D, Grob JJ. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venereol. 2020 Sep;34(9):1944-1956. doi: 10.1111/jdv.16230. Epub 2020 Mar 4. PMID: 31990414.

➔ Excluded after screening, expert opinion

32: Sternfeld A, Rosenwasser-Weiss S, Ben-Yehuda G, Shefer HK, Friedman-Gohas M, Yassur I, Tauber G, Bejar J, Olshinka A, Vardizer Y, Ad El D, Goldenberg-Cohen N. Gene-Related Response of Basal Cell Carcinoma to Biologic Treatment with Vismodegib. Sci Rep. 2020 Jan 27;10(1):1244. doi: 10.1038/s41598-020-58117-0. PMID: 31988301; PMCID: PMC6985141.

➔ Excluded after screening, research to gene-related response in laBCC

33: Unsworth SP, Heisel CJ, Kahana A. A New Paradigm in the Treatment of Advanced Periocular Basal Cell Carcinoma? Am J Ophthalmol. 2019 Oct;206:215-216. doi: 10.1016/j.ajo.2019.06.027. Epub 2019 Aug 14. PMID: 31957698.

➔ Excluded after screening, editorial

34: Liao S, Floyd C, Verratti N, Leung L, Wu C. Analysis of vismodegib resistance in D473G and W535L mutants of SMO receptor and design of novel drug derivatives using molecular dynamics simulations. Life Sci. 2020 Mar

1;244:117302. doi: 10.1016/j.lfs.2020.117302. Epub 2020 Jan 14. PMID: 31953165.

➔ Excluded after screening, molecular study

35: Hussain A, Tucker N, DeAngelis DD, Yin VT, Ing E, Arthurs B, Gill HS, Hardy I, Hurwitz J, Kratky V, Maleki B, Nijhawan N, Oestreicher J, Zafar A. Guidelines for vismodegib in the management of periocular basal cell carcinoma. Can J Ophthalmol. 2020 Jun;55(3):245-252. doi: 10.1016/j.jcjo.2019.11.004. Epub 2020 Jan 1. PMID: 31901307.

➔ Excluded after screening, guidelines

36: F AG, Sayed OM, Abo El-Ela FI, Kharshoum RM, Salem HF. Treatment of Basal Cell Carcinoma Via Binary Ethosomes of Vismodegib: In Vitro and In Vivo Studies. AAPS PharmSciTech. 2020 Jan 3;21(2):51. doi: 10.1208/s12249-019-1574-x. PMID: 31900659.

➔ Excluded after screening, in vitro studies

37: Fosko SW, Chu MB, Armbrecht E, Galperin T, Potts GA, Mattox A, Kurta A, Polito K, Slutsky JB, Burkemper NM, Hurley MY. Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial. J Am Acad Dermatol. 2020 Apr;82(4):946-954. doi: 10.1016/j.jaad.2019.12.002. Epub 2019 Dec 10. PMID: 31836564.

➔ Duplicate (clinicaltrials)

38: Ikehara H, Fujii K, Miyashita T, Ikemoto Y, Nagamine M, Shimojo N, Umezawa A. Establishment of a Gorlin syndrome model from induced neural progenitor cells exhibiting constitutive GLI1 expression and high sensitivity to inhibition by smoothened (SMO). Lab Invest. 2020 Apr;100(4):657-664. doi: 10.1038/s41374-019-0346-2. Epub 2019 Nov 22. PMID: 31758086.

➔ Excluded after screening, cell study

39: Gibson M, Murrell DF. Drug-related adverse effects of vismodegib and

sonidegib for locally advanced or metastatic basal cell carcinoma. Australas J Dermatol. 2020 May;61(2):176-177. doi: 10.1111/ajd.13205. Epub 2019 Nov 20. PMID: 31747714.

➔ Excluded after screening, research on advanced BCC

40: Tognetti L, Cinotti E, Fiorani D, Couzan C, Cavarretta C, Chazelle M, Labeille B, Pianigiani E, Cevenini G, Perrot JL, Rubegni P. Long-term therapy of multiple basal cell carcinomas: Clinicodermoscopic score for monitoring of intermittent vismodegib treatment. Dermatol Ther. 2019 Nov;32(6):e13097. doi: 10.1111/dth.13097. Epub 2019 Oct 17. PMID: 31612619.

→ excluded after eligibility assessment → only dermatoscopy described

41: Herms F, Lambert J, Grob JJ, Haudebourg L, Bagot M, Dalac S, Dutriaux C, Guillot B, Jeudy G, Mateus C, Monestier S, Mortier L, Poulalhon N, Prey S, Robert C, Vabres P, Lebbe C, Meyer N, Basset-Seguin N. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients. J Clin Oncol. 2019 Dec 1;37(34):3275-3282. doi: 10.1200/JCO.18.00794. Epub 2019 Oct 14. PMID: 31609670.

➔ Excluded after screening, research on laBCC

42: Spallone G, Sollena P, Ventura A, Fargnoli MC, Gutierrez C, Piccerillo A, Tambone S, Bianchi L, Peris K. Efficacy and safety of Vismodegib treatment in patients with advanced basal cell carcinoma and multiple comorbidities. Dermatol Ther. 2019 Nov;32(6):e13108. doi: 10.1111/dth.13108. Epub 2019 Oct 30. PMID: 31606940.

➔ Excluded after screening, research on aBCC

43: Li R, Lee G, Huang M, El-Sherief A. Rare basal cell metastasis of a basal-squamous skin collision tumour to the lung and axillary lymph node. BMJ Case Rep. 2019 Oct 3;12(10):e231487. doi: 10.1136/bcr-2019-231487. PMID: 31585957; PMCID: PMC6782041.

➔ Excluded after screening, research on mBCC

44: Caplash G, Curragh DS, Halliday L, Huilgol SC, Selva D. Report of cutaneous side effects of vismodegib treatment. Clin Exp Ophthalmol. 2020 Jan;48(1):123-125. doi: 10.1111/ceo.13651. Epub 2019 Oct 20. PMID: 31569297.

➔ Excluded after eligibility assessment, only discusses side effect in 2 patients treated for laBCC

45: Monteiro AF, Rato M, Trigo M, Martins C. Aggressive Inferior Eyelid Basal Cell Carcinoma: Advantage of Neoadjuvant Vismodegib. Actas Dermosifiliogr (Engl Ed). 2019 Dec;110(10):863-865. English, Spanish. doi: 10.1016/j.ad.2018.05.022. Epub 2019 Sep 9. PMID: 31514962.

➔ Excluded after screening, article concerns vismodegib as neoadjuvant treatment

46: Collins A, Savas J, Doerfler L. Nonsurgical Treatments for Nonmelanoma Skin Cancer. Dermatol Clin. 2019 Oct;37(4):435-441. doi: 10.1016/j.det.2019.05.003. Epub 2019 Jul 18. PMID: 31466584.

➔ Excluded after screening, review

47: Bancalari B, Llombart B, Serra-Guillén C, Bernia E, Requena C, Nagore E, Traves V, Calomarde L, Diago A, Guillén C, Sanmartín O. Histologic Changes During Treatment With Vismodegib in Locally Advanced Basal Cell Carcinoma: A Series of 19 Cases. Am J Dermatopathol. 2019 Oct;41(10):711-717. doi: 10.1097/DAD.0000000000001384. PMID: 31436575.

➔ Excluded after screening, research on laBCC

48: Riera-Monroig J, Combalia A, Rodríguez A, Alós L, Mangas C, Ferrando J, Carrera C. Hedgehog-like moustache trichomegaly during treatment with vismodegib. J Eur Acad Dermatol Venereol. 2020 Jan;34(1):e11-e13. doi: 10.1111/jdv.15842. Epub 2019 Sep 4. PMID: 31393645.

➔ Excluded after screening, rare side effect case report

49: Velter C, Blanc J, Robert C. Acute pancreatitis after vismodegib for basal cell carcinoma: a causal relation? Eur J Cancer. 2019 Sep;118:67-69. doi:

10.1016/j.ejca.2019.06.010. Epub 2019 Jul 17. PMID: 31325874.

➔ Excluded after screening, rare side effect case report

50: Routt E, Ratner D. Outcomes for Basal Cell Carcinoma Treated With Vismodegib Extended Alternate Day Dosing. Dermatol Surg. 2020 Aug;46(8):1109-1112. doi: 10.1097/DSS.0000000000001985. PMID: 31274526.

→ Excluded after eligibility assessment, only discusses alternate day dosing in aBCC patients

51: Ighilahriz M, Benfodda M, Sharpe H, Soufir N, Mourah S, Dumaz N, Battistella M, Savina A, Bouquet F, Nikolaev S, Basset-Seguin N. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation. J Eur Acad Dermatol Venereol. 2019 Nov;33(11):e422-e424. doi: 10.1111/jdv.15741. Epub 2019 Jul 15. PMID: 31187903.

➔ Excluded after screening, research on laBCC

52: Scalvenzi M, Villani A, Costa C, Cappello M. Efficacy and safety of vismodegib in patients with basal cell carcinoma: An Italian Center experience. Dermatol Ther. 2019 Jul;32(4):e12971. doi: 10.1111/dth.12971. Epub 2019 Jun 12. PMID: 31124200.

➔ Excluded after eligibility assessment,does not discuss specific results in multiple BCC patients although 8 were included in their centre

53: Rodríguez-Cerdeira C, Muñoz-Garzón V, González-Cespón JL. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach. Drug Discov Ther. 2019;13(2):122-127. doi: 10.5582/ddt.2019.01020. PMID: 31080204.

➔ Excluded after screening, research on laBCC

54: Eiger-Moscovich M, Reich E, Tauber G, Berliner O, Priel A, Ben Simon G, Elkader AA, Yassur I. Efficacy of Vismodegib for the Treatment of Orbital and Advanced Periocular Basal Cell Carcinoma. Am J Ophthalmol. 2019 Nov;207:62-70. doi: 10.1016/j.ajo.2019.04.013. Epub 2019 May 9. PMID: 31077664.

➔ Excluded after screening, research on laBCC

55: Bánvölgyi A, Anker P, Lőrincz K, Kiss N, Márton D, Fésűs L, Gyöngyösi N, Wikonkál N. Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects. J Dermatolog Treat. 2020 Jun;31(4):387-398. doi: 10.1080/09546634.2019.1601155. Epub 2019 May 1. PMID: 31039644.

➔ Included after eligibility assessment

56: Tang JC, Buckel L, Hanke CW. Histopathology of Basal Cell Carcinoma After Treatment With Vismogedib. J Drugs Dermatol. 2019 Feb 1;18(2):136-138. PMID: 30794363.

➔ Excluded after screening, research on histologic changes

57: Lam C, Larson E, Vidimos AT, Billingsley EM. Palliative Use of Vismodegib. Dermatol Surg. 2020 Feb;46(2):272-276. doi: 10.1097/DSS.0000000000001826. PMID: 30789523.

➔ Excluded after screening, vismodegib in palliative setting

58: Gualdi G, Moro R, Regina V, Caravello S, Monari P, Calzavara-Pinton PG. PRISModegib: the use of the PRISM test to assess the health-related quality of life of patients with locally advanced basal cell carcinoma undergoing Hedgehog pathway inhibitor therapy. Br J Dermatol. 2019 Aug;181(2):406-407. doi: 10.1111/bjd.17754. Epub 2019 May 6. PMID: 30737996.

➔ Excluded after screening, quality of life during vismodegib in laBCC

59: Scalvenzi M, Costa C, Cappello M, Villani A. Reply to Woltsche N. et al. Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a single-centre experience. J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e145-e147. doi: 10.1111/jdv.15469. Epub 2019 Mar 20. PMID: 30720897.

➔ Excluded after screening, dose reduction for laBCC

60: Kuonen F, Huskey NE, Shankar G, Jaju P, Whitson RJ, Rieger KE, Atwood SX,

Sarin KY, Oro AE. Loss of Primary Cilia Drives Switching from Hedgehog to Ras/MAPK Pathway in Resistant Basal Cell Carcinoma. J Invest Dermatol. 2019 Jul;139(7):1439-1448. doi: 10.1016/j.jid.2018.11.035. Epub 2019 Jan 29. PMID: 30707899; PMCID: PMC6591089.

➔ Excluded after screening, molecular research

61: Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Yim YM, Dimier N, Fittipaldo A, Basset-Séguin N, Hauschild A. Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study. Eur J Dermatol. 2018 Dec 1;28(6):775-783. doi: 10.1684/ejd.2018.3448. PMID: 30698147.

➔ Excluded after screening, quality of life during vismodegib in laBCC

62: Yan BY, Hibler BP, Menge T, Dunn L, Ho AL, Rossi AM. Sonic Hedgehog pathway inhibitors: from clinical trials to clinical practice. Br J Dermatol. 2019 May;180(5):1260-1261. doi: 10.1111/bjd.17692. Epub 2019 Mar 7. PMID: 30693471; PMCID: PMC6486429.

➔ Excluded after eligibility assessment does not report on reoccurence/resistance/dosing regiment/QoL

63: Dessinioti C, Plaka M, Dimitrakopoulou A, Stratigos AJ. Complete response is reversible upon vismodegib withdrawal and re-inducible upon vismodegib rechallenge in a patient with locally advanced basal cell carcinoma. J Eur Acad Dermatol Venereol. 2019 May;33(5):e187-e188. doi: 10.1111/jdv.15428. Epub 2019 Feb 27. PMID: 30653740.

➔ Excluded after screening, vismodegib rechallende in laBCC

64: Wetzel M, Jung JY, Brown TS. Multiple Lesions in Irradiated Skin. JAMA Oncol. 2019 May 1;5(5):728-729. doi: 10.1001/jamaoncol.2018.5852. PMID: 30653217.

➔ Excluded after screening, clinical photo challenge

65: Soon SL, Ibrahim SF, Arron ST. A randomized phase II study evaluating vismodegib as neoadjuvant treatment of basal cell carcinoma preceding Mohs micrographic surgery: results and lessons learned. Br J Dermatol. 2019 Jul;181(1):208-209. doi: 10.1111/bjd.17623. Epub 2019 Apr 1. PMID: 30628055.

➔ Duplicate (clinicaltrial.gov)

66: Zhai J, Zhang H, Zhang J, Zhang R, Hong Y, Qu J, Chen F, Li T. Effect of the sonic hedgehog inhibitor GDC-0449 on an in vitro isogenic cellular model simulating odontogenic keratocysts. Int J Oral Sci. 2019 Jan 5;11(1):4. doi: 10.1038/s41368-018-0034-x. PMID: 30610186; PMCID: PMC6320367.

➔ Excluded after screening, vismodegib for odontogenic keratocysts

67: López Rojo I, Rivas Fidalgo S, Gómez Valdazo A, Díaz Miguel M. Extensive thoracic skin lesion in a patient with history of breast cancer. Cir Esp (Engl Ed). 2019 Jun-Jul;97(6):346. English, Spanish. doi: 10.1016/j.ciresp.2018.11.007. Epub 2018 Dec 27. PMID: 30595224.

➔ Excluded after screening, clinical photo challenge

68: Mathis J, Doerr T, Lin E, Ibrahim SF. Oral Hedgehog Pathway Inhibition as a Means for Ocular Salvage in Locally Advanced Intraorbital Basal Cell Carcinoma. Dermatol Surg. 2019 Jan;45(1):17-25. doi: 10.1097/DSS.0000000000001640. PMID: 30586344.

➔ Excluded after screening, review

69: Basset-Seguin N. Traitement médical des carcinomes basocellulaires avancés: Medical treatment of advanced basal cell carcinoma. Ann Dermatol Venereol. 2018 Nov;145 Suppl 5:VS36-VS41. French. doi: 10.1016/S0151-9638(18)31257-2. PMID: 30477683.

➔ Excluded after screening, review

70: Woltsche N, Pichler N, Wolf I, Di Meo N, Zalaudek I. Managing adverse effects by dose reduction during routine treatment of locally advanced basal

cell carcinoma with the hedgehog inhibitor vismodegib: a single centre experience. J Eur Acad Dermatol Venereol. 2019 Apr;33(4):e144-e145. doi: 10.1111/jdv.15367. Epub 2018 Dec 17. PMID: 30472793.

➔ Excluded after screening, dose reduction for laBCC

71: González AR, Etchichury D, Gil ME, Del Aguila R. Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma. Ophthalmic Plast Reconstr Surg. 2019 Jan/Feb;35(1):56-61. doi: 10.1097/IOP.0000000000001166. PMID: 30444747.

➔ Excluded after screening, neoadjuvant vismodegib for laBCC

72: Sagiv O, Ding S, Ferrarotto R, Glisson B, Altan M, Johnson F, Elamin Y, Thakar SD, Nagarajan P, Esmaeli B. Impact of Food and Drug Administration Approval of Vismodegib on Prevalence of Orbital Exenteration as a Necessary Surgical Treatment for Locally Advanced Periocular Basal Cell Carcinoma. Ophthalmic Plast Reconstr Surg. 2019 Jul/Aug;35(4):350-353. doi: 10.1097/IOP.0000000000001251. PMID: 30365473.

➔ Excluded after screening, vismodegib for periorbital laBCC

73: Biehs B, Dijkgraaf GJP, Piskol R, Alicke B, Boumahdi S, Peale F, Gould SE, de Sauvage FJ. A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. Nature. 2018 Oct;562(7727):429-433. doi: 10.1038/s41586-018-0596-y. Epub 2018 Oct 8. PMID: 30297801.

➔ Excluded after screening, molecular research on tumor resistance

74: Sánchez-Danés A, Larsimont JC, Liagre M, Muñoz-Couselo E, Lapouge G, Brisebarre A, Dubois C, Suppa M, Sukumaran V, Del Marmol V, Tabernero J, Blanpain C. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Nature. 2018 Oct;562(7727):434-438. doi: 10.1038/s41586-018-0603-3. Epub 2018 Oct 8. PMID: 30297799; PMCID: PMC6295195.

➔ Excluded after screening, molecular research on tumor resistance

75: Zullo SW, Zeitouni NC, Segal RJ. Long-term efficacy of combination

vismodegib and photodynamic therapy for multiple basal cell carcinomas. Photodiagnosis Photodyn Ther. 2018 Dec;24:164-165. doi: 10.1016/j.pdpdt.2018.09.016. Epub 2018 Oct 3. PMID: 30291952.

➔ Excluded after screening, long-term follow-up of combination therapy

76: Scalvenzi M, Villani A, Mazzella C, Cappello M, Salvatores GF, Costa C. Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2018 Nov-Dec;84(6):758-760. doi: 10.4103/ijdvl.IJDVL_92_18. PMID: 30226476.

➔ Excluded after screening, laBCC treatment

77: Soura E, Plaka M, Dessinioti C, Chasapi V, Stefanaki C, Antoniou C, Stratigos A. Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum. Pediatr Dermatol. 2018 Nov;35(6):e334-e336. doi: 10.1111/pde.13610. Epub 2018 Sep 3. PMID: 30178564.

➔ Excluded after eligibility assessment, does not report on reoccurence/resistance/dosing regiment/QoL

78: Chang ALS, Tran DC, Cannon JGD, Li S, Jeng M, Patel R, Van der Bokke L, Pague A, Brotherton R, Rieger KE, Satpathy AT, Yost KE, Reddy S, Sarin K, Colevas AD. Pembrolizumab for advanced basal cell carcinoma: An investigator-initiated, proof-of-concept study. J Am Acad Dermatol. 2019 Feb;80(2):564-566. doi: 10.1016/j.jaad.2018.08.017. Epub 2018 Aug 24. PMID: 30145186; PMCID: PMC6839543.

➔ Excluded after screening, anti-PD1 therapy for aBCC

79: Hehlgans S, Booms P, Güllülü Ö, Sader R, Rödel C, Balermpas P, Rödel F, Ghanaati S. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib. Int J Mol Sci. 2018 Aug 23;19(9):2485. doi: 10.3390/ijms19092485. PMID: 30142876; PMCID: PMC6164565.

➔ Excluded after screening, in vitro study

80: Giorgini C, Barbaccia V, Croci GA, Imarisio I, Vassallo C. Rapid development

of atypical fibroxanthoma during vismodegib treatment. Clin Exp Dermatol. 2019 Jan;44(1):86-88. doi: 10.1111/ced.13736. Epub 2018 Aug 21. PMID: 30132948.

➔ Excluded after screening, rare side effect case report

81: Pasquali P. Local Experience with Vismodegib. Actas Dermosifiliogr (Engl Ed). 2018 Nov;109(9):765-766. English, Spanish. doi: 10.1016/j.ad.2018.06.008. Epub 2018 Aug 1. PMID: 30077392.

➔ Excluded after screening, does not report patients

82: Bernia E, Llombart B, Serra-Guillén C, Bancalari B, Nagore E, Requena C, Calomarde L, Diago A, Lavernia J, Traves V, Guillén C, Sanmartín O. Experience With Vismodegib in the Treatment of Advanced Basal Cell Carcinoma at a Cancer Center. Actas Dermosifiliogr (Engl Ed). 2018 Nov;109(9):813-820. English, Spanish. doi: 10.1016/j.ad.2018.06.003. Epub 2018 Jul 25. PMID: 30055751.

➔ Excluded after screening, treatment of laBCC

83: Nayyar PM, Chang ALS, Sarin K, Ratner D. Unique Tumor Heterogeneity Within a Single Locally Advanced Basal Cell Carcinoma Resulting in a Partial Response Despite Continuous Vismodegib Treatment. Dermatol Surg. 2019 Apr;45(4):608-610. doi: 10.1097/DSS.0000000000001607. PMID: 30045109.

➔ Excluded after screening, resistance in laBCC

84: Chen L, Aria AB, Silapunt S, Migden MR. Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer. Dermatol Surg. 2019 Jan;45(1):1-16. doi: 10.1097/DSS.0000000000001601. PMID: 30045105.

➔ Excluded after screening, review

85: Frampton JE, Basset-Séguin N. Vismodegib: A Review in Advanced Basal Cell Carcinoma. Drugs. 2018 Jul;78(11):1145-1156. doi: 10.1007/s40265-018-0948-9. PMID: 30030732.

➔ Excluded after screening, review

86: Sagiv O, Nagarajan P, Ferrarotto R, Kandl TJ, Thakar SD, Glisson BS, Altan

M, Esmaeli B. Ocular preservation with neoadjuvant vismodegib in patients with locally advanced periocular basal cell carcinoma. Br J Ophthalmol. 2019 Jun;103(6):775-780. doi: 10.1136/bjophthalmol-2018-312277. Epub 2018 Jul 18. PMID: 30021814.

➔ Excluded after screening, treatment of laBCC

87: Awad R, Andrade JCB, Mousa H, Mahmoud F. Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report. Perm J. 2018;22:17-181. doi: 10.7812/TPP/17-181. PMID: 30005721; PMCID: PMC6045509.

➔ Excluded after screening, treatment of laBCC

88: Xie P, Lefrançois P. Efficacy, safety, and comparison of sonic hedgehog inhibitors in basal cell carcinomas: A systematic review and meta-analysis. J Am Acad Dermatol. 2018 Dec;79(6):1089-1100.e17. doi: 10.1016/j.jaad.2018.07.004. Epub 2018 Jul 10. PMID: 30003981.

➔ Excluded after screening, review

89: Sbrana A, Antonuzzo A, Galli L, Biasco E, Musettini G, Paolieri F, Ricci S. A case of a patient with severe renal failure on hemodialysis treated with vismodegib for relapsing basal cell carcinoma. Tumori. 2018 Dec;104(6):NP2-NP4. doi: 10.1177/0300891618778952. Epub 2018 Jun 13. PMID: 29895211.

➔ Excluded after screening, treatment of laBCC

90: Cameron MC, Lee E, Hibler BP, Giordano CN, Barker CA, Mori S, Cordova M, Nehal KS, Rossi AM. Basal cell carcinoma: Contemporary approaches to diagnosis, treatment, and prevention. J Am Acad Dermatol. 2019 Feb;80(2):321-339. doi: 10.1016/j.jaad.2018.02.083. Epub 2018 May 19. Erratum in: J Am Acad Dermatol. 2019 Jul;81(1):310. PMID: 29782901.

➔ Excluded after screening, erratum

91: Russo F, Mancini V, Trovato E, Fimiani M, Taddeucci P. BCC and vismodegib: can we treat and remold at the same time? G Ital Dermatol Venereol. 2020 Feb;155(1):119-120. doi: 10.23736/S0392-0488.18.06043-1. Epub 2018 May 16. PMID:

29781264.

➔ Excluded after screening, letter

92: Buetti-Dinh A, Jensen R, Friedman R. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy. BMC Cancer. 2018 May 18;18(1):569. doi: 10.1186/s12885-018-4451-1. PMID: 29776351; PMCID: PMC5960207.

➔ Excluded after screening, molecular research

93: Tang JC, Hanke CW, Caro I. Vismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application. J Drugs Dermatol. 2018 May 1;17(5):506-508. PMID: 29742180.

➔ Excluded after screening, review

94: Lucero OM, Fitzmaurice S, Thompson C, Leitenberge J. A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib. Dermatol Online J. 2018 Feb 15;24(2):13030/qt92k2f96t. PMID: 29630158.

➔ Excluded after screening, treatment of laBCC

95: Čeović R, Petković M, Mokos ZB, Kostović K. Nonsurgical treatment of nonmelanoma skin cancer in the mature patient. Clin Dermatol. 2018 Mar-Apr;36(2):177-187. doi: 10.1016/j.clindermatol.2017.10.009. Epub 2017 Nov 3. PMID: 29566922.

➔ Excluded after screening, review

96: Khalid B, Mukherjee S, Ibrahimi S, Cannon T, Gilles E, Moreau A, Razaq M. Switching the Smoothened Inhibitor May Have Benefit in Advanced Basal Cell Carcinoma. Am J Ther. 2018 May/Jun;25(3):e394-e396. doi: 10.1097/MJT.0000000000000721. PMID: 29557803.

➔ Excluded after screening, treatment of laBCC

97: Hanke CW, Mhatre SK, Oliveri D, Zivkovic M, Caro I, Bergström D, Dawson K,

Sima CS. Vismodegib Use in Clinical Practice: Analysis of a United States Medical Claims Database. J Drugs Dermatol. 2018 Feb 1;17(2):143-148. PMID: 29462221.

➔ Excluded after eligibility assessment, only reports on laBCC

98: Kutiel TS, Vornicova O, Bar-Sela G. Cannabis for Vismodegib-Related Muscle Cramps in a Patient With Advanced Basal Cell Carcinoma. J Pain Symptom Manage. 2018 May;55(5):e1-e2. doi: 10.1016/j.jpainsymman.2018.02.004. Epub 2018 Feb 16. PMID: 29454899.

➔ Excluded after screening, adverse event treatment during vismodegib treatment of laBCC

99: Bedi PS, Rai MP, Tageja N, Laird-Fick H. Hepatotoxicity Associated With Vismodegib. BMJ Case Rep. 2018 Feb 8;2018:bcr2017222969. doi: 10.1136/bcr-2017-222969. PMID: 29437771; PMCID: PMC5836615.

➔ Excluded after screening, rare adverse event

100: Russo F, Mancini V, Taddeucci P, Cirocco A, Cusano F, Pellegrino M, Sirna R. Neglected skin carcinomas and Vismodegib: our experience. G Ital Dermatol Venereol. 2019 Oct;154(5):597-599. doi: 10.23736/S0392-0488.18.05873-X. Epub 2018 Feb 7. PMID: 29417798.

➔ Excluded after screening, treatment of laBCC

101: Cannon JGD, Tran DC, Li S, Chang AS. Levocarnitine for vismodegib-associated muscle spasms: a pilot randomized, double-blind, placebo-controlled, investigator-initiated trial. J Eur Acad Dermatol Venereol. 2018 Jul;32(7):e298-e299. doi: 10.1111/jdv.14844. Epub 2018 Feb 23. PMID: 29405443.

➔ Excluded after eligibility assessment, no information on vismodegib indication

102: Giuffrida R, Kashofer K, Dika E, Patrizi A, Baraldi C, Di Meo N, Zalaudek I. Fast growing melanoma following treatment with vismodegib for locally advanced basal cell carcinomas: report of two cases. Eur J Cancer. 2018 Mar;91:177-179. doi: 10.1016/j.ejca.2017.11.031. Epub 2018 Jan 16. PMID: 29373258.

➔ Excluded after screening, rare adverse event

103: Work Group; Invited Reviewers, Kim JYS, Kozlow JH, Mittal B, Moyer J, Olencki T, Rodgers P. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018 Mar;78(3):540-559. doi: 10.1016/j.jaad.2017.10.006. Epub 2018 Jan 10. PMID: 29331385.

➔ Excluded after screening, guidelines

104: Alfieri S, Bergamini C, Granata R, Locati L, Licitra L, Bossi P. Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience. Target Oncol. 2018 Apr;13(2):253-256. doi: 10.1007/s11523-017-0545-y. PMID: 29235062.

➔ Excluded after screening, retreatment of aBCC

105: Girard E, Lacour A, Abi Rached H, Ramdane N, Templier C, Dziwniel V, Desmedt E, Le Rhun E, Mortier L. Occurrence of vismodegib-induced cramps (muscular spasms) in the treatment of basal cell carcinoma: A prospective study in 30 patients. J Am Acad Dermatol. 2018 Jun;78(6):1213-1216.e2. doi: 10.1016/j.jaad.2017.11.045. Epub 2017 Dec 1. PMID: 29203435.

➔ Excluded after screening, adverse event in patients treated for aBCC

106: Rizzo JM, Segal RJ, Zeitouni NC. Combination vismodegib and photodynamic therapy for multiple basal cell carcinomas. Photodiagnosis Photodyn Ther. 2018 Mar;21:58-62. doi: 10.1016/j.pdpdt.2017.10.028. Epub 2017 Nov 2. PMID: 29102653.

➔ Excluded after screening, combination therapy

107: Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5. PMID: 29073584.

➔ Excluded after eligibility assessment, no specific multiple BCC/BCNS outcomes

108: Kieny A, Kremer V, Scheidecker S, Lipsker D. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient. Acta Derm Venereol. 2018 Feb 7;98(2):287-288. doi: 10.2340/00015555-2822. PMID: 29057423.

➔ Excluded after eligibility assessment does not report on reoccurence/resistance/dosing regiment/QoL

109: Couzan C, Cinotti E, Labeille B, Vercherin P, Rubegni P, Cambazard F, Perrot JL. Reflectance confocal microscopy identification of subclinical basal cell carcinomas during and after vismodegib treatment. J Eur Acad Dermatol Venereol. 2018 May;32(5):763-767. doi: 10.1111/jdv.14650. Epub 2017 Nov 9. PMID: 29055164.

➔ Excluded after screening, RCM for detection of BCC during and after vismodegib

110: Soura E, Plaka M, Chasapi V, Antoniou C, Stratigos A. Vismodegib persistence and discontinuation patterns in Greek patients from a real world setting. Dermatol Ther. 2018 Jan;31(1). doi: 10.1111/dth.12553. Epub 2017 Oct 4. PMID: 28976624.

➔ Excluded after eligibility assessment, no specific multiple BCC/BCNS outcomes

111: Mohr M, Schumacher N, Zillikens D, Terheyden P. Follicular and cystic regression of locally advanced basal cell carcinoma following short-term neoadjuvant vismodegib therapy. J Dtsch Dermatol Ges. 2017 Oct;15(10):1031-1033. doi: 10.1111/ddg.13326. Epub 2017 Sep 12. PMID: 28898543.

➔ Excluded after screening, treatment of laBCC

112: Danhof R, Lewis K, Brown M. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin. Am J Clin Dermatol. 2018 Apr;19(2):195-207. doi: 10.1007/s40257-017-0319-4. PMID: 28887802.

➔ Excluded after screening, review

113: Deng M, Marsch AF, Petronic-Rosic V. Molecular Variations in Histologic Subtypes of Basal Cell Carcinoma. Skinmed. 2017 Aug 1;15(4):265-268. PMID: 28859735.

➔ Excluded after screening, review

114: Bhutani T, Abrouk M, Sima CS, Sadetsky N, Hou J, Caro I, Chren MM, Arron ST. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J Am Acad Dermatol. 2017 Oct;77(4):713-718. doi: 10.1016/j.jaad.2017.03.038. Epub 2017 Aug 2. PMID: 28780365.

➔ Excluded after eligibility assessment, no specific outcomes for multiple BCC/BCNS patients

115: Koelblinger P, Dummer R, Laimer M, Hecht S, Bauer JW, Gaggl A, Kugler A. Vismodegib for recurrent locally destructive basal cell carcinoma in a renal transplant patient. J Eur Acad Dermatol Venereol. 2018 Jan;32(1):e7-e8. doi: 10.1111/jdv.14430. Epub 2017 Jul 20. PMID: 28646606.

➔ Excluded after screening, treatment of laBCC

116: Chang ALS. Commentary on Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment. Dermatol Surg. 2017 Jul;43(7):991-992. doi: 10.1097/DSS.0000000000001059. PMID: 28640761.

➔ Excluded after screening, treatment of laBCC

117: Zargari O, Azimi SZ, Geranmayeh S. Inoperable infiltrative basal cell carcinoma successfully treated with vismodegib. Dermatol Ther. 2017 Jul;30(4). doi: 10.1111/dth.12509. Epub 2017 Jun 19. PMID: 28631369.

➔ Excluded after screening, treatment of laBCC

118: Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, Miller C, Mortier L, Murrell DF, Hamid O, Quevedo JF, Hou J, McKenna E, Dimier N, Williams S, Schadendorf D, Hauschild A; ERIVANCE BCC Investigators. Long-term

safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017 May 16;17(1):332. doi: 10.1186/s12885-017-3286-5. Erratum in: BMC Cancer. 2019 Apr 18;19(1):366. PMID: 28511673; PMCID: PMC5433030.

➔ Excluded after eligibility assessment, only results on aBCC

119: Ariza S, Espinosa S, Naranjo M. Nonsurgical Therapies for Basal Cell Carcinoma: A Review. Actas Dermosifiliogr. 2017 Nov;108(9):809-817. English, Spanish. doi: 10.1016/j.ad.2017.01.018. Epub 2017 Apr 19. PMID: 28433227.

➔ Excluded after screening, review

120: Kwong B, Danial C, Liu A, Chun KA, Chang AL. Reversible cutaneous side effects of vismodegib treatment. Cutis. 2017 Mar;99(3):E19-E20. PMID: 28398426.

➔ Excluded after screening, common adverse event

121: Jacobsen AA, Kydd AR, Strasswimmer J. Practical management of the adverse effects of Hedgehog pathway inhibitor therapy for basal cell carcinoma. J Am Acad Dermatol. 2017 Apr;76(4):767-768. doi: 10.1016/j.jaad.2016.04.063. PMID: 28325399.

➔ Excluded after screening, review

122: Fife D, Laitinen MA, Myers DJ, Landsteiner PB. Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum. Pediatr Dermatol. 2017 Mar;34(2):163-165. doi: 10.1111/pde.13080. PMID: 28297142.

➔ Excluded after eligibility assessment does not report on reoccurence/resistance/dosing regiment/QoL

123: Lima JP. Statistical Concerns on Vismodegib for Basal Cell Carcinoma Meta-analysis. JAMA Dermatol. 2017 Apr 1;153(4):337. doi: 10.1001/jamadermatol.2016.5689. PMID: 28196186.

➔ Excluded after screening, response to review

124: Jacobsen AA, Strasswimmer J. Statistical Concerns on Vismodegib for Basal Cell Carcinoma Meta-Analysis-Reply. JAMA Dermatol. 2017 Apr 1;153(4):337-338. doi: 10.1001/jamadermatol.2016.5688. PMID: 28196183.

➔ Excluded after screening, response to review

125: Thomas CL, Arasaratnam M, Carlos G, Parasyn A, Baumgart KW, Fernandez-Penas P, Marx G. Drug reaction with eosinophilia and systemic symptoms in metastatic basal cell carcinoma treated with vismodegib. Australas J Dermatol. 2017 Feb;58(1):69-70. doi: 10.1111/ajd.12472. PMID: 28195319.

➔ Excluded after screening, rare adverse event in mBCC treated with vismodegib

126: Mosterd K. Intermittent vismodegib dosing to treat multiple basal-cell carcinomas. Lancet Oncol. 2017 Mar;18(3):284-286. doi: 10.1016/S1470-2045(17)30079-7. Epub 2017 Feb 8. PMID: 28188087.

➔ Excluded after screening, commentary

127: Dréno B, Kunstfeld R, Hauschild A, Fosko S, Zloty D, Labeille B, Grob JJ, Puig S, Gilberg F, Bergström D, Page DR, Rogers G, Schadendorf D. Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):404-412. doi: 10.1016/S1470-2045(17)30072-4. Epub 2017 Feb 8. PMID: 28188086.

➔ Duplicate from clinicaltrial

128: Keserü M, Green S, Dulz S. Die Behandlung periokulärer Basalzellkarzinome mit Vismodegib [Vismodegib Therapy for Periocular Basal Cell Carcinoma]. Klin Monbl Augenheilkd. 2017 Jan;234(1):64-69. German. doi: 10.1055/s-0042-121606. Epub 2017 Jan 30. PMID: 28135752.

➔ Excluded after screening, vismodegib for laBCC

129: Becker LR, Aakhus AE, Reich HC, Lee PK. A Novel Alternate Dosing of Vismodegib for Treatment of Patients With Advanced Basal Cell Carcinomas. JAMA Dermatol. 2017 Apr 1;153(4):321-322. doi: 10.1001/jamadermatol.2016.5058. PMID:

28114606.

➔ Excluded after screening, dose reduction for aBCC

130: Feigenbaum L, Scott BL, Moye MS, Nijhawan RI. Development of Basal Cell Carcinoma With Squamous Differentiation During Vismodegib Treatment. Dermatol Surg. 2017 Jul;43(7):989-991. doi: 10.1097/DSS.0000000000001012. PMID: 28002101.

➔ Excluded after screening, rare adverse event in aBCC

131: Reinders MG, Terra JB, Reyners AK, Aarts MJ, de Haas ER, Mosterd K. Vismodegib voor gevorderd basaalcelcarcinoom [Vismodegib for basal cell carcinoma: targeted therapy in case of locally advanced or metastasised disease]. Ned Tijdschr Geneeskd. 2016;160:D187. Dutch. PMID: 28000572.

➔ Excluded after screening, treatment for laBCC

132: McGrane J, Carswell S, Talbot T. Metastatic spinal cord compression from basal cell carcinoma of the skin treated with surgical decompression and vismodegib: case report and review of Hedgehog signalling pathway inhibition in advanced basal cell carcinoma. Clin Exp Dermatol. 2017 Jan;42(1):80-83. doi: 10.1111/ced.12991. Epub 2016 Nov 30. PMID: 27905158.

➔ Excluded after screening, treatment for laBCC

133: Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, Ulerio G, Rezaee MR, Gildengorin G, Marji J, Clark C, Bickers DR, Epstein EH Jr. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 Dec;17(12):1720-1731. doi: 10.1016/S1470-2045(16)30566-6. Epub 2016 Nov 10. PMID: 27838224.

➔ Duplicate from clinicaltrial

134: Castillo JM, Knol AC, Nguyen JM, Khammari A, Saint-Jean M, Dreno B. Immunohistochemical markers of advanced basal cell carcinoma: CD56 is associated with a lack of response to vismodegib. Eur J Dermatol. 2016 Oct 1;26(5):452-459. doi: 10.1684/ejd.2016.2826. PMID: 27346829.

➔ Excluded after screening, histologic markers for aBCC response to vismodegib

135: Alarcon I, Pasquali P, Malvehy J, Puig S. Tumor regrowth and development of keratinocytic neoplasms in patients under smoothened inhibition: in vivo assessment with reflectance confocal microscopy. Skin Res Technol. 2017 Aug;23(3):283-288. doi: 10.1111/srt.12332. Epub 2016 Oct 27. PMID: 27785832.

➔ Excluded after eligibility assessment, discusses regrowth in laBCC cases

136: Chang AL, Lewis KD, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma. Oncotarget. 2016 Nov 15;7(46):76118-76124. doi: 10.18632/oncotarget.12660. PMID: 27764798; PMCID: PMC5342800.

➔ Excluded after screening, treatment of laBCC in elderly

137: Li S, Chang AL. Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma-Reply. JAMA Dermatol. 2016 Oct 1;152(10):1173. doi: 10.1001/jamadermatol.2016.2429. PMID: 27732729.

➔ Excluded after screening, well known adverse event, not proven in large study

138: Puig S, Sampogna F, Tejera-Vaquerizo A. Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma: Not a Case-Control Study. JAMA Dermatol. 2016 Oct 1;152(10):1172-1173. doi: 10.1001/jamadermatol.2016.2428. PMID: 27732728.

➔ Excluded after screening, well known adverse event, not proven in large study

139: Gjersvik P. Study on the Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma: Not a Case-Control Study. JAMA Dermatol. 2016 Oct 1;152(10):1172. doi: 10.1001/jamadermatol.2016.2427. PMID: 27732727.

➔ Excluded after screening, well known adverse event, not proven in large study

140: Fife K, Herd R, Lalondrelle S, Plummer R, Strong A, Jones S, Lear JT.

Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. Future Oncol. 2017 Jan;13(2):175-184. doi: 10.2217/fon-2016-0296. Epub 2016 Sep 19. PMID: 27640448.

➔ Excluded after screening, expert opinion on managing adverse events

141: Chang AL, Arron ST, Migden MR, Solomon JA, Yoo S, Day BM, McKenna EF, Sekulic A. Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: pooled analysis of two trials. Orphanet J Rare Dis. 2016 Sep 1;11(1):120. doi: 10.1186/s13023-016-0506-z. PMID: 27581207; PMCID: PMC5007799.

➔ Excluded after eligibility assessment, no outcomes reported for multiple BCCs

142: Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. Oncologist. 2016 Oct;21(10):1218-1229. doi: 10.1634/theoncologist.2016-0186. Epub 2016 Aug 10. PMID: 27511905; PMCID: PMC5061532.

➔ Excluded after screening, adverse events in patients with aBCC

143: Paulsen JF, Øregaard JS, Nielsen AL, Gehl J, Venzo A. Vismodegib and surgery combined - effective treatment of locally advanced basal cell carcinoma. Acta Oncol. 2016 Dec;55(12):1492-1494. doi: 10.1080/0284186X.2016.1206212. Epub 2016 Jul 22. PMID: 27448604.

➔ Excluded after screening, neoadjuvant treatment of laBCC

144: Scott JF, Bordeaux JS. Severe Rheumatoid Arthritis Developing in Conjunction with Gorlin Syndrome. J Rheumatol. 2016 Jul;43(7):1447-9. doi: 10.3899/jrheum.160062. PMID: 27371652.

➔ Excluded after eligibility assessment, case report on rare treatment benefit on rheumatoid arthritis

145: Kwon GP, Ally MS, Bailey-Healy I, Oro AE, Kim J, Chang AL, Aasi S, Tang JY. Update to an open-label clinical trial of vismodegib as neoadjuvant before

surgery for high-risk basal cell carcinoma (BCC). J Am Acad Dermatol. 2016 Jul;75(1):213-5. doi: 10.1016/j.jaad.2016.02.1235. PMID: 27317518.

➔ Duplicate (clinicaltrial.gov)

146: Cox KF, Margo CE. Role of Vismodegib in the Management of Advanced Periocular Basal Cell Carcinoma. Cancer Control. 2016 Apr;23(2):133-9. doi: 10.1177/107327481602300207. PMID: 27218790.

➔ Excluded after screening, vismodegib for aBCC

147: Powell EM, Stratton JS, Shendrik I, Blalock TW. Histologic Findings of Tumor Lysis in Advanced Basal Cell Carcinoma Treated With Vismodegib. Dermatol Surg. 2016 Jul;42(7):904-7. doi: 10.1097/DSS.0000000000000731. PMID: 27191782.

➔ Excluded after screening, vismodegib for aBCC

148: Simone PD, Schwarz JM, Strasswimmer JM. Four-year experience with vismodegib hedgehog inhibitor therapy. J Am Acad Dermatol. 2016 Jun;74(6):1264-5. doi: 10.1016/j.jaad.2015.12.035. PMID: 27185433.

➔ Excluded after screening, vismodegib for laBCC

149: Guo D, Kossintseva I, Leitenberger J. Neoadjuvant Vismodegib Before Mohs: Lack of Tissue Sparing and Squamous Differentiation of Basal Cell Carcinoma in a Patient With Chronic Lymphocytic Leukemia. Dermatol Surg. 2016 Jun;42(6):780-3. doi: 10.1097/DSS.0000000000000716. PMID: 27153042.

➔ Excluded after screening, neoadjuvant vismodegib for laBCC

150: Kirkpatrick E, Dobriansky D, Scurry J. Gorlin Syndrome, Vulvar Basal Cell Carcinomas, Vismodegib, and Lichen Sclerosus: From the ISSVD Case Consultation Committee. J Low Genit Tract Dis. 2016 Jul;20(3):e40-1. doi: 10.1097/LGT.0000000000000209. PMID: 27105331.

➔ Excluded after eligibility assessment does not report on reoccurence/resistance/dosing regiment/QoL

151: Jacobsen AA, Aldahan AS, Hughes OB, Shah VV, Strasswimmer J. Hedgehog

Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies. JAMA Dermatol. 2016 Jul 1;152(7):816-24. doi: 10.1001/jamadermatol.2016.0780. PMID: 27096888.

➔ Excluded after screening, review

152: Wiznia LE, Federman DG. Treatment of Basal Cell Carcinoma in the Elderly: What Nondermatologists Need to Know. Am J Med. 2016 Jul;129(7):655-60. doi: 10.1016/j.amjmed.2016.03.003. Epub 2016 Apr 1. PMID: 27046242.

➔ Excluded after screening, review

153: Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, Seplyarskiy VB, Sharpe HJ, McKee T, Letourneau A, Ribaux PG, Popadin K, Basset-Seguin N, Ben Chaabene R, Santoni FA, Andrianova MA, Guipponi M, Garieri M, Verdan C, Grosdemange K, Sumara O, Eilers M, Aifantis I, Michielin O, de Sauvage FJ, Antonarakis SE, Nikolaev SI. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet. 2016 Apr;48(4):398-406. doi: 10.1038/ng.3525. Epub 2016 Mar 7. PMID: 26950094.

➔ Excluded after screening, molecular research

154: Li C, Athar M. Ionizing Radiation Exposure and Basal Cell Carcinoma Pathogenesis. Radiat Res. 2016 Mar;185(3):217-28. doi: 10.1667/RR4284.S1. Epub 2016 Mar 1. PMID: 26930381; PMCID: PMC4821498.

➔ Excluded after screening, commentary/review

155: Sekulic A, Von Hoff D. Hedgehog Pathway Inhibition. Cell. 2016 Feb 25;164(5):831. doi: 10.1016/j.cell.2016.02.021. PMID: 26919418.

➔ Excluded after screening, short communication

156: Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang AL. Increased Risk of Cutaneous Squamous Cell Carcinoma After Vismodegib Therapy for Basal Cell Carcinoma. JAMA Dermatol. 2016 May 1;152(5):527-32. doi: 10.1001/jamadermatol.2015.4330. PMID: 26914338.

➔ Excluded after screening, adverse event association not confirmed in large study

157: Khoo AB, Ali FR, Lear JT. Defining locally advanced basal cell carcinoma and integrating smoothened inhibitors into clinical practice. Curr Opin Oncol. 2016 Mar;28(2):180-4. doi: 10.1097/CCO.0000000000000259. PMID: 26780190.

➔ Excluded after screening, laBCC

158: Feinstein EG, Zhou M, Setabutr P. Enlarging Multiple Neoplastic Skin Growths. JAMA Ophthalmol. 2016 Mar;134(3):337-8. doi: 10.1001/jamaophthalmol.2015.3600. PMID: 26767432.

➔ Excluded after screening, clinical challenge

159: Maul LV, Kähler KC, Hauschild A. Effective and Tolerable Treatment of Advanced Basal Cell Carcinoma With Vismodegib Despite Renal Insufficiency. JAMA Dermatol. 2016 Dec 1;152(12):1387-1388. doi: 10.1001/jamadermatol.2015.4592. PMID: 26720040.

➔ Excluded after screening, report on aBCC

160: Wahid M, Jawed A, Mandal RK, Dar SA, Khan S, Akhter N, Haque S. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas. Crit Rev Oncol Hematol. 2016 Feb;98:235-41. doi: 10.1016/j.critrevonc.2015.11.006. Epub 2015 Nov 21. PMID: 26614022.

➔ Excluded after screening, review

161: Sand M, Bechara FG, Gambichler T, Sand D, Friedländer MR, Bromba M, Schnabel R, Hessam S. Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study. Ann Oncol. 2016 Feb;27(2):332-8. doi: 10.1093/annonc/mdv551. Epub 2015 Nov 16. PMID: 26578727.

➔ Excluded after screening, molecular study

162: Rudnick EW, Thareja S, Cherpelis B. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. Int J Dermatol. 2016 Mar;55(3):249-58; quiz 256, 258. doi: 10.1111/ijd.12961. Epub 2015 Nov 13. PMID: 26566923.

➔ Excluded after screening, review

163: Danial C, Sarin KY, Oro AE, Chang AL. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Clin Cancer Res. 2016 Mar 15;22(6):1325-9. doi: 10.1158/1078-0432.CCR-15-1588. Epub 2015 Nov 6. PMID: 26546616; PMCID: PMC4794361.

➔ Excluded after screening, sonidegib for aBCC

164: Schmidt C. Targeted Therapy Makes Inroads in Medulloblastoma. J Natl Cancer Inst. 2015 Nov 4;107(11):djv353. doi: 10.1093/jnci/djv353. PMID: 26538622.

➔ Excluded after screening, treatment for medulloblastoma

165: Yang X, Dinehart SM. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome. JAMA Dermatol. 2016 Feb;152(2):223-4. doi: 10.1001/jamadermatol.2015.3210. PMID: 26509945.

➔ Included after eligibility assessment

166: Rajan N, Brown S, Ward S, Hainsworth P, Hodgkinson P, Pieniazek P, Husain A, Plummer R. Mesenteric cysts in naevoid basal cell carcinoma syndrome: a mimic of metastatic disease. Br J Dermatol. 2016 Mar;174(3):684-5. doi: 10.1111/bjd.14224. Epub 2015 Dec 14. PMID: 26473628; PMCID: PMC4832287.

➔ Excluded after screening, rare symptom of BCNS.

167: Huizenga T, Newsom E, Fakhouri T, Kado J. New-Onset Congestive Heart Failure in a Patient on Vismodegib. Dermatol Surg. 2015 Nov;41(11):1329-32. doi: 10.1097/DSS.0000000000000444. PMID: 26458043.

➔ Excluded after screening, rare adverse event in vismodegib

168: Schulze B, Meissner M, Ghanaati S, Burck I, Rödel C, Balermpas P. Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : First clinical experience with vismodegib for locally advanced disease. Strahlenther Onkol. 2016 Jan;192(1):25-31. doi: 10.1007/s00066-015-0902-7. Epub 2015 Oct 8. PMID: 26449347.

➔ Excluded after screening, vismodegib combination with radiation therapy

169: Piérard-Franchimont C, Hermanns-Lê T, Paquet P, Herfs M, Delvenne P, Piérard GE. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas. Future Oncol. 2015 Nov;11(22):2997-3002. doi: 10.2217/fon.15.181. Epub 2015 Oct 5. PMID: 26437034.

➔ Excluded after screening, review

170: Le Moigne M, Saint-Jean M, Jirka A, Quéreux G, Peuvrel L, Brocard A, Gaultier A, Khammari A, Darmaun D, Dréno B. Dysgeusia and weight loss under treatment with vismodegib: benefit of nutritional management. Support Care Cancer. 2016 Apr;24(4):1689-95. doi: 10.1007/s00520-015-2932-1. Epub 2015 Sep 29. PMID: 26416491.

➔ Excluded after eligibility assessment, vismodegib for aBCC

171: Papastefanou VP, René C. Secondary Resistance to Vismodegib After Initial Successful Treatment of Extensive Recurrent Periocular Basal Cell Carcinoma with Orbital Invasion. Ophthalmic Plast Reconstr Surg. 2017 May/Jun;33(3S Suppl 1):S68-S70. doi: 10.1097/IOP.0000000000000565. PMID: 26398246.

➔ Excluded after screening, resistance in laBCC

172: Viscusi KS, Hanke CW. Vismodegib for Locally Advanced Basal Cell Carcinoma: Descriptive Analysis of a Case Series and Comparison to the Literature. J Drugs Dermatol. 2015 Sep;14(9):956-62. PMID: 26355613.

➔ Excluded after screening, vismodegib for laBCC

173: Ransohoff KJ, Tang JY, Sarin KY. Squamous Change in Basal-Cell Carcinoma with Drug Resistance. N Engl J Med. 2015 Sep 10;373(11):1079-82. doi: 10.1056/NEJMc1504261. PMID: 26352826.

➔ Excluded after screening, vismodegib for laBCC

174: Tauber G, Pavlovsky L, Fenig E, Hodak E. Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp. J Am Acad Dermatol. 2015 Nov;73(5):799-801. doi: 10.1016/j.jaad.2015.07.016. Epub 2015 Aug 25. PMID: 26320385.

➔ Included after eligibility assessment, vismodegib for multiple radiation-induced BCCs

175: Savoia P, Cremona O, Fava P. New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer. Curr Drug Targets. 2016;17(3):353-74. doi: 10.2174/1389450116666150806123717. PMID: 26245477.

➔ Excluded after screening, review

176: Ally MS, Tang JY, Lindgren J, Acosta-Raphael M, Rezaee M, Chanana AM, Epstein EH Jr. Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps. JAMA Dermatol. 2015 Oct;151(10):1132-4. doi: 10.1001/jamadermatol.2015.1937. PMID: 26200175.

➔ Excluded after eligibility assessment, concerns adverse effect treatment

177: Zhao X, Ponomaryov T, Ornell KJ, Zhou P, Dabral SK, Pak E, Li W, Atwood SX, Whitson RJ, Chang AL, Li J, Oro AE, Chan JA, Kelleher JF, Segal RA. RAS/MAPK Activation Drives Resistance to Smo Inhibition, Metastasis, and Tumor Evolution in Shh Pathway-Dependent Tumors. Cancer Res. 2015 Sep 1;75(17):3623-35. doi: 10.1158/0008-5472.CAN-14-2999-T. Epub 2015 Jun 30. PMID: 26130651; PMCID: PMC4558230.

➔ Excluded after screening, molecular research

178: Fosko SW, Chu MB, Mattox AR, Richart JM, Burkemper NM, Slutsky JB. Lichenoid reaction as a potential immune response marker of intratreatment histological response during successful vismodegib treatment for a giant basal

cell carcinoma. Dermatol Ther. 2015 Nov-Dec;28(6):359-62. doi: 10.1111/dth.12260. Epub 2015 Jun 25. PMID: 26114264.

➔ Excluded after screening, vismodegib for laBCC

179: Soura E, Chasapi V, Stratigos AJ. Pharmacologic treatment options for advanced epithelial skin cancer. Expert Opin Pharmacother. 2015;16(10):1479-93. doi: 10.1517/14656566.2015.1052743. Epub 2015 Jun 1. PMID: 26027692.

➔ Excluded after screening, review

180: Lepesant P, Crinquette M, Alkeraye S, Mirabel X, Dziwniel V, Cribier B, Mortier L. Vismodegib induces significant clinical response in locally advanced trichoblastic carcinoma. Br J Dermatol. 2015 Oct;173(4):1059-62. doi: 10.1111/bjd.13919. Epub 2015 Aug 27. PMID: 25998864.

➔ Excluded after screening, treatment for different disease

181: Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Jouary T, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Williams S, Fittipaldo A, Xynos I, Hansson J. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015 Jun;16(6):729-36. doi: 10.1016/S1470-2045(15)70198-1. Epub 2015 May 13. PMID: 25981813.

➔ Excluded after eligibility assessment, no reported outcome of multiple BCC/BCNS

182: Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Dirix L, Hou J, Yue H, Hauschild A; ERIVANCE BCC investigators. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015 Jun;72(6):1021-6.e8. doi: 10.1016/j.jaad.2015.03.021. PMID: 25981002.

➔ Excluded after eligibility assessment, no reported outcome of multiple BCC/BCNS

183: Fernandez A. Dermatology update: The dawn of targeted treatment. Cleve Clin

J Med. 2015 May;82(5):309-20. doi: 10.3949/ccjm.82gr.15002. PMID: 25973879.

➔ Excluded after screening, review

184: Calzavara Pinton P, Licitra L, Peris K, Santoro A, Ascierto PA. Vismodegib in the treatment of basal cell carcinoma: indications for clinical practice. Future Oncol. 2015;11(9):1429-35. doi: 10.2217/fon.15.20. PMID: 25952787.

➔ Excluded after eligibility assessment, does not report new outcomes

185: Ozgur OK, Yin V, Chou E, Ball S, Kies M, William WN, Migden M, Thuro BA, Esmaeli B. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome. Am J Ophthalmol. 2015 Aug;160(2):220-227.e2. doi: 10.1016/j.ajo.2015.04.040. Epub 2015 Apr 30. PMID: 25935097.

➔ Excluded after eligibility assessment, 2 patients with multiple bcc does not report on reoccurence/resistance/dosing regiment/QoL

186: Sofen H, Gross KG, Goldberg LH, Sharata H, Hamilton TK, Egbert B, Lyons B, Hou J, Caro I. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul;73(1):99-105.e1. doi: 10.1016/j.jaad.2015.03.013. Epub 2015 Apr 24. PMID: 25913533.

➔ Duplicate (clinicaltrials.gov)

187: Andersen RM, Lei U. A massive neglected giant basal cell carcinoma in a schizophrenic patient treated successfully with vismodegib. J Dermatolog Treat. 2015;26(6):575-6. doi: 10.3109/09546634.2015.1034073. Epub 2015 Apr 24. PMID: 25909367.

➔ Excluded after screening, laBCC treatment

188: Pollom EL, Bui TT, Chang AL, Colevas AD, Hara WY. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma. JAMA Dermatol. 2015 Sep;151(9):998-1001. doi: 10.1001/jamadermatol.2015.0326. PMID: 25874733.

➔ Excluded after screening, aBCC combination treatment

189: Otsuka A, Levesque MP, Dummer R, Kabashima K. Hedgehog signaling in basal cell carcinoma. J Dermatol Sci. 2015 May;78(2):95-100. doi: 10.1016/j.jdermsci.2015.02.007. Epub 2015 Feb 23. PMID: 25766766.

➔ Excluded after screening, review

190: Atwood SX, Sarin KY, Whitson RJ, Li JR, Kim G, Rezaee M, Ally MS, Kim J, Yao C, Chang AL, Oro AE, Tang JY. Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell. 2015 Mar 9;27(3):342-53. doi: 10.1016/j.ccell.2015.02.002. PMID: 25759020; PMCID: PMC4357167.

➔ Excluded after screening, molecular research

191: Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ. Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015 Mar 9;27(3):327-41. doi: 10.1016/j.ccell.2015.02.001. PMID: 25759019; PMCID: PMC5675004.

➔ Excluded after screening, molecular research

192: Ridky TW, Cotsarelis G. Vismodegib resistance in basal cell carcinoma: not a smooth fit. Cancer Cell. 2015 Mar 9;27(3):315-6. doi: 10.1016/j.ccell.2015.02.009. PMID: 25759014.

➔ Excluded after screening, commentary

193: Ojevwe FO, Ojevwe CD, Zacny JP, Dudek AZ, Lin A, Kohlitz P. Treatment of multiple unresectable basal cell carcinomas from Gorlin-Goltz syndrome: a case report. Anticancer Res. 2015 Mar;35(3):1777-81. PMID: 25750342.

➔ Excluded after eligibility assessment, case report multiple BCCs in BCNS treated with vismodegib does not report on reoccurence/resistance/dosing regiment/QoL

194: Alcalay J, Tauber G, Fenig E, Hodak E. Vismodegib as a neoadjuvant treatment to Mohs surgery for aggressive basal cell carcinoma. J Drugs Dermatol.

2015 Mar;14(3):219-23. PMID: 25738842.

➔ Excluded after screening, vismodegib as neoadjuvant for aBCC

195: Umanoff N, Sarbib K, Mulvaney M, Iorizzo L. Vismodegib for the treatment of aggressive basal cell carcinoma in a patient unable to swallow pills. Dermatol Surg. 2015 Mar;41(3):433-5. doi: 10.1097/DSS.0000000000000299. PMID: 25738448.

➔ Excluded after screening, vismodegib for laBCC

196: Vismodegib (ERIVEDGE°) In basal cell carcinoma: too many unknowns. Prescrire Int. 2015 Jan;24(156):11-4. PMID: 25729822.

➔ Excluded after screening, commentary

197: Foley P. Current landscape for treatment of advanced basal cell carcinoma. Australas J Dermatol. 2015 Mar;56 Suppl 1:1-7. doi: 10.1111/ajd.12319. PMID: 25715811.

➔ Excluded after screening, review

198: Amici JM, Beylot-Barry M. Carcinomes basocellulaires localement avancés: intérêt de traitements combinés, alternatifs à la chirurgie [Locally advanced basal-cell carcinoma: Combined alternative treatments beyond surgery]. Ann Chir Plast Esthet. 2015 Aug;60(4):321-5. French. doi: 10.1016/j.anplas.2015.01.002. Epub 2015 Feb 20. PMID: 25708732.

➔ Excluded after screening, review and combination treatment

199: Raleigh DR, Algazi A, Arron ST, Neuhaus IM, Yom SS. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma. Br J Dermatol. 2015 Aug;173(2):544-6. doi: 10.1111/bjd.13748. Epub 2015 Jun 11. PMID: 25702621.

➔ Excluded after screening, treatment of laBCC with combination therapy

200: Ching JA, Curtis HL, Braue JA, Kudchadkar RR, Mendoza TI, Messina JL, Cruse CW, Smith DJ Jr, Harrington MA. The impact of neoadjuvant hedgehog inhibitor therapy on the surgical treatment of extensive basal cell carcinoma. Ann Plast

Surg. 2015 Jun;74 Suppl 4:S193-7. doi: 10.1097/SAP.0000000000000452. PMID: 25695449.

➔ Excluded after screening, neoadjuvant vismodegib

201: Erdem GU, Sendur MA, Ozdemir NY, Yazıcı O, Zengin N. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma. Curr Med Res Opin. 2015 Apr;31(4):743-56. doi: 10.1185/03007995.2015.1018988. Epub 2015 Mar 17. PMID: 25690490.

➔ Excluded after screening, review

202: Peris K, Licitra L, Ascierto PA, Corvò R, Simonacci M, Picciotto F, Gualdi G, Pellacani G, Santoro A. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future Oncol. 2015;11(4):703-12. doi: 10.2217/fon.14.281. PMID: 25686123.

➔ Excluded after screening, concerns laBCC

203: Demirci H, Worden F, Nelson CC, Elner VM, Kahana A. Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area. Ophthalmic Plast Reconstr Surg. 2015 Nov-Dec;31(6):463-6. doi: 10.1097/IOP.0000000000000388. PMID: 25675162; PMCID: PMC4564370.

➔ Excluded after screening, concerns laBCC

204: Puig S, Berrocal A. Management of high-risk and advanced basal cell carcinoma. Clin Transl Oncol. 2015 Jul;17(7):497-503. doi: 10.1007/s12094-014-1272-9. Epub 2015 Feb 3. PMID: 25643667; PMCID: PMC4495248.

➔ Excluded after screening, review

205: Poulalhon N, Dalle S, Balme B, Thomas L. Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib. Dermatology. 2015;230(2):101-4. doi: 10.1159/000368350. Epub 2015 Jan 24. PMID: 25633488.

➔ Excluded after screening, case report on known reported adverse event

206: Otsuka A, Dreier J, Cheng PF, Nägeli M, Lehmann H, Felderer L, Frew IJ,

Matsushita S, Levesque MP, Dummer R. Hedgehog pathway inhibitors promote adaptive immune responses in basal cell carcinoma. Clin Cancer Res. 2015 Mar 15;21(6):1289-97. doi: 10.1158/1078-0432.CCR-14-2110. Epub 2015 Jan 15. PMID: 25593302.

➔ Excluded after screening, research on immune markers

207: Mizuochi H, Fujii K, Shiohama T, Uchikawa H, Shimojo N. Hedgehog signaling is synergistically enhanced by nutritional deprivation and ligand stimulation in human fibroblasts of Gorlin syndrome. Biochem Biophys Res Commun. 2015 Feb 13;457(3):318-23. doi: 10.1016/j.bbrc.2014.12.108. Epub 2015 Jan 7. PMID: 25576868.

➔ Excluded after screening, cell research

208: Alkeraye S, Maire C, Desmedt E, Templier C, Mortier L. Persistent alopecia induced by vismodegib. Br J Dermatol. 2015 Jun;172(6):1671-1672. doi: 10.1111/bjd.13630. Epub 2015 Apr 1. PMID: 25546344.

➔ Excluded after screening, report on known adverse event

209: Ferguson JS, Hannam S, Toholka R, Chong AH, Magee J, Foley P. Hair loss and Hedgehog inhibitors: a class effect? Br J Dermatol. 2015 Jul;173(1):262-4. doi: 10.1111/bjd.13619. Epub 2015 May 12. PMID: 25523648.

➔ Excluded after screening, report on known adverse event

210: Reinders MG, Brinkhuizen T, Soetekouw PM, Kelleners-Smeets NW, Hamid MA, Mosterd K. Epidermal cyst formation and hyperkeratosis in a patient treated with vismodegib for locally advanced Basal cell carcinoma. Acta Derm Venereol. 2015 May;95(5):618-9. doi: 10.2340/00015555-2020. PMID: 25425396.

➔ Excluded after screening, report on laBCC

211: Cusack CA, Nijhawan R, Miller B, Henien M, Malat G, Doyle A, Abdelmalek M. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient. JAMA Dermatol. 2015 Jan;151(1):70-2. doi: 10.1001/jamadermatol.2014.1894. PMID: 25337679.

➔ Excluded after screening, laBCC case

212: Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, Licitra L, Pilotti S, Bossi P, Perrone F. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015 Feb;9(2):389-97. doi: 10.1016/j.molonc.2014.09.003. Epub 2014 Sep 26. PMID: 25306392; PMCID: PMC5528667.

➔ Excluded after screening, molecular research on resistance

213: Sligh JE Jr. New therapeutic options for actinic keratosis and basal cell carcinoma. Semin Cutan Med Surg. 2014 Jun;33(4 Suppl):S76-80. doi: 10.12788/j.sder.0100. PMID: 25268601.

➔ Excluded after screening, review

214: DiBaise M. Attacking the hedgehog pathway: video game or novel skin cancer therapy? JAAPA. 2014 Oct;27(10):52-3. doi: 10.1097/01.JAA.0000451867.56072.e6. PMID: 25251656.

➔ Excluded after screening, short update

215: O'Kane GM, Lyons T, McDonald I, Mulligan N, Moloney FJ, Murray D, Kelly CM. Vismodegib in the treatment of advanced BCC. Ir Med J. 2014 Jul-Aug;107(7):215-6. PMID: 25226719.

➔ Excluded after screening, case of laBCC

216: Falto-Aizpurua L, Griffith RD, Abyaneh MY, Nouri K. Cells to surgery quiz: October 2014. J Invest Dermatol. 2014 Oct;134(10):1-2. doi: 10.1038/jid.2014.337. PMID: 25219654.

➔ Excluded after screening, photo quiz

217: Zutt M, Mazur F, Bergmann M, Lemke AJ, Kaune KM. Erfolgreiche Therapie eines metastasierten Basalzellkarzinoms mit Vismodegib [Successful therapy of metastatic basal cell carcinoma with vismodegib]. Hautarzt. 2014 Nov;65(11):974-7. German. doi: 10.1007/s00105-014-3503-y. PMID: 25217085.

➔ Excluded after screening, vismodegib for mBCC

218: Brinkhuizen T, Reinders MG, van Geel M, Hendriksen AJ, Paulussen AD, Winnepenninckx VJ, Keymeulen KB, Soetekouw PM, van Steensel MA, Mosterd K. Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol. 2014 Nov;71(5):1005-8. doi: 10.1016/j.jaad.2014.08.001. Epub 2014 Sep 4. PMID: 25199678.

➔ Excluded after screening, resistance in laBCC treated with vismodegib

219: Sehgal VN, Chatterjee K, Pandhi D, Khurana A. Basal cell carcinoma: pathophysiology. Skinmed. 2014 May-Jun;12(3):176-81. PMID: 25134314.

➔ Excluded after screening, review

220: Meani RE, Lim SW, Chang AL, Kelly JW. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449). Australas J Dermatol. 2014 Aug;55(3):218-21. doi: 10.1111/ajd.12196. PMID: 25117162.

➔ Excluded after screening, resistance in mBCC treated with vismodegib

221: Mohan SV, Chang AL. Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond. Semin Cutan Med Surg. 2014 Jun;33(2):68-71. doi: 10.12788/j.sder.0082. PMID: 25085664.

➔ Excluded after screening, review

222: Richey JD, Graham TA, Katona T, Travers JB. Development of trichodysplasia spinulosa: case report of a patient with Gorlin syndrome treated with vismodegib. JAMA Dermatol. 2014 Sep;150(9):1016-8. doi: 10.1001/jamadermatol.2013.9322. PMID: 25054782.

→ Excluded after eligibility assessment, does not describe BCC outcomes with vismodegib

223: Kaehler KC, Gutzmer R, Egberts F, Hauschild A. Regression of a basal cell carcinoma infiltrating the brain after vismodegib therapy. J Dtsch Dermatol Ges.

2014 Oct;12(10):906-7. doi: 10.1111/ddg.12342. Epub 2014 Jul 17. PMID: 25041591.

➔ Excluded after screening, aBCC treated with vismodegib

224: Ash MM, Jolly PS. Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety. Int J Dermatol. 2015 Mar;54(3):370-4. doi: 10.1111/ijd.12543. Epub 2014 Jul 11. PMID: 25039741.

➔ Excluded after screening, case report hepatotoxicity

225: Lyons TG, O'Kane GM, Kelly CM. Efficacy and safety of vismodegib : a new therapeutic agent in the treatment of basal cell carcinoma. Expert Opin Drug Saf. 2014 Aug;13(8):1125-32. doi: 10.1517/14740338.2014.939952. PMID: 25033383.

➔ Excluded after screening, review

226: Dreno B, Basset-Seguin N, Caro I, Yue H, Schadendorf D. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist. 2014 Aug;19(8):790-6. doi: 10.1634/theoncologist.2014-0003. Epub 2014 Jul 7. PMID: 25001266; PMCID: PMC4122481.

➔ Excluded after screening, clinical benefit of aBCCs treated in ERIVANCE trial

227: Atwood SX, Whitson RJ, Oro AE. Advanced treatment for basal cell carcinomas. Cold Spring Harb Perspect Med. 2014 Jul 1;4(7):a013581. doi: 10.1101/cshperspect.a013581. PMID: 24985127; PMCID: PMC4066644.

➔ Excluded after screening, review

228: Saintes C, Saint-Jean M, Brocard A, Peuvrel L, Renaut JJ, Khammari A, Quéreux G, Dréno B. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib. J Eur Acad Dermatol Venereol. 2015 May;29(5):1006-9. doi: 10.1111/jdv.12526. Epub 2014 Jul 1. PMID: 24980899.

➔ Excluded after screening, well-known adverse event not confirmed in large cohort

229: Berking C, Hauschild A, Kölbl O, Mast G, Gutzmer R. Basal cell carcinoma-treatments for the commonest skin cancer. Dtsch Arztebl Int. 2014 May

30;111(22):389-95. doi: 10.3238/arztebl.2014.0389. PMID: 24980564; PMCID: PMC4078227.

➔ Excluded after screening, review

230: Peris K, Tambone S, Kostaki D, Varrassi E, Fargnoli MC. Treatments of advanced basal cell carcinoma: a review of the literature. G Ital Dermatol Venereol. 2016 Feb;151(1):77-86. Epub 2014 Jun 30. PMID: 24975948.

➔ Excluded after screening, review

231: Dessinioti C, Plaka M, Stratigos AJ. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial. Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50. PMID: 24941979.

➔ Excluded after screening, opinion

232: Martín-Gorgojo A, Pastushenko I. New perspectives in the management of basal cell carcinoma. Actas Dermosifiliogr. 2014 Nov;105(9):874-5. English, Spanish. doi: 10.1016/j.ad.2014.04.007. Epub 2014 Jun 14. PMID: 24934656.

➔ Excluded after screening, review

233: Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, Oro A, Kim J, Chang AL, Tang JY. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014 Nov;71(5):904-911.e1. doi: 10.1016/j.jaad.2014.05.020. Epub 2014 Jun 11. PMID: 24929884.

➔ Duplicate (clinicaltrials.gov)

234: Maier T, Kulichova D, Ruzicka T, Berking C. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression. J Am Acad Dermatol. 2014 Oct;71(4):725-30. doi: 10.1016/j.jaad.2014.04.007. Epub 2014 Jun 11. PMID: 24928708.

➔ Excluded after screening, RCM and OCT for morphologic changes in BCC treated with sonidegib/vismodegib

235: Juhasz ML, Marmur ES. Systematic review of vismodegib toxicity profile in the treatment of advanced basal cell carcinomas compared to other systemic therapies in dermatology. J Drugs Dermatol. 2014 Jun;13(6):729-33. PMID: 24918565.

➔ Excluded after screening, review

236: Zhu GA, Li AS, Chang AL. Patient with Gorlin syndrome and metastatic basal cell carcinoma refractory to smoothened inhibitors. JAMA Dermatol. 2014 Aug;150(8):877-9. doi: 10.1001/jamadermatol.2013.8744. PMID: 24898076.

➔ Excluded after eligibility assessment, BCNS patients with multiple BCCs does not report on reoccurence/resistance/dosing regiment/QoL

237: Strasswimmer J, Latimer B, Ory S. Amenorrhea secondary to a vismodegib-induced blockade of follicle-stimulating hormone-receptor activation. Fertil Steril. 2014 Aug;102(2):555-7. doi: 10.1016/j.fertnstert.2014.04.045. Epub 2014 Jun 2. PMID: 24890268.

➔ Excluded after screening, case report of adverse event

238: Gould SE, Low JA, Marsters JC Jr, Robarge K, Rubin LL, de Sauvage FJ, Sutherlin DP, Wong H, Yauch RL. Discovery and preclinical development of vismodegib. Expert Opin Drug Discov. 2014 Aug;9(8):969-84. doi: 10.1517/17460441.2014.920816. Epub 2014 May 23. PMID: 24857041.

➔ Excluded after screening, review

239: Maly TJ, Sligh JE. Defining locally advanced Basal cell carcinoma. J Drugs Dermatol. 2014 May;13(5):528-9. PMID: 24809873.

➔ Excluded after screening, opinion on laBCC

240: Meiss F, Zeiser R. Vismodegib. Recent Results Cancer Res. 2014;201:405-17. doi: 10.1007/978-3-642-54490-3_25. PMID: 24756807.

➔ Excluded after screening, review

241: Zhu GA, Sundram U, Chang AL. Two different scenarios of squamous cell

carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. JAMA Dermatol. 2014 Sep;150(9):970-3. doi: 10.1001/jamadermatol.2014.583. PMID: 24740281.

➔ Excluded after screening, resistance of laBCC treated with vismodegib appeared to be squamous cell carcinoma

242: Gathings RM, Orscheln CS, Huang WW. Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin. J Am Acad Dermatol. 2014 Apr;70(4):e88-e89. doi: 10.1016/j.jaad.2013.11.032. PMID: 24629372.

➔ Excluded after screening, review

243: Ally MS, Tang JY, Joseph T, Thompson B, Lindgren J, Raphael MA, Ulerio G, Chanana AM, Mackay-Wiggan JM, Bickers DR, Epstein EH Jr. The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndrome. JAMA Dermatol. 2014 May;150(5):542-5. doi: 10.1001/jamadermatol.2013.7444. PMID: 24623282; PMCID: PMC4024084.

➔ Excluded after screening, effect of vismodegib on odontogenic keratocysts

244: Ruiz Salas V, Alegre M, Garcés JR, Puig L. Locally advanced and metastatic basal cell carcinoma: molecular pathways, treatment options and new targeted therapies. Expert Rev Anticancer Ther. 2014 Jun;14(6):741-9. doi: 10.1586/14737140.2014.895326. Epub 2014 Mar 10. PMID: 24611655.

➔ Excluded after screening, review

245: Wu C, Gudivada RC, Aronow BJ, Jegga AG. Computational drug repositioning through heterogeneous network clustering. BMC Syst Biol. 2013;7 Suppl 5(Suppl 5):S6. doi: 10.1186/1752-0509-7-S5-S6. Epub 2013 Dec 9. PMID: 24564976; PMCID: PMC4029299.

➔ Excluded after screening, computational research

246: Abidi A. Hedgehog signaling pathway: a novel target for cancer therapy:

vismodegib, a promising therapeutic option in treatment of basal cell carcinomas. Indian J Pharmacol. 2014 Jan-Feb;46(1):3-12. doi: 10.4103/0253-7613.124884. PMID: 24550577; PMCID: PMC3912804.

➔ Excluded after screening, review

247: Lam T, Wolverton SE, Davis CL. Drug hypersensitivity syndrome in a patient receiving vismodegib. J Am Acad Dermatol. 2014 Mar;70(3):e65-6. doi: 10.1016/j.jaad.2013.11.018. PMID: 24528922.

➔ Excluded after screening, case report on rare adverse event

248: Kunstfeld R. Smoothened inhibitors in the treatment of advanced basal cell carcinomas. Curr Opin Oncol. 2014 Mar;26(2):184-95. doi: 10.1097/CCO.0000000000000058. PMID: 24469022.

➔ Excluded after screening, review

249: Orouji A, Goerdt S, Utikal J, Leverkus M. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. Br J Dermatol. 2014 Aug;171(2):431-3. doi: 10.1111/bjd.12840. Epub 2014 Aug 2. PMID: 24446722.

➔ Excluded after screening, well-known adverse event not confirmed in large cohort

250: Ruiz-Salas V, Alegre M, López-Ferrer A, Garcés JR. Vismodegib: a review. Actas Dermosifiliogr. 2014 Oct;105(8):744-51. English, Spanish. doi: 10.1016/j.ad.2013.09.012. Epub 2013 Dec 18. PMID: 24359667.

➔ Excluded after screening, review

251: Proctor AE, Thompson LA, O'Bryant CL. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma. Ann Pharmacother. 2014 Jan;48(1):99-106. doi: 10.1177/1060028013506696. Epub 2013 Oct 15. PMID: 24259609.

➔ Excluded after screening, review

252: Amin SH, Motamedi KK, Ochsner MC, Song TE, Hybarger CP. Mechanisms and

efficacy of vismodegib in the treatment of basal cell carcinoma. Discov Med. 2013 Nov;16(89):229-32. PMID: 24229739.

➔ Excluded after screening, review

253: Hamid O, Goldenberg G. Identifying patients at risk for recurrent or advanced BCC. J Drugs Dermatol. 2013 Nov;12(11):1246-52; quiz 1253-4. PMID: 24196332.

➔ Excluded after screening, review

254: Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, Chen DM, Weiss GJ. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012. Epub 2013 Nov 1. PMID: 24189279.

➔ Excluded after eligibility assessment, no data on multiple BCC outcome

255: Gill HS, Moscato EE, Chang AL, Soon S, Silkiss RZ. Vismodegib for periocular and orbital basal cell carcinoma. JAMA Ophthalmol. 2013 Dec;131(12):1591-4. doi: 10.1001/jamaophthalmol.2013.5018. PMID: 24136169.

➔ Excluded after screening, vismodegib for laBCC

256: Sobanko JF, Okman J, Miller C. Vismodegib: a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas. J Drugs Dermatol. 2013 Oct;12(10 Suppl):s154-5. PMID: 24085062.

➔ Excluded after screening, review

257: Haves AW, Schaffer PR, Carucci JA. The impact of inoperable advanced basal cell carcinoma: the economic, physical, and psychological burden of the disease. J Drugs Dermatol. 2013 Oct;12(10 Suppl):s151-3. PMID: 24085061.

➔ Excluded after screening, review

258: Bayers S, Kapp DL, Beer KR, Slavin B. Treatment of margin positive basal

cell carcinoma with vismodegib: case report and consideration of treatment options and their implications. J Drugs Dermatol. 2013 Oct;12(10 Suppl):s147-50. PMID: 24085060.

➔ Excluded after screening, case report of vismodegib for laBCC

259: Goldenberg G, Hamid O. Understanding BCC pathogenesis: treatment advancements and challenges. J Drugs Dermatol. 2013 Oct;12(10):1110-20. PMID: 24085046.

➔ Excluded after screening, review

260: Kahana A, Worden FP, Elner VM. Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma. JAMA Ophthalmol. 2013 Oct;131(10):1364-6. doi: 10.1001/jamaophthalmol.2013.4430. PMID: 23907144; PMCID: PMC4104203.

➔ Excluded after screening, vismodegib for laBCC

261: Gonnissen A, Isebaert S, Haustermans K. Hedgehog signaling in prostate cancer and its therapeutic implication. Int J Mol Sci. 2013 Jul 4;14(7):13979-4007. doi: 10.3390/ijms140713979. PMID: 23880852; PMCID: PMC3742228.

➔ Excluded after screening, different disease studied

262: Aldabagh B, Yu J, Perkocha LA, Arron S. Histologic changes in basal cell carcinoma after treatment with vismodegib. Dermatol Surg. 2013 Nov;39(11):1703-5. doi: 10.1111/dsu.12281. Epub 2013 Jul 23. PMID: 23879864.

➔ Excluded after screening, histologic changes of BCC after vismodegib

263: Walls B. Basal cell carcinoma: hedgehog pathway inhibitors and beyond. Cutis. 2013 Jun;91(6):E1-4. PMID: 23837158.

➔ Excluded after screening, review

264: Iarrobino A, Messina JL, Kudchadkar R, Sondak VK. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma

with vismodegib. J Am Acad Dermatol. 2013 Jul;69(1):e33-4. doi: 10.1016/j.jaad.2013.01.023. PMID: 23768306.

➔ Excluded after screening, well-known adverse event not confirmed in large cohort

265: Lam C, Ou JC, Billingsley EM. "PTCH"-ing it together: a basal cell nevus syndrome review. Dermatol Surg. 2013 Nov;39(11):1557-72. doi: 10.1111/dsu.12241. Epub 2013 May 31. PMID: 23725561.

➔ Excluded after screening, review

266: Wolodarski M, Lapins J, Hansson J. Hedgehoghämmare. Ny lovande behandling av avancerad basalcellscancer [Hedgehog inhibitors. New promising treatment of advanced basal cell carcinoma]. Lakartidningen. 2013 Apr 24-May 6;110(17-18):886-8. Swedish. PMID: 23717940.

➔ Excluded after screening, editorial

267: Liu LS, Colegio OR. Molecularly targeted therapies for nonmelanoma skin cancers. Int J Dermatol. 2013 Jun;52(6):654-65. doi: 10.1111/ijd.12017. PMID: 23679874.

➔ Excluded after screening, review

268: Chang AL, Atwood SX, Tartar DM, Oro AE. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome. JAMA Dermatol. 2013 May;149(5):639-41. doi: 10.1001/jamadermatol.2013.30. PMID: 23677114; PMCID: PMC4006072.

➔ Excluded after screening, vismodegib as neoadjuvant treatment

269: Harms KL, Dlugosz AA. Harnessing hedgehog for the treatment of basal cell carcinoma. JAMA Dermatol. 2013 May;149(5):607-8. doi: 10.1001/jamadermatol.2013.448. PMID: 23677088.

➔ Excluded after screening, editorial

270: Dreier J, Felderer L, Barysch M, Rozati S, Dummer R. Basal cell carcinoma:

a paradigm for targeted therapies. Expert Opin Pharmacother. 2013 Jul;14(10):1307-18. doi: 10.1517/14656566.2013.798644. Epub 2013 May 8. PMID: 23656611.

➔ Excluded after screening, review

271: Geeraert P, Williams JS, Brownell I. Targeting the hedgehog pathway to treat basal cell carcinoma. J Drugs Dermatol. 2013 May;12(5):519-23. PMID: 23652945.

➔ Excluded after screening, review

272: Dubey AK, Dubey S, Handu SS, Qazi MA. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma. J Postgrad Med. 2013 Jan-Mar;59(1):48-50. doi: 10.4103/0022-3859.109494. PMID: 23525058.

➔ Excluded after screening, review

273: Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, Kufrin D, Palmby T, Dong Z, Russell AM, Miksinski S, Keegan P, Pazdur R. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013 May 1;19(9):2289-93. doi: 10.1158/1078-0432.CCR-12-1956. Epub 2013 Mar 20. PMID: 23515405.

➔ Excluded after screening, approval publication

274: Reinders MG, Dirix L, Mosterd K, van Doorn R. Vismodegib bij een gemetastaseerd basaalcelcarcinoom [Vismodegib in metastasized basal cell carcinoma]. Ned Tijdschr Geneeskd. 2013;157(12):A6011. Dutch. PMID: 23515044.

➔ Excluded after screening, vismodegib for mBCC

275: Ali FR, Lear JT. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC. Br J Dermatol. 2013 Jul;169(1):53-7. doi: 10.1111/bjd.12311. PMID: 23488543.

➔ Excluded after screening, review

276: Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular

basal cell carcinoma and squamous cell carcinoma. Ophthalmic Plast Reconstr Surg. 2013 Mar-Apr;29(2):87-92. doi: 10.1097/IOP.0b013e3182831bf3. PMID: 23446297; PMCID: PMC3878052.

➔ Excluded after screening, treatment for laBCC

277: Aasi S, Silkiss R, Tang JY, Wysong A, Liu A, Epstein E, Oro AE, Chang AL. New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol. 2013 Feb;149(2):242-3. doi: 10.1001/jamadermatol.2013.1798. PMID: 23426496; PMCID: PMC3768013.

➔ Excluded after screening, well-known adverse event not confirmed in large cohort

278: Thacker CA, Weiss GJ, Tibes R, Blaydorn L, Downhour M, White E, Baldwin J, Hoff DD, Korn RL. 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib. Cancer Med. 2012 Oct;1(2):230-6. doi: 10.1002/cam4.33. Epub 2012 Sep 17. PMID: 23342272; PMCID: PMC3544445.

➔ Excluded after screening, different research topic

279: Lyseng-Williamson KA, Keating GM. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma. Am J Clin Dermatol. 2013 Feb;14(1):61-4. doi: 10.1007/s40257-012-0004-6. PMID: 23329081.

➔ Excluded after screening, vismodegib for aBCC

280: Kim J, Aftab BT, Tang JY, Kim D, Lee AH, Rezaee M, Kim J, Chen B, King EM, Borodovsky A, Riggins GJ, Epstein EH Jr, Beachy PA, Rudin CM. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell. 2013 Jan 14;23(1):23-34. doi: 10.1016/j.ccr.2012.11.017. Epub 2013 Jan 3. PMID: 23291299; PMCID: PMC3548977.

➔ Duplicate (clinicaltrials.gov)

281: Witte F. Basaliome mit neuen Medikamenten gezielt behandeln [A new drug for basal cell carcinoma]. Schweiz Monatsschr Zahnmed. 2013;123(12):1104-6. German.

PMID: 24730087.

➔ Excluded after screening, vismodegib for laBCC

282: Atwood SX, Chang AL, Oro AE. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol. 2012 Oct 15;199(2):193-7. doi: 10.1083/jcb.201207140. PMID: 23071148; PMCID: PMC3471227.

➔ Excluded after screening, review

283: Cirrone F, Harris CS. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Clin Ther. 2012 Oct;34(10):2039-50. doi: 10.1016/j.clinthera.2012.08.011. Epub 2012 Oct 1. PMID: 23036338.

➔ Excluded after screening, review

284: Kelleher FC, Cain JE, Healy JM, Watkins DN, Thomas DM. Prevailing importance of the hedgehog signaling pathway and the potential for treatment advancement in sarcoma. Pharmacol Ther. 2012 Nov;136(2):153-68. doi: 10.1016/j.pharmthera.2012.08.004. Epub 2012 Aug 11. PMID: 22906929.

➔ Excluded after screening, different disease

285: Dirix L, Rutten A. Vismodegib: a promising drug in the treatment of basal cell carcinomas. Future Oncol. 2012 Aug;8(8):915-28. doi: 10.2217/fon.12.82. PMID: 22894666.

➔ Excluded after screening, drug evaluation

286: Wilkes GM. Vismodegib, a hedgehog pathway inhibitor for adults with locally advanced or metastatic basal cell carcinoma. Oncology (Williston Park). 2012 Aug;26(8 Suppl Nurse Ed):31-3. PMID: 25375009.

➔ Excluded after screening, drug evaluation

287: Amaria RN, Bowles DW, Lewis KD, Jimeno A. Vismodegib in basal cell carcinoma. Drugs Today (Barc). 2012 Jul;48(7):459-67. doi: 10.1358/dot.2012.48.7.1808490. PMID: 22844657.

➔ Excluded after screening, review

288: Wolfe CM, Green WH, Cognetta AB Jr, Hatfield HK. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg. 2012 Nov;38(11):1863-6. doi: 10.1111/j.1524-4725.2012.02513.x. Epub 2012 Jul 17. PMID: 22805146.

➔ Included after eligibility assessment

289: Keating GM. Vismodegib: in locally advanced or metastatic basal cell carcinoma. Drugs. 2012 Jul 30;72(11):1535-41. doi: 10.2165/11209590-000000000-00000. PMID: 22788238.

➔ Excluded after screening, review

290: Vismodegib (Erivedge) for basal cell carcinoma. Med Lett Drugs Ther. 2012 Jul 9;54(1394):53-4. PMID: 22777303.

➔ Excluded after screening, drug report

291: Rudin CM. Vismodegib. Clin Cancer Res. 2012 Jun 15;18(12):3218-22. doi: 10.1158/1078-0432.CCR-12-0568. Epub 2012 Jun 7. PMID: 22679179; PMCID: PMC3715061.

➔ Excluded after screening, drug report

292: Lear JT. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med. 2012 Jun 7;366(23):2225-6. doi: 10.1056/NEJMe1202170. PMID: 22670909.

➔ Excluded after screening, editorial

293: Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, Coppola C, Chanana AM, Marji J, Bickers DR, Epstein EH Jr. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538. PMID: 22670904; PMCID: PMC4362529.

➔ Included after eligibility assessment, duplicate from clinicaltrials.gov

294: Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin CM, Chang AL, Low JA, Mackey HM, Yauch RL, Graham RA, Reddy JC, Hauschild A. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713. PMID: 22670903; PMCID: PMC5278761.

➔ Excluded after eligibility assessment, only outcomes for aBCC

295: Dlugosz A, Agrawal S, Kirkpatrick P. Vismodegib. Nat Rev Drug Discov. 2012 Jun 1;11(6):437-8. doi: 10.1038/nrd3753. PMID: 22653209; PMCID: PMC3383648.

➔ Excluded after screening, drug report

296: Vismodegib granted FDA approval for treatment of basal cell carcinoma. Oncology (Williston Park). 2012 Feb;26(2):174, 213. PMID: 22489352.

➔ Excluded after screening, drug report

297: Allison M. Hedgehog hopes lifted by approval... and stung by failure. Nat Biotechnol. 2012 Mar 7;30(3):203. doi: 10.1038/nbt0312-203. PMID: 22398601.

➔ Excluded after screening, drug report

298: Tang JY. Elucidating the role of molecular signaling pathways in the tumorigenesis of basal cell carcinoma. Semin Cutan Med Surg. 2011 Dec;30(4 Suppl):S6-9. doi: 10.1016/j.sder.2011.11.001. PMID: 22177103.

➔ Excluded after screening, review

299: Tang JY, Marghoob AA. Emerging treatments and signaling pathway inhibitors. Semin Cutan Med Surg. 2011 Dec;30(4 Suppl):S14-8. doi: 10.1016/j.sder.2011.11.002. PMID: 22177102.

➔ Excluded after screening, review

300: Metcalfe C, de Sauvage FJ. Hedgehog fights back: mechanisms of acquired resistance against Smoothened antagonists. Cancer Res. 2011 Aug 1;71(15):5057-61. doi: 10.1158/0008-5472.CAN-11-0923. Epub 2011 Jul 19. Erratum in: Cancer Res. 2011 Sep 15;71(18):6087. PMID: 21771911.

➔ Excluded after screening, review

301: O'Bryan KW, Ratner D. The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer. Semin Cutan Med Surg. 2011 Mar;30(1):57-61. doi: 10.1016/j.sder.2011.01.004. PMID: 21540021.

➔ Excluded after screening, review

302: Camp WL, Turnham JW, Athar M, Elmets CA. New agents for prevention of ultraviolet-induced nonmelanoma skin cancer. Semin Cutan Med Surg. 2011 Mar;30(1):6-13. doi: 10.1016/j.sder.2011.01.003. PMID: 21540016; PMCID: PMC3488433.

➔ Excluded after screening, review

303: Goldberg LH, Landau JM, Moody MN, Kazakevich N, Holzer AM, Myers A. Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449. Arch Dermatol. 2011 Jul;147(7):839-41. doi: 10.1001/archdermatol.2011.50. Epub 2011 Mar 21. PMID: 21422324.

➔ Excluded after screening, reports on response of odontogenic keratocysts to vismodegib

304: Watson S, Serrate C, Vignot S. Voie de signalisation Sonic Hedgehog : du développement embryonnaire aux thérapies moléculaires ciblées [Sonic Hedgehog signaling pathway: from embryology to molecular targeted therapies]. Bull Cancer. 2010 Dec;97(12):1477-83. French. doi: 10.1684/bdc.2010.1231. PMID: 21220225.

➔ Excluded after screening, review

305: Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol. 2010 Dec 20;28(36):5321-6. doi: 10.1200/JCO.2010.27.9943. Epub 2010 Nov 1. PMID: 21041712.

➔ Excluded after screening, review

306: Amin SH, Tibes R, Kim JE, Hybarger CP. Hedgehog antagonist GDC-0449 is effective in the treatment of advanced basal cell carcinoma. Laryngoscope. 2010

Dec;120(12):2456-9. doi: 10.1002/lary.21145. PMID: 20927781.

➔ Excluded after screening, vismodegib for laBCC

307: Vidal V. Les inhibiteurs de la voie Hedgehog : un espoir pour le traitement des carcinomes basocellulaires [Inhibitors of the Hedgehog signalling pathway: hope for the treatment of basal cell carcinoma]. Med Sci (Paris). 2010 Mar;26(3):231-3. French. doi: 10.1051/medsci/2010263231. PMID: 20346268.

➔ Excluded after screening, editorial

308: Dierks C. GDC-0449--targeting the hedgehog signaling pathway. Recent Results Cancer Res. 2010;184:235-8. doi: 10.1007/978-3-642-01222-8_17. PMID: 20072843.

➔ Excluded after screening, review

309: Kean S. Medicine. Disrupting Hedgehog may reverse advanced cancer, if only temporarily. Science. 2009 Sep 4;325(5945):1188. doi: 10.1126/science.325_1188. PMID: 19729622.

➔ Excluded after screening, reports on resistance in aBCC

310: Dlugosz AA, Talpaz M. Following the hedgehog to new cancer therapies. N Engl J Med. 2009 Sep 17;361(12):1202-5. doi: 10.1056/NEJMe0906092. Epub 2009 Sep 2. PMID: 19726764.

➔ Excluded after screening, editorial

311: Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC, Marsters JC Jr, de Sauvage FJ, Low JA. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009 Sep 17;361(12):1164-72. doi: 10.1056/NEJMoa0905360. Epub 2009 Sep 2. PMID: 19726763.

➔ Excluded after eligibility assessment, only outcomes for aBCC

312: Robarge KD, Brunton SA, Castanedo GM, Cui Y, Dina MS, Goldsmith R, Gould SE, Guichert O, Gunzner JL, Halladay J, Jia W, Khojasteh C, Koehler MF, Kotkow

K, La H, Lalonde RL, Lau K, Lee L, Marshall D, Marsters JC Jr, Murray LJ, Qian C, Rubin LL, Salphati L, Stanley MS, Stibbard JH, Sutherlin DP, Ubhayaker S, Wang S, Wong S, Xie M. GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett. 2009 Oct 1;19(19):5576-81. doi: 10.1016/j.bmcl.2009.08.049. Epub 2009 Aug 15. Erratum in: Bioorg Med Chem Lett. 2010 Jan 15;20(2):771. PMID: 19716296.

➔ Excluded after screening, erratum

("HhAntag691" [Supplementary Concept]) AND "Basal Cell Nevus Syndrome"[Mesh] → 43 results

N=0 unique results, n= 0 inclusions

("Basal cell carcinoma, multiple" [Supplementary Concept]) AND "HhAntag691" [Supplementary Concept] → 6 results

N= 0 unique results, n= 0 inclusions

("sonidegib" [Supplementary Concept]) AND "Carcinoma, Basal Cell"[Mesh] → 62 results

N=32 duplicates, N= 30 unique results, n= inclusions

1: Fania L, Dellambra E, Moretta G, Grilli E, Di Rocco CZ, Morelli FM, Zappalà AR, Abeni D, Morese R. Efficacy of sonidegib for basal cell carcinoma in a patient affected by multiple infectious diseases. Dermatol Ther. 2021 Jul;34(4):e14969. doi: 10.1111/dth.14969. Epub 2021 May 9. PMID: 33928734.

➔ Excluded after eligibility assessment, only reported on laBCC outcomes

2: Moscarella E, Brancaccio G, Briatico G, Ronchi A, Verolino P, Argenziano G, Alfano R. Management of advanced basal cell carcinoma: Real-life data with sonidegib. Dermatol Ther. 2021 May;34(3):e14948. doi: 10.1111/dth.14948. Epub 2021 Mar 23. PMID: 33728757.

➔ Excluded after eligibility assessment, only reported on laBCC outcomes

3: Villani A, Fabbrocini G, Costa C, Scalvenzi M. Response to "Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT) trial at 42 months". J Am Acad Dermatol. 2021

Jun;84(6):e299-e300. doi: 10.1016/j.jaad.2021.02.074. Epub 2021 Mar 4. PMID: 33677004.

➔ Excluded after eligibility assessment, only reported on laBCC outcomes

5: Hoffmann V, Husak R, Maiwirth F, Sasama B, Zahn A, Guski S, Peitsch WK. Sonidegib in a patient with multiple basal cell carcinomas and HIV infection. J Dtsch Dermatol Ges. 2021 Apr;19(4):592-594. doi: 10.1111/ddg.14355. Epub 2021 Jan 14. PMID: 33448149.

➔ Included after eligibility assessment, case report on sonidegib for patient with multiple basal cell carcinomas

6: Dummer R, Lear JT, Guminski A, Leow LJ, Squittieri N, Migden M. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months. J Am Acad Dermatol. 2021 Apr;84(4):1162-1164. doi: 10.1016/j.jaad.2020.08.042. Epub 2020 Dec 24. PMID: 33358380.

➔ Excluded after eligibility assessment, no outcomes reported on multiple BCC/BCNS

7: Villani A, Costa C, Fabbrocini G, Ruggiero A, Scalvenzi M. Dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor sonidegib to manage adverse effects: A retrospective case series. J Am Acad Dermatol. 2021 Apr;84(4):e211-e212. doi: 10.1016/j.jaad.2020.12.006. Epub 2020 Dec 7. PMID: 33301802.

➔ Excluded after screening, sonidegib for laBCC

8: Sanmartín O, Llombart B, Carretero Hernández G, Flórez Menéndez Á, Botella-Estrada R, Herrera Ceballos E, Puig S. Sonidegib in the Treatment of Locally Advanced Basal Cell Carcinoma. Actas Dermosifiliogr (Engl Ed). 2021 Apr;112(4):295-301. English, Spanish. doi: 10.1016/j.ad.2020.11.002. Epub 2020 Nov 13. PMID: 33197438.

➔ Excluded after screening, sonidegib for laBCC

9: Conforti C, Giuffrida R, Di Meo N, Zalaudek I. Management of locally advanced basal cell carcinoma treated with sonidegib: The experience of an Italian reference hospital. Dermatol Ther. 2020 Nov;33(6):e14511. doi: 10.1111/dth.14511. Epub 2020 Nov 17. PMID: 33166006.

➔ Excluded after screening, sonidegib for laBCC

11: Villani A, Fabbrocini G, Costa C, Scalvenzi M. Complete remission of an advanced basal cell carcinoma after only 3-month treatment with sonidegib: Report of a case and drug management during COVID-19 pandemic. Dermatol Ther. 2020 Nov;33(6):e14200. doi: 10.1111/dth.14200. Epub 2020 Sep 14. PMID: 32870541.

➔ Excluded after screening, sonidegib for laBCC

14: Hou X, Rokohl AC, Ortmann M, Heindl LM. Effective treatment of locally advanced periocular basal cell carcinoma with oral hedgehog pathway inhibitor? Graefes Arch Clin Exp Ophthalmol. 2020 Oct;258(10):2335-2337. doi: 10.1007/s00417-020-04779-5. Epub 2020 Jun 9. PMID: 32514773; PMCID: PMC7550312.

➔ Excluded after screening, case report on sonidegib for laBCC

17: Fife K. Hedgehog pathway inhibitors come of age. Br J Dermatol. 2020 Jun;182(6):1322-1323. doi: 10.1111/bjd.18737. Epub 2019 Dec 17. PMID: 31849041.

➔ Excluded after screening, commentary

19: Dummer R, Guminksi A, Gutzmer R, Lear JT, Lewis KD, Chang ALS, Combemale P, Dirix L, Kaatz M, Kudchadkar R, Loquai C, Plummer R, Schulze HJ, Stratigos AJ, Trefzer U, Squittieri N, Migden MR. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020 Jun;182(6):1369-1378. doi: 10.1111/bjd.18552. Epub 2019 Dec 8. PMID: 31545507; PMCID: PMC7318253.

➔ Excluded after eligibility assessment, no outcomes reported on multiple BCC/BCNS

27: Gupta AK, Mays RR, Abramovits W, Vincent KD. Odomzo® (Sonidegib). Skinmed. 2018 Feb 1;16(1):35-38. PMID: 29551110.

➔ Excluded after screening, approval publication

28: Tran DC, Moffat A, Brotherton R, Pague A, Zhu GA, Chang ALS. An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas. J Am Acad Dermatol. 2018 May;78(5):1011-1013.e3. doi: 10.1016/j.jaad.2017.11.031. Epub 2017 Nov 23. PMID: 29175429.

➔ Duplicate (clinicaltrials.gov)

29: Kumari A, Ermilov AN, Grachtchouk M, Dlugosz AA, Allen BL, Bradley RM, Mistretta CM. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib. Proc Natl Acad Sci U S A. 2017 Nov 28;114(48):E10369-E10378. doi: 10.1073/pnas.1712881114. Epub 2017 Nov 13. PMID: 29133390; PMCID: PMC5715770.

➔ Excluded after eligibility assessment, research on cells/molecular research

30: Chen L, Aria AB, Silapunt S, Lee HH, Migden MR. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Future Oncol. 2018 Mar;14(6):515-525. doi: 10.2217/fon-2017-0457. Epub 2017 Nov 9. PMID: 29119833.

➔ Excluded after eligibility assessment, no outcomes reported on multiple BCC/BCNS

31: Shord SS, Casey D, Zhao H, Demko S, Keegan P, Pazdur R. FDA Approval Summary: Sonidegib-Response. Clin Cancer Res. 2017 Oct 1;23(19):5994. doi: 10.1158/1078-0432.CCR-17-2135. PMID: 28972086.

➔ Excluded after screening, approval publication

32: Gyawali B, Ando Y. FDA Approval Summary: Sonidegib-Letter. Clin Cancer Res. 2017 Oct 1;23(19):5993. doi: 10.1158/1078-0432.CCR-17-1460. PMID: 28972085.

➔ Excluded after screening, approval publication

34: Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, Dirix L, Combemale P, Stratigos A, Plummer R, Castro H, Yi T, Mone M, Zhou J, Trefzer U,

Kaatz M, Loquai C, Kudchadkar R, Sellami D, Dummer R. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):372-381. doi: 10.1111/jdv.14542. Epub 2017 Nov 6. PMID: 28846163; PMCID: PMC5873455.

➔ Excluded after eligibility assessment, no outcomes reported on multiple BCC/BCNS

37: Casey D, Demko S, Shord S, Zhao H, Chen H, He K, Putman A, Helms W, Keegan P, Pazdur R. FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. Clin Cancer Res. 2017 May 15;23(10):2377-2381. doi: 10.1158/1078-0432.CCR-16-2051. Epub 2017 Jan 10. PMID: 28073840.

➔ Excluded after screening, approval publication

38: Shokeen D. Update on new drugs in dermatology. Cutis. 2016 Nov;98(5):E26-E27. PMID: 28040823.

➔ Excluded after screening, approval publication

39: Sonidegib (Odomzo°) and extensive basal cell carcinoma. Prescrire Int. 2017 Jan;26(178):14-15. PMID: 30730637.

➔ Excluded after screening, approval publication

40: Collier NJ, Ali FR, Lear JT. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. Expert Rev Anticancer Ther. 2016 Oct;16(10):1011-8. doi: 10.1080/14737140.2016.1230020. Epub 2016 Sep 22. PMID: 27636236.

➔ Excluded after screening, review

41: Ramelyte E, Amann VC, Dummer R. Sonidegib for the treatment of advanced basal cell carcinoma. Expert Opin Pharmacother. 2016 Oct;17(14):1963-8. doi: 10.1080/14656566.2016.1225725. Epub 2016 Aug 29. PMID: 27538055.

➔ Excluded after screening, review

43: Tibes R. Sonidegib phosphate: new approval for basal cell carcinoma. Drugs

Today (Barc). 2016 May;52(5):295-303. doi: 10.1358/dot.2016.52.5.2470697. PMID: 27376162.

➔ Excluded after screening, approval publication

44: Chen L, Silapunt S, Migden MR. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncol. 2016 Sep;12(18):2095-105. doi: 10.2217/fon-2016-0118. Epub 2016 May 18. PMID: 27189494.

➔ Excluded after screening, review

46: Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Gogov S, Pallaud C, Yi T, Mone M, Chang AL, Cornélis F, Kudchadkar R, Trefzer U, Lear JT, Sellami D, Migden MR. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5. doi: 10.1016/j.jaad.2016.02.1226. Epub 2016 Apr 7. PMID: 27067394.

➔ Excluded after eligibility assessment, no outcomes reported on multiple BCC/BCNS

47: Sonidegib (Odomzo) for basal cell carcinoma. Med Lett Drugs Ther. 2016 Feb 29;58(1489):31-2. PMID: 26938701.

➔ Excluded after screening, approval publication

49: Burness CB, Scott LJ. Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma. Target Oncol. 2016 Apr;11(2):239-46. doi: 10.1007/s11523-016-0418-9. PMID: 26867946.

➔ Excluded after screening, review

54: Burness CB. Sonidegib: First Global Approval. Drugs. 2015 Sep;75(13):1559-66. doi: 10.1007/s40265-015-0458-y. PMID: 26323341.

➔ Excluded after screening, approval publication

55: Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Gogov S, Pallaud C, Yi T, Mone M, Kaatz M, Loquai C, Stratigos AJ, Schulze HJ, Plummer R, Chang AL, Cornélis F, Lear JT, Sellami D, Dummer R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015 Jun;16(6):716-28. doi: 10.1016/S1470-2045(15)70100-2. Epub 2015 May 14. PMID: 25981810.

➔ Excluded after eligibility assessment, no reported outcomes on multiple BCC/BCNS

59: Rodon J, Tawbi HA, Thomas AL, Stoller RG, Turtschi CP, Baselga J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L, Granvil C, Hurh E, Rose KL, Amakye DD, Dummer R, Mita AC. A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res. 2014 Apr 1;20(7):1900-9. doi: 10.1158/1078-0432.CCR-13-1710. Epub 2014 Feb 12. PMID: 24523439.

➔ Duplicate (clinicaltrials.gov)

62: Skvara H, Kalthoff F, Meingassner JG, Wolff-Winiski B, Aschauer H, Kelleher JF, Wu X, Pan S, Mickel L, Schuster C, Stary G, Jalili A, David OJ, Emotte C, Antunes AM, Rose K, Decker J, Carlson I, Gardner H, Stuetz A, Bertolino AP, Stingl G, De Rie MA. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol. 2011 Aug;131(8):1735-44. doi: 10.1038/jid.2011.48. Epub 2011 Mar 24. PMID: 21430703.

➔ Duplicate (clinicaltrials.gov) included

("Basal Cell Nevus Syndrome"[Mesh]) AND "sonidegib" [Supplementary Concept] → 2 results

N= 2 duplicates, n=0 unique results, n=0 inclusions

("sonidegib" [Supplementary Concept]) AND "Basal cell carcinoma, multiple" [Supplementary Concept] → 1 result

N=1 duplicate, n= 0 unique results, n=0 inclusions

("IPI-926" [Supplementary Concept]) AND "Carcinoma, Basal Cell"[Mesh] → 1 result

N=1 duplicate, n= 0 unique results, n=0 inclusions

"IPI-926" [Supplementary Concept] AND "Basal cell carcinoma, multiple" [Supplementary Concept] → 0 results

("Basal Cell Nevus Syndrome"[Mesh]) AND "IPI-926" [Supplementary Concept] → 1 result

N=1 duplicate, n= 0 unique results, n=0 inclusions

("Itraconazole"[Mesh]) AND "Carcinoma, Basal Cell"[Mesh] → 13 results

N= 6 duplicates, n=7 unique results, n= inclusions

1: Ciążyńska M, Narbutt J, Skibińska M, Lesiak A. Itraconazole-A New Player in the Therapy of Advanced Basal Cell Carcinoma: A Case Report. JCO Oncol Pract. 2020 Dec;16(12):837-838. doi: 10.1200/OP.20.00273. Epub 2020 Aug 19. PMID: 32813585.

→ Excluded after screening, itraconazole for laBCC

2: D'Arcy ME, Pfeiffer RM, Rivera DR, Hess GP, Cahoon EK, Arron ST, Brownell I, Cowen EW, Israni AK, Triplette MA, Yanik EL, Engels EA. Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States. JAMA Dermatol. 2020 Jul 1;156(7):772-779. doi: 10.1001/jamadermatol.2020.1141. PMID: 32401271; PMCID: PMC7221851.

→ Excluded after screening, different population

4: Gupta H, Tankhiwale SS. A case of bilateral eyelid histoplasmosis mistaken as basal cell carcinoma. Can J Ophthalmol. 2017 Apr;52(2):e45-e46. doi:

10.1016/j.jcjo.2016.11.030. Epub 2017 Jan 10. PMID: 28457299.

➔ Excluded after screening, different disease

7: Piérard-Franchimont C, Hermanns-Lê T, Paquet P, Herfs M, Delvenne P, Piérard GE. Hedgehog- and mTOR-targeted therapies for advanced basal cell carcinomas. Future Oncol. 2015 Nov;11(22):2997-3002. doi: 10.2217/fon.15.181. Epub 2015 Oct 5. PMID: 26437034.

➔ Excluded after screening, review

9: Dirix L. Discovery and exploitation of novel targets by approved drugs. J Clin Oncol. 2014 Mar 10;32(8):720-1. doi: 10.1200/JCO.2013.53.7118. Epub 2014 Feb 3. PMID: 24493724.

➔ Excluded after screening, editorial

10: Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, Fu T, Gilliam A, Molgo M, Beachy PA, Tang JY. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014 Mar 10;32(8):745-51. doi: 10.1200/JCO.2013.49.9525. Epub 2014 Feb 3. PMID: 24493717.

➔ Duplicate (clinicaltrials.gov), included

12: Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, Chong CR, Chang KS, Fereshteh M, Gardner D, Reya T, Liu JO, Epstein EH, Stevens DA, Beachy PA. Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell. 2010 Apr 13;17(4):388-99. doi: 10.1016/j.ccr.2010.02.027. PMID: 20385363; PMCID: PMC4039177.

➔ Excluded after eligibility assessment, cell research

13: Manohar A, Nizlan MN. Chronic nonhealing ulcer of the right thumb with multiple subcutaneous nodules. Orthopedics. 2008 Jul;31(7):710. PMID: 19292371.

➔ Excluded after screening, different disease

("Basal Cell Nevus Syndrome"[Mesh]) AND "Itraconazole"[Mesh] → 0 results
N= 0 unique results, n=0 inclusions

("Itraconazole"[Mesh]) AND "Basal cell carcinoma, multiple" [Supplementary Concept] → 0 results
N= 0 unique results, n=0 inclusions

("Carcinoma, Basal Cell"[Mesh]) AND "BMS-833923" [Supplementary Concept] → 2 results

N=2 duplicates, n= 0 unique results, n=0 inclusions

("BMS-833923" [Supplementary Concept]) AND "Basal Cell Nevus Syndrome"[Mesh] → 1 result

N= 0 unique results, n=0 inclusions

("Basal cell carcinoma, multiple" [Supplementary Concept]) AND "BMS-833923" [Supplementary Concept] → 0 results
N= 0 unique results, n=0 inclusions

("Carcinoma, Basal Cell"[Mesh]) AND "NVP-LEQ506" [Supplementary Concept] → 0 results
N= 0 unique results, n=0 inclusions

("NVP-LEQ506" [Supplementary Concept]) AND "Basal Cell Nevus Syndrome"[Mesh] → 0 results
N= 0 unique results, n=0 inclusions

("Basal cell carcinoma, multiple" [Supplementary Concept]) AND "NVP-LEQ506" [Supplementary Concept] → 0 results
N= 0 unique results, n=0 inclusions

("Carcinoma, Basal Cell"[Mesh]) AND "TAK-441" [Supplementary Concept] → 0 results
N= 0 unique results, n=0 inclusions

("TAK-441" [Supplementary Concept]) AND "Basal Cell Nevus Syndrome"[Mesh] → 0 results
N= 0 unique results, n=0 inclusions

("TAK-441" [Supplementary Concept]) AND "Basal cell carcinoma, multiple" [Supplementary Concept] → 0 results
N= 0 unique results, n=0 inclusions

EMBASE VISMODEGIB AND BASAL CELL CARCINOMA

Database: Embase <1974 to 2021 Week 37>

Search Strategy:

---

1 basal cell carcinoma/ (28620)

2 vismodegib/ (2276)

3 1 and 2 (1074)

AND publication type: article (206)

****

Duplicates: 66

Screened:

Assesses:

Inclusion:

1.

Hedgehog inhibitors with and without adjunctive therapy in treatment of locally advanced basal cell carcinoma.

Patel A.D., Ravichandran S., Kheterpal M.

International Journal of Dermatology. (no pagination), 2021. Date of Publication: 2021.

[Article]

Publisher

John Wiley and Sons Inc

➔ Excluded after screening, treatment of laBCC

2.

Vismodegib for treatment of periocular basal cell carcinoma - 6-year experience from a tertiary cancer center.

Xavier C., Lopes E., Bexiga C., Moura C., Gouveia E., Duarte A.F.

Anais Brasileiros de Dermatologia. (no pagination), 2021. Date of Publication: 2021.

[Article]

Publisher

Elsevier Espana S.L.

➔ Excluded after screening, vismodegib for laBCC

3.

ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic.

Wang J., Zhang Y., Huang W.-J., Yang J., Tang W.-G., Huang T.-M., Tan W.-F.

Acta Pharmacologica Sinica. 42(6) (pp 1005-1013), 2021. Date of Publication: June 2021.

[Article]

Publisher

Springer Nature

➔ Excluded after screening, molecular research on new hedhehog pathway inhibitor

4.

Expert opinion on sonidegib efficacy, safety and tolerability.

Villani A., Fabbrocini G., Costa C., Ocampo-Garza S.S., Lallas A., Scalvenzi M.

Expert Opinion on Drug Safety. 20(8) (pp 877-882), 2021. Date of Publication: 2021.

[Article]

Publisher

Taylor and Francis Ltd.

➔ Excluded after screening, review

5.

Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis.

Gutzmer R., Loquai C., Robert C., Dreno B., Guminski A., Lewis K., Arntz R., Martelli S., Squittieri N., Kheterpal M.

Dermatology and Therapy. (no pagination), 2021. Date of Publication: 2021.

[Article]

Publisher

Adis

➔ Excluded after screening, vismodegib and sonidegib for laBCC

6.

Metastatic basal cell carcinoma: complete remission under vismodegib.

Wruhs M., Muin D., Stella A., Steiner A., Feldmann R.

JDDG - Journal of the German Society of Dermatology. (no pagination), 2021. Date of Publication: 2021.

[Letter]

Publisher

John Wiley and Sons Inc

➔ Excluded after screening, vismodegib for mBCC

7.

Familial multiple basaloid follicular hamartoma.

Cerejeira A., Gomes N., Pacheco J., Pedrosa A., Baudrier T., Azevedo F.

Dermatology Online Journal. 27(6) (no pagination), 2021. Article Number: A10. Date of Publication: 2021.

[Article]

Publisher

Dermatology Online Journal

➔ Excluded after screening, different disease and no hedgehog pathway inhibitor treatment

8.

Clinical determinants of complete response to vismodegib in locally advanced basal cell carcinoma: a multicentre experience.

Fargnoli M.C., Pellegrini C., Piccerillo A., Spallone G., Rocco T., Ventura A., Necozione S., Bianchi L., Peris K., Cortellini A.

Journal of the European Academy of Dermatology and Venereology. (no pagination), 2021. Date of Publication: 2021.

[Letter]

Publisher

John Wiley and Sons Inc

➔ Excluded after screening, vismodegib for laBCC

9.

Management of Advanced Basal Cell Carcinoma of the Head and Neck.

Monroe M., Kakarala K.

Otolaryngologic Clinics of North America. 54(2) (pp 271-280), 2021. Date of Publication: April 2021.

[Review]

Publisher

W.B. Saunders

➔ Excluded after screening, vismodegib for laBCC

11.

Non-Melanoma Skin Cancer in People Living With HIV: From Epidemiology to Clinical Management.

Venanzi Rullo E., Maimone M.G., Fiorica F., Ceccarelli M., Guarneri C., Berretta M., Nunnari G.

Frontiers in Oncology. 11 (no pagination), 2021. Article Number: 689789. Date of Publication: 04 Aug 2021.

[Review]

Publisher

Frontiers Media S.A.

➔ Excluded after screening, review on different topic

12.

Multiple non-syndromic basal cell carcinoma with the chest as primary site and lung metastases: A rare case.

Roditis K., Metaxas G., Neofotistou O., Papaparaskeva K., Koutsoumbi A., Louis K.

Dermatology Reports. 13(2) (no pagination), 2021. Article Number: 9106. Date of Publication: August 2021.

[Article]

Publisher

Page Press Publications

➔ Excluded after eligibility assessment, outcomes focuses on aBCC

13.

Diagnosis and management of skin cancer.

Craythorne E., Nicholson P.

Medicine (United Kingdom). 49(7) (pp 435-440), 2021. Date of Publication: July 2021.

[Review]

Publisher

Elsevier Ltd

➔ Excluded after screening, review

14.

A Brief Review of Treatment Modalities for Non-Melanoma Skin Cancer.

Shah H.

Asian Journal of Pharmaceutical and Clinical Research. 14(6) (pp 22-28), 2021. Date of Publication: June 2021.

[Review]

Publisher

Innovare Academics Sciences Pvt. Ltd

➔ Excluded after screening, review

15.

Immunotherapy in Xeroderma Pigmentosum: A case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review.

Rubatto M., Merli M., Avallone G., Agostini A., Mastorino L., Caliendo V., Barcellini A., Vitolo V., Valvo F., Fierro M.T., Ribero S., Quaglino P.

Oncotarget. 12(11) (pp 1116-1121), 2021. Date of Publication: 25 May 2021.

[Review]

Publisher

Impact Journals LLC

➔ Excluded after screening, different treatment

16.

27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: A report of 8 cases.

Castillo Molina D.A., Fierro Lozada J.D., Garcia C A.M., Molano Perez M.A., Avilez M.C., Guerrero-Roncancio L., Munoz-Ordonez S., Slebi I.C., Alvis-Zakzuk N.J., Castillo Saavedra D.E., Martinez Zuniga D.M.

Journal of the American Academy of Dermatology. Conference: 2021 AAD VMX Vertual Meeting. Virtual, Online. 85(3 Supplement) (pp AB131), 2021. Date of Publication: September 2021.

[Conference Abstract]

Publisher

Mosby Inc.

➔ Excluded after screening, combination therapy in laBCC

17.

26503 Efficacy of combined hedgehog inhibitors with and without adjunctive therapy in the treatment of locally advanced basal cell carcinoma.

Patel A.D., Ravichandran S., Kheterpal M.

Journal of the American Academy of Dermatology. Conference: 2021 AAD VMX Vertual Meeting. Virtual, Online. 85(3 Supplement) (pp AB103), 2021. Date of Publication: September 2021.

[Conference Abstract]

Publisher

Mosby Inc.

➔ Excluded after screening, combination therapy in laBCC

18.

Bekanntes und Neues zum Basalzellkarzinom.

Seidl-Philipp M., Frischhut N., Hollweger N., Schmuth M., Nguyen V.A.

JDDG - Journal of the German Society of Dermatology. 19(7) (pp 1021-1043), 2021. Date of Publication: July 2021.

[Article]

Publisher

John Wiley and Sons Inc

➔ Excluded after screening, review

19.

Known and new facts on basal cell carcinoma.

Seidl-Philipp M., Frischhut N., Hollweger N., Schmuth M., Nguyen V.A.

JDDG - Journal of the German Society of Dermatology. 19(7) (pp 1021-1041), 2021. Date of Publication: July 2021.

[Article]

Publisher

John Wiley and Sons Inc

➔ Excluded after screening, review

21.

Xanthomatous Dermal Changes in a Patient With Locally Advanced Basal Cell Carcinoma Treated Using Vismodegib.

Smith S.D.B., Clarke C.N., Clark M.A., Harker-Murray A.K., Sokumbi O.

The American Journal of dermatopathology. 43(8) (pp 585-587), 2021. Date of Publication: 01 Aug 2021.

[Article]

Publisher

NLM (Medline)

➔ Excluded after screening, vismodegib for laBCC

22.

Budget impact (BI) analysis of cemiplimab-rwlc for advanced basal cell carcinoma (BCC) after hedgehog inhibitor (HHI) therapy in the United States.

Paul E., Chen C.-I., Chowdhury Z., Xu Y., Konidaris G., LaFontaine P.R., Atsou K., Cope S., Philips Z., Kuznik A.

Journal of Clinical Oncology. Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO 2021. Online. 39(15 SUPPL) (no pagination), 2021. Date of Publication: 2021.

[Conference Abstract]

Publisher

American Society of Clinical Oncology

➔ Excluded after screening, combination therapy

23.

Frequency, characteristics, and subsequent treatment (Tx) of realworld patients (pts) who discontinue hedgehog inhibitors (HHIs) as first-line (1L) systemic Tx for advanced basal cell carcinoma (aBCC).

Cowey C.L., Chen C.-I., Aguilar K.M., Davies K., LaFontaine P.R., Fury M.G., Bowler T.G., Golozar A., Jalbert J.J.

Journal of Clinical Oncology. Conference: Annual Meeting of the American Society of Clinical Oncology, ASCO 2021. Online. 39(15 SUPPL) (no pagination), 2021. Date of Publication: 2021.

[Conference Abstract]

Publisher

American Society of Clinical Oncology

➔ Excluded after eligibility assessment, hedgehog pathway inhibitors for aBCC

28.

New targeted therapies and immunotherapies for locally advanced periocular malignant tumours: Towards a new 'eye-sparing' paradigm?.

Martel A., Lassalle S., Picard-Gauci A., Gastaud L., Montaudie H., Bertolotto C., Nahon-Esteve S., Poissonnet G., Hofman P., Baillif S.

Cancers. 13(11) (no pagination), 2021. Article Number: 2822. Date of Publication: 01 Jun 2021.

[Review]

Publisher

MDPI AG

➔ Excluded after screening, review

29.

Investigative Landscape in Advanced Non-Melanoma Skin Cancers.

Reddy P., Yao M., Patel M.

Current Treatment Options in Oncology. 22(7) (no pagination), 2021. Article Number: 56. Date of Publication: July 2021.

[Review]

Publisher

Springer

➔ Excluded after screening, review

30.

Vismodegib in treatment of reccurence, locally advanced basal cell carcinoma. Vismodegib v lecbe recidivujiciho, lokalne pokrocileho bazocelularniho karcinomu <Vismodegib v lecbe recidivujiciho, lokalne pokrocileho bazocelularniho karcinomu.>

Michalcova S., Micanikova H.

Onkologie (Czech Republic). 15(3) (pp 136-138), 2021. Date of Publication: 2021.

[Article]

Publisher

SOLEN s.r.o.

➔ Excluded after screening, vismodegib for laBCC

31.

Examining the relationship of immunotherapy and wound complications following flap reconstruction in patients with head and neck cancer.

Mays A.C., Yarlagadda B., Achim V., Jackson R., Pipkorn P., Huang A.T., Rajasekaran K., Sridharan S., Rosko A.J., Orosco R.K., Coughlin A.M., Wax M.K., Shnayder Y., Spanos W.C., Farwell D.G., McDaniel L.S., Hanasono M.M.

Head and Neck. 43(5) (pp 1509-1520), 2021. Date of Publication: May 2021.

[Article]

Publisher

John Wiley and Sons Inc

➔ Excluded after screening, immunotherapy and wound complications after surgery

32.

Treatment of basal cell carcinoma with vismodegib: future or present?.

Velleman J., Kaarela O., Vranckx J.J.

Acta chirurgica Belgica. 121(3) (pp 198-203), 2021. Date of Publication: 01 Jun 2021.

[Article]

Publisher

NLM (Medline)

➔ Excluded after screening, laBCC

33.

Emerging drugs for the treatment of basal cell carcinoma.

Herms F., Basset-Seguin N.

Expert Opinion on Emerging Drugs. 26(1) (pp 17-26), 2021. Date of Publication: 2021.

[Review]

Publisher

Taylor and Francis Ltd.

➔ Excluded after screening, review

34.

Neo-adjuvant Vismodegib followed by radiation in locally advanced basal cell carcinoma.

Sabu D.M., Kroes J., Gilham C., Fleming A., Kelleher F.C.

Current Problems in Cancer. (no pagination), 2021. Article Number: 100736. Date of Publication: 2021.

[Article]

Publisher

Mosby Inc.

➔ Excluded after screening, neoadjuvant vismodegib for laBCC

35.

Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma.

Zelin E., Zalaudek I., Agozzino M., Dianzani C., Dri A., Di Meo N., Giuffrida R., Marangi G.F., Neagu N., Persichetti P., Toffoli L., Conforti C.

Current Treatment Options in Oncology. 22(4) (no pagination), 2021. Article Number: 35. Date of Publication: April 2021.

[Review]

Publisher

Springer

➔ Excluded after screening, review on neoadjuvant treatments

37.

Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma.

Boutros C., Rouleau E., Majer M., Nikolaev S., Robert C.

European Journal of Cancer. 150 (pp 130-132), 2021. Date of Publication: June 2021.

[Letter]

Publisher

Elsevier Ltd

➔ Excluded after screening, combination therapy

38.

Cancer stem cells and nucleolin as drivers of carcinogenesis.

Carvalho L.S., Goncalves N., Fonseca N.A., Moreira J.N.

Pharmaceuticals. 14(1) (pp 1-21), 2021. Article Number: 60. Date of Publication: 2021.

[Review]

Publisher

MDPI AG

➔ Excluded after screening, review

39.

The transcriptional landscape analysis of basal cell carcinomas reveals novel signalling pathways and actionable targets.

Litvinov I.V., Xie P., Gunn S., Sasseville D., Lefrancois P.

Life science alliance. 4(7) (no pagination), 2021. Date of Publication: 01 Jul 2021.

[Article]

Publisher

NLM (Medline)

➔ Excluded after screening, molecular research

40.

Orbito-scleral-sinus invasion of basal cell carcinoma in an immunocompromised patient on vismodegib.

Tran A.Q., Patete C.L., Blessing N.W., Rong A.J., Garcia A.L., Dubovy S., Tse D.T.

Orbit (London). 40(2) (pp 155-158), 2021. Date of Publication: 2021.

[Article]

Publisher

Taylor and Francis Ltd.

➔ Excluded after screening , treatment of laBCC

43.

Oral itraconazole in the treatment of metastatic basal cell carcinoma-a case report and review of literature.

Ip K.H.-K., McKerrow K.

Australasian Journal of Dermatology. Conference: 53rd Annual Scientific Meeting of the Australasian College of Dermatologists, The Art of Dermatology. Virtual. 62(SUPPL 1) (pp 69), 2021. Date of Publication: April 2021.

[Conference Abstract]

Publisher

Blackwell Publishing

➔ Excluded after screening, itraconazole for mBCC

44.

Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.

Verkouteren B.J.A., Wakkee M., Reyners A.K.L., Nelemans P., Aarts M.J.B., Racz E., Terra J.B., Devriese L.A., Alers R.-J., Kapiteijn E., van Doorn R., Bekkenk M.W., Reinders M.G.H.C., Mosterd K.

British Journal of Cancer. 124(7) (pp 1199-1206), 2021. Date of Publication: 30 Mar 2021.

[Article]

Publisher

Springer Nature

➔ Included after eligibility assessment

45.

Digital ischemia triggered by coronavirus disease 2019 in a patient under cemiplimab treatment.

Serra-Garcia L., Bosch-Amate X., Alamon-Reig F., Giavedoni P., Fuertes I., Morgado-Carrasco D., Iglesias P., Puig S., Mascaro Jr J.M.

International Journal of Dermatology. 60(1) (pp e30-e32), 2021. Date of Publication: January 2021.

[Letter]

Publisher

Blackwell Publishing Ltd

➔ Excluded after screening, different treatment

46.

Vismodegib: A complement to the basal cell carcinoma surgery. Vismodegib como complemento a la cirugia del carcinoma basocelular <Vismodegib como complemento a la cirugia del carcinoma basocelular.>

Bernia Petit E., Llombart B., Serra C., Sanmartin Jimenez O.

Piel. 36(2) (pp 121-125), 2021. Date of Publication: February 2021.

[Article]

Publisher

Ediciones Doyma, S.L.

➔ Excluded after screening, combination therapy

47.

Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial.

Gershoni A., Tiosano A., Ben Ishai M., Barayev E., J. Ben Simon G., Yassur I.

Eye (Basingstoke). (no pagination), 2021. Date of Publication: 2021.

[Article]

Publisher

Springer Nature

➔ Excluded after screening, QoL in laBCC

48.

Vismodegib Efficacy in Advanced Basal Cell Carcinoma Maintained with 8-Week Dose Interruptions: A Model-Based Evaluation.

Chanu P., Musib L., Wang X., Cheeti S., Girish S., Bruno R., Lu T., Reddy J., Jin J.Y., Caro I.

Journal of Investigative Dermatology. 141(4) (pp 930-933), 2021. Date of Publication: April 2021.

[Article]

Publisher

Elsevier B.V.

➔ Excluded after eligibility assessment, Model over 8 weken pause nog steeds effectief voor laBCC >> introductie!

50.

Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy.

Carlberg V.M., Davies O.M.T., Brandling-Bennett H.A., Leary S.E.S., Huang J.T., Coughlin C.C., Gupta D.

Pediatric Dermatology. 38(1) (pp 18-30), 2021. Date of Publication: January/February 2021.

[Review]

Publisher

Blackwell Publishing Inc.

➔ Excluded after screening, review on different treatment & disease

51.

Beyond Mohs surgery and excisions: A focused review of treatment options for subtypes of basal cell carcinoma.

Altun E., Schwartzman G., Cartron A.M., Khachemoune A.

Dermatologic Therapy. 34(1) (no pagination), 2021. Article Number: e14476. Date of Publication: January/February 2021.

[Review]

Publisher

Blackwell Publishing Inc.

➔ Excluded after screening, review

52.

How to break resistance to hedgehog inhibitors in advanced basal cell carcinoma?.

Ramelyte E., Restivo G., Imhof L., Nageli M.C., Dummer R.

British Journal of Dermatology. 184(2) (pp 359-361), 2021. Date of Publication: February 2021.

[Letter]

Publisher

Blackwell Publishing Ltd

➔ Excluded after screening, combination therapy of hedgehog pathway inhibitor and itraconazole for laBCC

53.

Pathologic complete response with radiation and vismodegib in a patient with advanced basal cell carcinoma: A case report.

Amini A., Freeman M., Melstrom L., Margolin K.A., Parekh V., Abdulla F.R., Modi B.

Molecular and Clinical Oncology. 14(3) (pp 1-4), 2021. Article Number: 46. Date of Publication: 2021.

[Article]

Publisher

Spandidos Publications

➔ Excluded after screening, combination therapy of vismodegib and radiotherapy for laBCC

54.

Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma.

Marescassier H., Dousset L., Beylot-Barry M., Celerier P., Vaillant L., Bedane C., Leclere F., Wierzbicka-Hainaut E., Masson Regnault M.

Dermatology. (no pagination), 2021. Date of Publication: 2021.

[Article]

Publisher

S. Karger AG

→ Excluded after screening, predictive factors for laBCC

55.

Hedgehog signaling, a critical pathway governing the development and progression of hepatocellular carcinoma.

Ding J., Li H.-Y., Zhang L., Zhou Y., Wu J.

Cells. 10(1) (pp 1-18), 2021. Article Number: 123. Date of Publication: January 2021.

[Review]

Publisher

MDPI AG

➔ Excluded after screening, different disease

56.

Cancer stem cells-key players in tumor relapse.

Marzagalli M., Fontana F., Raimondi M., Limonta P.

Cancers. 13(3) (pp 1-23), 2021. Article Number: 376. Date of Publication: 01 Feb 2021.

[Review]

Publisher

MDPI AG

➔ Excluded after screening, review on stem cells

57.

Vismodegib dose reduction effective when combined with itraconazole for the treatment of advanced basal cell carcinoma.

Yoon J.

JAAD Case Reports. 7 (pp 107-109), 2021. Date of Publication: January 2021.

[Article]

Publisher

Elsevier Inc.

➔ Excluded after screening, combination therapy for laBCC

58.

Stimuli-responsive and cellular targeted nanoplatforms for multimodal therapy of skin cancer.

Padya B.S., Pandey A., Pisay M., Koteshwara K.B., Chandrashekhar Hariharapura R., Bhat K.U., Biswas S., Mutalik S.

European Journal of Pharmacology. 890 (no pagination), 2021. Article Number: 173633. Date of Publication: 05 Jan 2021.

[Review]

Publisher

Elsevier B.V.

➔ Excluded after screening, review on nanoplatforms

59.

Treatment of advanced basal cell carcinoma with vismodegib followed by radiotherapy. Remission complete d'un carcinome basocellulaire localement avance par l'association de vismodegib et radiotherapie <Remission complete d'un carcinome basocellulaire localement avance par l'association de vismodegib et radiotherapie.>

Janela-Lapert R., Dubray B., Duval-Modeste A., Castel M.

Annales de Dermatologie et de Venereologie. 147(11) (pp 780-782), 2020. Date of Publication: November 2020.

[Letter]

Publisher

Elsevier Masson s.r.l.

➔ Excluded after screening, combination therapy for aBCC

60.

The hedgehog pathway in basal cell carcinoma. De hedgehog-signaalroute in basaalcelcarcinoom <De hedgehog-signaalroute in basaalcelcarcinoom.>

Verkouteren B.J.A., Mosterd K.

Nederlands Tijdschrift voor Dermatologie en Venereologie. 30(3) (pp 12-14), 2020. Date of Publication: March 2020.

[Article]

Publisher

Stichting Beheer Tijdschriften Dermatologie

➔ Excluded after screening, review

61.

Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis.

Tronconi M.C., Solferino A., Giordano L., Borroni R., Mancini L., Santoro A.

Frontiers in Oncology. 10 (no pagination), 2020. Article Number: 563404. Date of Publication: 13 Nov 2020.

[Article]

Publisher

Frontiers Media S.A.

➔ Included after eligibility assessment, multiple BCC patients with tailored vismodegib treatment

62.

Cancer Predisposition Syndromes and Medulloblastoma in the Molecular Era.

Carta R., Del Baldo G., Miele E., Po A., Besharat Z.M., Nazio F., Colafati G.S., Piccirilli E., Agolini E., Rinelli M., Lodi M., Cacchione A., Carai A., Boccuto L., Ferretti E., Locatelli F., Mastronuzzi A.

Frontiers in Oncology. 10 (no pagination), 2020. Article Number: 566822. Date of Publication: 29 Oct 2020.

[Review]

Publisher

Frontiers Media S.A.

➔ Excluded after screening, review on cancer predisposition syndromes

64.

Vismodegib-Induced Alopecia: Trichoscopic and Confocal Microscopy Evaluation.

Cantelli M., Cappello M., Vastarella M., Patri A., Scalvenzi M., Fabbrocini G.

Skin Appendage Disorders. 6(6) (pp 384-388), 2020. Date of Publication: November 2020.

[Article]

Publisher

S. Karger AG=

➔ Excluded after screening, report on common adverse event of vismodegib

65.

BCC metastasis: A very rare sequela of a common disease- a case report documenting lymphatic invasion and a literature review.

Mohammad M., Schumacher K., Nayar R., Morton J.

BMJ Case Reports. 13(12) (no pagination), 2020. Article Number: e234888. Date of Publication: 21 Dec 2020.

[Note]

Publisher

BMJ Publishing Group

-→ Excluded after screening, mBCC

67.

Periocular skin cancer: Diagnosis and management.

Moran J.M., Phelps P.O.

Disease-a-Month. 66(10) (no pagination), 2020. Article Number: 101046. Date of Publication: October 2020.

[Article]

Publisher

Mosby Inc.

➔ Excluded after screening, review

68.

Metastatic basal cell carcinoma with evidence of intravascular invasion: A case report.

West L., Fathi R., Nijhawan R., Srivastava D.

SAGE Open Medical Case Reports. 8 (no pagination), 2020. Date of Publication: 2020.

[Article]

Publisher

SAGE Publications Ltd

➔ Excluded after screening, mBCC

69.

Vismodegib for patients with advanced basal cell carcinoma: One center's experience.

Yesil Cinkir H., Sever O.N., Teker F.

Journal of Oncological Science. 6(1) (pp 5-9), 2020. Date of Publication: 2020.

[Article]

Publisher

Turkiye Klinikleri

➔ Excluded after screening, only aBCC patients

70.

Super giant basal cell carcinoma in an autistic patient: A case report.

Hudson E., Abu Hilal M.

SAGE Open Medical Case Reports. 8 (no pagination), 2020. Date of Publication: 2020.

[Article]

Publisher

SAGE Publications Ltd

➔ Excluded after screening, aBCC

71.

Overgrowth of undifferentiated pleomorphic sarcoma during vismodegib treatment of locally advanced basal cell carcinosarcoma.

Mijuskovic Z., Brasanac D., Rajovic M., Sekulovic L.K.

JCO Oncology Practice. 16(12) (pp 839-841), 2020. Date of Publication: 01 Dec 2020.

[Article]

Publisher

American Society of Clinical Oncology

➔ Excluded after screening, rare adverse event in vismodegib for laBCC

72.

Basal cell carcinoma of the periauricular region treated with oral itraconazole and topical 5% imiqimod cream.

Nowakowska A., Slowinska M., Owczarek W.

Journal of the Dermatology Nurses' Association. Conference: 24th World Congress of Dermatology. Milan Italy. 12(2) (no pagination), 2020. Date of Publication: March-April 2020.

[Conference Abstract]

Publisher

Lippincott Williams and Wilkins

➔ Excluded after screening, combination treatment of laBCC

73.

Pigmented basal cell carcinoma in upper eyelid: Case report.

De Melo Carvalho R., Correa A., Botarelli T., Marques Da Costa J.

Journal of the Dermatology Nurses' Association. Conference: 24th World Congress of Dermatology. Milan Italy. 12(2) (no pagination), 2020. Date of Publication: March-April 2020.

[Conference Abstract]

Publisher

Lippincott Williams and Wilkins

➔ Excluded after screening, laBCC

76.

The pendant earring: An aggressive basal cell carcinoma in a particular kind of presentation.

Peduto T., Blasio C., Scalvenzi M., Gallo L.

Journal of the Dermatology Nurses' Association. Conference: 24th World Congress of Dermatology. Milan Italy. 12(2) (no pagination), 2020. Date of Publication: March-April 2020.

[Conference Abstract]

Publisher

Lippincott Williams and Wilkins

➔ Excluded after screening, aBCC

78.

Vismodegib for the treatment of locally advanced basal cell carcinoma.

Luna A., Molinari L., Rodriguez Kowalczuk M., Ferrario D., Galimberti G., Mazzuoccolo L.

Journal of the Dermatology Nurses' Association. Conference: 24th World Congress of Dermatology. Milan Italy. 12(2) (no pagination), 2020. Date of Publication: March-April 2020.

[Conference Abstract]

Publisher

Lippincott Williams and Wilkins

➔ Excluded after screening, vismodegib for laBCC

79.

Vismodegib for advanced basal-cell carcinoma: report of two patients.

Lopes S., Esteves M., Santos P., Pedrosa A., Azevedo F.

Journal of the Dermatology Nurses' Association. Conference: 24th World Congress of Dermatology. Milan Italy. 12(2) (no pagination), 2020. Date of Publication: March-April 2020.

[Conference Abstract]

Publisher

Lippincott Williams and Wilkins

➔ Excluded after screening, vismodegib for laBCC

82.

Metastatic basal-cell carcinoma associated with gunshot wound trauma.

Kojima N., Darragh K., Cowan B.J.

Journal of General Internal Medicine. Conference: Annual Meeting of the Society of General Internal Medicine, SGIM 2020. Birmingham, AL United States. 35(SUPPL 1) (pp S508-S509), 2020. Date of Publication: July 2020.

[Conference Abstract]

Publisher

Springer New York LLC

➔ Excluded after screening, mBCC

83.

Experience with treating basal cell carcinoma of the occipital region with regional lymph node metastasis. OblT pMeHeH yeBo Tepa B koMbHpoBaHHoM eeH ba3abHokeToHoo paka ko 3aTbloHo obacT c MeTacTa3oM B peoHapHbl MaTeck y3e <OblT pMeHeH yeBo Tepa B koMbHpoBaHHoM eeH ba3abHokeToHoo paka ko 3aTbloHo obacT c MeTacTa3oM B peoHapHbl MaTeck y3e.>

Abramova O.E., Kudryavtsev D.V., Gumenetskaya Yu.V.

Radiation and Risk. 29(4) (pp 126-135), 2020. Date of Publication: 2020.

[Article]

Publisher

National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

➔ Excluded after screening, aBCC

84.

Periocular basal cell carcinoma - Clinical perspectives.

Furdova A., Kapitanova K., Kollarova A., Sekac J.

Oncology Reviews. 14(1) (pp 36-42), 2020. Date of Publication: 30 Apr 2020.

[Review]

Publisher

Page Press Publications

➔ Excluded after screening, review

85.

Sensitivity of treatment patterns to grace period selection in medications with tolerability issues: A real-world example of hedgehog inhibitor use in basal cell carcinoma.

Ge W., Wu N., Chen C.-I., Fury M.G., Ruiz E., Jalbert J.J.

Pharmacoepidemiology and Drug Safety. Conference: 36th International Conference on Pharmacoepidemiology and Therapeutic Risk Management. Virtual. 29(SUPPL 3) (pp 227), 2020. Date of Publication: October 2020.

[Conference Abstract]

Publisher

John Wiley and Sons Ltd

➔ Excluded after screening, unknown indication of vismodegib treatment

87.

Real-life data on basal cell carcinoma treatment: Insights on clinicians' therapeutic choices from an institutional hospital registry.

Manoli S.-M., Moutsoudis A., Papageorgiou C., Lallas K., Rigas H.-M., Kyrmanidou E., Papadimitriou I., Paschou E., Spyridis I., Gkentsidi T., Sotiriou E., Vakirlis E., Ioannidis D., Apalla Z., Lallas A.

Dermatologic Therapy. 33(6) (no pagination), 2020. Article Number: e14414. Date of Publication: November/December 2020.

[Article]

Publisher

Blackwell Publishing Inc.

➔ Excluded after eligibility assessment, no information on indication/response/qol/reoccurrence/side effects of vismodegib treatment

89.

Long non-coding RNAs in cutaneous biology and keratinocyte carcinomas.

Piipponen M., Nissinen L., Kahari V.-M.

Cellular and Molecular Life Sciences. 77(22) (pp 4601-4614), 2020. Date of Publication: 01 Nov 2020.

[Review]

Publisher

Springer Science and Business Media Deutschland GmbH

➔ Excluded after screening, review on RNAs in skin and skin carcinomas

91.

Non-melanoma skin cancers: Biological and clinical features.

Cives M., Mannavola F., Lospalluti L., Sergi M.C., Cazzato G., Filoni E., Cavallo F., Giudice G., Stucci L.S., Porta C., Tucci M.

International Journal of Molecular Sciences. 21(15) (pp 1-24), 2020. Article Number: 15394. Date of Publication: 01 Aug 2020.

[Review]

Publisher

MDPI AG (Postfach, Basel CH-4005, Switzerland. E-mail: rasetti@mdpi.com)

➔ Excluded after screening, review on nonmelanoma skin cancers

92.

Lentivirus-mediated CD44s expression increases human basal cell carcinoma cell resistance against vismodegib.

Ren J., Ma X., Tu C., Li Z.

Oncology Reports. 43(5) (pp 1650-1658), 2020. Date of Publication: 2020.

[Article]

Publisher

Spandidos Publications (10 Vriaxidos Street, Athens 116 10, Greece. E-mail: subscriptions@spandidos-publications.com)

➔ Excluded after eligibility assessment, in vitro and in vivo models on resistance to vismodegib

95.

Novel therapies for advanced skin carcinomas.

Modrakowska P., Balik K., Maj M., Bajek A.

Postepy Dermatologii i Alergologii. 37(5) (pp 660-670), 2020. Date of Publication: 2020.

[Review]

Publisher

Termedia Publishing House Ltd.

➔ Excluded after screening, review

96.

Basal cell carcinoma: A comprehensive review.

Dika E., Scarfi F., Ferracin M., Broseghini E., Marcelli E., Bortolani B., Campione E., Riefolo M., Ricci C., Lambertini M.

International Journal of Molecular Sciences. 21(15) (pp 1-11), 2020. Article Number: 5572. Date of Publication: 01 Aug 2020.

[Review]

Publisher

MDPI AG

➔ Excluded after screening, review

97.

SMO (Smoothened transmembrane protein) inhibitors (vismodegib) in treatment of basal cell carcinoma (BCC) of ocular adnexa.

Balchev G., Balabanov C., Murgova S.

Journal of IMAB - Annual Proceeding (Scientific Papers). 26(2) (pp 3102-3106), 2020. Date of Publication: 2020.

[Article]

Publisher

Peytchinski, Gospodin Iliev ET

➔ Excluded after screening, review

99.

Journal Club.

Machado A., Lesort C., Gran F., Vilas Boas P., Arianayagam S., Frings V.

European Journal of Dermatology. 30(4) (pp 446-447), 2020. Date of Publication: July 2020.

[Article]

Publisher

John Libbey

➔ Excluded after screening, journal club

100.

The use of hedgehog antagonists in cancer therapy: a comparison of clinical outcomes and gene expression analyses.

Booker B.E., Steg A.D., Kovac S., Landen C.N., Amm H.M.

Cancer Biology and Therapy. 21(10) (pp 873-883), 2020. Date of Publication: 02 Oct 2020.

[Review]

Publisher

Bellwether Publishing, Ltd.

➔ Excluded after screening, review

102.

The role of smoothened in cancer.

Jeng K.-S., Sheen I.-S., Leu C.-M., Tseng P.-H., Chang C.-F.

International Journal of Molecular Sciences. 21(18) (pp 1-20), 2020. Article Number: 6863. Date of Publication: 02 Sep 2020.

[Review]

Publisher

MDPI AG

➔ Excluded after screening, review

103.

Sonidegib for the Treatment of Advanced Basal Cell Carcinoma.

Brancaccio G., Pea F., Moscarella E., Argenziano G.

Frontiers in Oncology. 10 (no pagination), 2020. Article Number: 582866. Date of Publication: 30 Oct 2020.

[Review]

Publisher

Frontiers Media S.A.

➔ Excluded after screening, review

104.

Locally Advanced Recurrence of Periocular Squamous Cell Carcinoma and Basal Cell Carcinoma After Mohs Micrographic Surgery.

Prat D., Eiger-Moscovich M., Loebenstein R., Zloto O., Reich E., Ben Simon G.J., Yassur I.

Advances in Ophthalmology and Optometry. 5 (pp 247-254), 2020. Date of Publication: August 2020.

[Review]

Publisher

Elsevier Inc.

➔ Excluded after screening, review

105.

Metastatic basal cell carcinoma with atypical pattern of spread.

Gellatly M., Cruzval-O'Reilly E., Mervak J.E., Mervak B.M.

Radiology Case Reports. 15(12) (pp 2641-2644), 2020. Date of Publication: December 2020.

[Article]

Publisher

Elsevier Inc.

➔ Excluded after screening, mBCC

106.

The role of classical and novel forms of vitamin d in the pathogenesis and progression of nonmelanoma skin cancers.

Slominski A.T., Brozyna A.A., Zmijewski M.A., Janjetovic Z., Kim T.-K., Slominski R.M., Tuckey R.C., Mason R.S., Jetten A.M., Guroji P., Reichrath J., Elmets C., Athar M.

Advances in Experimental Medicine and Biology. 1268 (pp 257-283), 2020. Date of Publication: 2020.

[Chapter]

Publisher

Springer

➔ Excluded after screening, book chapter

107.

Prolonged response to vismodegib in a patient with systemic medulloblastoma metastases.

Climans S.A., MacDonald D.R., Sutherland D.E.K., Mason W.P.

BMJ Case Reports. 13(10) (no pagination), 2020. Article Number: e236406. Date of Publication: 29 Oct 2020.

[Article]

Publisher

BMJ Publishing Group

→ Excluded after screening, different disease

109.

AP-1 and TGFs cooperativity drives non-canonical Hedgehog signaling in resistant basal cell carcinoma.

Yao C.D., Haensel D., Gaddam S., Patel T., Atwood S.X., Sarin K.Y., Whitson R.J., McKellar S., Shankar G., Aasi S., Rieger K., Oro A.E.

Nature Communications. 11(1) (no pagination), 2020. Article Number: 5079. Date of Publication: 01 Dec 2020.

[Article]

Publisher

Nature Research

➔ Excluded after screening, marker research for vismodegib resistance

111.

The evolving story of laser therapeutics for basal cell carcinoma.

Ahluwalia J., Avram M.M., Ortiz A.E.

Dermatologic Surgery. 46(8) (pp 1045-1053), 2020. Date of Publication: 01 Aug 2020.

[Review]

Publisher

Lippincott Williams and Wilkins (E-mail: agents@lww.com)

➔ Excluded after screening, different treatment

112.

Hair Loss in Patients Treated with Vismodegib: A Single-Center Retrospective Study.

Villani A., Fabbrocini G., Costa C., Scalvenzi M.

Skin Appendage Disorders. 6(5) (pp 280-282), 2020. Date of Publication: 01 Sep 2020.

[Article]

Publisher

S. Karger AG

➔ Excluded after screening, article on well-known adverse event

115.

Cancer-associated fibroblasts: Versatile players in the tumor microenvironment.

Ganguly D., Chandra R., Karalis J., Teke M., Aguilera T., Maddipati R., Wachsmann M.B., Ghersi D., Siravegna G., Zeh H.J., Brekken R., Ting D.T., Ligorio M.

Cancers. 12(9) (pp 1-35), 2020. Article Number: 2652. Date of Publication: September 2020.

[Review]

Publisher

MDPI AG (E-mail: diversity@mdpi.com)

➔ Excluded after screening, review on cancer fibroblasts

116.

Ablative fractional laser-assisted treatments for keratinocyte carcinomas and its precursors-Clinical review and future perspectives.

Erlendsson A.M., Olesen U.H., Haedersdal M., Rossi A.M.

Advanced Drug Delivery Reviews. 153 (pp 185-194), 2020. Date of Publication: 1 January 2020.

[Review]

Publisher

Elsevier B.V. (Netherlands)

➔ Excluded after screening, different treatment

117.

Efficiency of long-term high-dose intravenous ascorbic acid therapy in locally advanced basal cell carcinoma - A pilot study.

Banvolgyi A., Lorincz K., Kiss N., Avci P., Fesus L., Szipocs R., Krenacs T., Gyongyosi N., Wikonkal N., Karpati S., Nemeth K.

Postepy Dermatologii i Alergologii. 37(4) (pp 548-558), 2020. Date of Publication: 2020.

[Article]

Publisher

Termedia Publishing House Ltd.

➔ Excluded after screening, different treatment

118.

Targeting the medulloblastoma: A molecular-based approach.

Luzzi S., Lucifero A.G., Brambilla I., Mantelli S.S., Mosconi M., Foiadelli T., Savasta S.

Acta Biomedica. 91(Supplement 7) (pp 79-100), 2020. Date of Publication: 2020.

[Article]

Publisher

Mattioli 1885 (E-mail: valeriaceci@mattioli1885.com)

➔ Excluded after screening, different disease

119.

Symptomatic iron deficiency anemia from neglected giant basal cell carcinoma.

Laageide L., Wendl E., Wadle J., Powers J.

JAAD Case Reports. 6(10) (pp 1019-1023), 2020. Date of Publication: October 2020.

[Article]

Publisher

Elsevier Inc.

➔ Excluded after screening, advanced BCC

120.

Enhanced and Sustained Cutaneous Delivery of Vismodegib by Ablative Fractional Laser and Microemulsion Formulation.

Olesen U.H., Clergeaud G., Hendel K.K., Yeung K., Lerche C.M., Andresen T.L., Haedersdal M.

Journal of Investigative Dermatology. 140(10) (pp 2051-2059), 2020. Date of Publication: October 2020.

[Article]

Publisher

Elsevier B.V.

➔ Excluded after screening, combination therapy of vismodegib and laser

123.

Advanced basal cell carcinoma: when a good drug is not enough.

De Giorgi V., Savarese I., Gori A., Scarfi F., Topa A., Trane L., Portelli F., Innocenti A., Covarelli P.

Journal of Dermatological Treatment. 31(6) (pp 552-553), 2020. Date of Publication: 17 Aug 2020.

[Letter]

Publisher

Taylor and Francis Ltd

➔ Excluded after screening, vismodegib for aBCC

126.

Hedgehog pathway inhibitors for periocular basal cell carcinoma.

Ashraf D.C., Vagefi M.R.

International Ophthalmology Clinics. 60(2) (pp 13-30), 2020. Date of Publication: 01 Mar 2020.

[Article]

Publisher

Lippincott Williams and Wilkins (E-mail: kathiest.clai@apta.org)

➔ Excluded after screening, aBCC

127.

Biologics in oculoplastic surgery: New frontiers of treatment.

Yen M.T.

International Ophthalmology Clinics. 60(2) (pp 1), 2020. Date of Publication: 01 Mar 2020.

[Editorial]

Publisher

Lippincott Williams and Wilkins (E-mail: kathiest.clai@apta.org)

➔ Excluded after screening, editorial

129.

Clinical Management of Locally Advanced Basal-Cell Carcinomas and Future Therapeutic Directions.

Niebel D., Sirokay J., Hoffmann F., Frohlich A., Bieber T., Landsberg J.

Dermatology and Therapy. 10(4) (pp 835-846), 2020. Date of Publication: 01 Aug 2020.

[Article]

Publisher

Adis

➔ Excluded after screening, short review

130.

In silico analyses of the tumor microenvironment highlight tumoral inflammation, a Th2 cytokine shift and a mesenchymal stem cell-like phenotype in advanced in basal cell carcinomas.

Lefrancois P., Xie P., Gunn S., Gantchev J., Villarreal A.M., Sasseville D., Litvinov I.V.

Journal of Cell Communication and Signaling. 14(2) (pp 245-254), 2020. Date of Publication: 01 Jun 2020.

[Article]

Publisher

Springer (E-mail: editorial@springerplus.com)

➔ Excluded after screening, cell research on aBCC

131.

Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib.

Su M.G., Potts L.B., Tsai J.H.

American Journal of Ophthalmology Case Reports. 19 (no pagination), 2020. Article Number: 100755. Date of Publication: September 2020.

[Article]

Publisher

Elsevier Inc

➔ Excluded after screening, vismodegib as neoadjuvant

133.

Rare bone toxicity associated with vismodegib.

Ciciarelli V., Cortellini A., Ventura A., Gutierrez Garcia-Rodrigo C., Ficorella C., Fargnoli M.C.

JAAD Case Reports. 6(6) (pp 482-485), 2020. Date of Publication: June 2020.

[Article]

Publisher

Elsevier Inc

➔ Excluded after screening, case report on rare adverse event

136.

Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors.

Cohen P.R., Kurzrock R.

Journal of the American Academy of Dermatology. 82(6) (pp e253-e254), 2020. Date of Publication: June 2020.

[Letter]

Publisher

Mosby Inc. (E-mail: customerservice@mosby.com)

➔ Excluded after screening, different treatment

137.

Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity.

Scalvenzi M., Cappello M., Costa C., Fabbrocini G., Luciano M., Villani A.

Dermatology and Therapy. 10(3) (pp 465-468), 2020. Date of Publication: 01 Jun 2020.

➔ Excluded after eligibility assessment, article only discusses dosing reduction in laBCC

138.

Secondary resistant mutations to small molecule inhibitors in cancer cells.

Hamid A.B., Petreaca R.C.

Cancers. 12(4) (no pagination), 2020. Article Number: 927. Date of Publication: April 2020.

[Review]

Publisher

MDPI AG (Postfach, Basel CH-4005, Switzerland. E-mail: rasetti@mdpi.com)

➔ Excluded after screening, review

140.

Vismodegib as novel treatment of periocular basal cell carcinoma: A mini review.

Soebagjo H.D.

Systematic Reviews in Pharmacy. 11(3) (pp 587-595), 2020. Date of Publication: 2020.

[Review]

Publisher

EManuscript Technologies (E-mail: journals@emanuscript.in)

➔ Excluded after screening, mini review

144.

Synergistic effect of anti-PD1 immunotherapy then radiotherapy in advanced basal cell carcinoma. Synergie de la sequence immunotherapie par anti-PD1 et radiotherapie au cours d'un carcinome basocellulaire avance <Synergie de la sequence immunotherapie par anti-PD1 et radiotherapie au cours d'un carcinome basocellulaire avance.>

Malmontet T., Dousset L., Gerard E., Ouhabrache N., Pham-Ledard A., Beylot-Barry M.

Annales de Dermatologie et de Venereologie. 147(3) (pp 228-232), 2020. Date of Publication: March 2020.

[Article]

Publisher

Elsevier Masson SAS (62 rue Camille Desmoulins, Issy les Moulineaux Cedex 92442, France)

➔ Excluded after screening, different combination therapy

145.

Pulmonary Metastasis of Basal Cell Cancer: Metastatic Basal Cell Cancer.

Rudkovskaia A.A., Kazmi S.A., Gitter L., Ayers M.L.

Journal of Bronchology and Interventional Pulmonology. 27(1) (pp E8-E10), 2020. Date of Publication: 01 Jan 2020.

[Letter]

Publisher

Lippincott Williams and Wilkins (E-mail: kathiest.clai@apta.org)

➔ Excluded after screening, mBCC

147.

Reappraisal of giant basal cell carcinoma: Clinical features and outcomes.

Oudit D., Pham H., Grecu T., Hodgson C., Grant M.E., Rashed A.A., Allan D., Green A.C.

Journal of Plastic, Reconstructive and Aesthetic Surgery. 73(1) (pp 53-57), 2020. Date of Publication: January 2020.

[Article]

Publisher

Churchill Livingstone

➔ Excluded after screening, aBCC

148.

Neoadjuvant vismodegib in the management of locally advanced periocular basal cell carcinoma.

Curragh D.S., Huilgol S.C., Selva D.

Eye (Basingstoke). (no pagination), 2020. Date of Publication: 2020.

[Article]

Publisher

Springer Nature

➔ Excluded after screening, neoadjuvant vismodegib for aBCC

149.

Basal cell carcinoma with extensive periorbital involvement response to vismodegib.

Shoji M.K., Pirakitikulr N., Tran A.Q., Wester S.T.

Orbit (London). (no pagination), 2020. Date of Publication: 2020.

[Note]

Publisher

Taylor and Francis Ltd

➔ Excluded after screening, aBCC

152.

The Landmark Series: Non-melanoma Skin Cancers.

Lee A.Y., Berman R.S.

Annals of Surgical Oncology. 27(1) (pp 22-27), 2020. Date of Publication: 01 Jan 2020.

[Review]

Publisher

Springer

➔ Excluded after screening, review

153.

Vismodegib, a hedgehog pathway inhibitor, causing severe liver injury.

Bui R., Strader M., Viterbo D.

American Journal of Gastroenterology. Conference: 2020 Annual Scientific Meeting of the American College of Gastroenterology, ACG 2020. Nashville, TN United States. 115(SUPPL) (pp S1319-S1320), 2020. Date of Publication: October 2020.

[Conference Abstract]

Publisher

Wolters Kluwer Health

➔ Excluded after screening, report on known, rare side effect

154.

18445 Basal cell carcinoma gene mutations and polymorphisms differ between Asian, Hispanic, and Caucasian patients.

Hass B., Higgins S., Lobl M., Clarey D., Sutton A.V., Wysong A.

Journal of the American Academy of Dermatology. Conference: AAD Annual Meeting. Denver United States. 83(6 Supplement) (pp AB100), 2020. Date of Publication: December 2020.

[Conference Abstract]

Publisher

Mosby Inc.

➔ Excluded after screening, molecular research in BCC

156.

PTCH1 Genomic Alterations (GA) in human malignancies: A pangenomic study.

Ross J.S., Sokol E.S., Pavlick D.C., Vergilio J.-A., Killian J.K., Williams E., Danziger N.A., Tse J., Ramkissoon S., Severson E., Hemmerich A., Duncan D., Huang R., Madison R., Schrock A.B., Alexander B., Venstrom J., Reddy P., McGregor K., Elvin J.

Annals of Oncology. Conference: ESMO Virtual Congress 2020. Virtual, Online. 31(Supplement 4) (pp S291-S292), 2020. Date of Publication: September 2020.

[Conference Abstract]

Publisher

Elsevier Ltd

➔ Excluded after screening, genomic alterations

157.

Vismodegib in real-life clinical settings: A multicenter, longitudinal cohort providing long-term data on efficacy and safety.

Apalla Z., Spyridis I., Kyrgidis A., Lazaridou E., Kyriakou A., Fotiadou C., Pikou O., Sotiriou E., Vakirlis E., Papageorgiou C., Delli F., Moutsoudis A., Manoli S.M., Ioannides D., Lallas A.

Journal of the American Academy of Dermatology. (no pagination), 2020. Date of Publication: 27 Nov 2020.

➔ Excluded after eligibility assessment, does not discuss outcomes for multiple BCC patients seperately

158.

The effectiveness of vismodegib in patients with advanced periocular basal cell carcinoma: a case series of 13 patients.

Villani A., Costa C., Cappello M., Fabbrocini G., Scalvenzi M.

Journal of Dermatological Treatment. (no pagination), 2020. Date of Publication: 2020.

[Letter]

Publisher

Taylor and Francis Ltd

➔ Excluded after screening, vismodegib for aBCC

159.

Vismodegib (ERIVEDGE) pregnancy prevention programme: assessment of risk awareness.

Schnetzler G., Cuberos M., Bucher R., Stassen K., Mingrino R.

Journal of Dermatological Treatment. (no pagination), 2020. Date of Publication: 2020.

[Article]

Publisher

Taylor and Francis Ltd

➔ Excluded after screening, discusses pregnancy prevention

160.

Molecular testing in metastatic basal cell carcinoma.

Verkouteren B.J.A., Wakkee M., van Geel M., van Doorn R., Winnepenninckx V.J., Korpershoek E., Mooyaart A.L., Reyners A.K.L., Terra J.B., Aarts M.J.B., Reinders M.G.H.C., Mosterd K.

Journal of the American Academy of Dermatology. (no pagination), 2020. Date of Publication: 2020.

[Article]

Publisher

Mosby Inc. (E-mail: customerservice@mosby.com)

➔ Excluded after screening, vismodegib for mBCC

161.

Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.

Lu T., Yang Y., Jin J.Y., Kagedal M.

CPT: Pharmacometrics and Systems Pharmacology. 9(2) (pp 96-105), 2020. Date of Publication: 01 Feb 2020.

[Article]

Publisher

American Society for Clinical Pharmacology and Therapeutics

➔ Excluded after screening, pharmacometric model for known adverse event

164.

Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.

Clara J.A., Monge C., Yang Y., Takebe N.

Nature Reviews Clinical Oncology. 17(4) (pp 204-232), 2020. Date of Publication: 01 Apr 2020.

[Review]

Publisher

Nature Research

➔ Excluded after screening, review

167.

S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 2: Treatment, Prevention and Follow-up.

Lang B.M., Balermpas P., Bauer A., Blum A., Brolsch G.F., Dirschka T., Follmann M., Frank J., Frerich B., Fritz K., Hauschild A., Heindl L.M., Howaldt H.-P., Ihrler S., Kakkassery V., Klumpp B., Krause-Bergmann A., Loser C., Meissner M., Sachse M.M., Schlaak M., Schon M.P., Tischendorf L., Tronnier M., Vordermark D., Welzel J., Weichenthal M., Wiegand S., Kaufmann R., Grabbe S.

JDDG - Journal of the German Society of Dermatology. 17(2) (pp 214-230), 2019. Date of Publication: February 2019.

[Article]

Publisher

Wiley-VCH Verlag

➔ Excluded after screening, BCC guidelines

168.

Diagnosis and management of basal cell carcinoma.

Tanese K.

Current Treatment Options in Oncology. 20(2) (no pagination), 2019. Article Number: 13. Date of Publication: February 2019.

[Article]

Publisher

Springer Science and Business Media, LLC

➔ Excluded after screening, BCC guidelines

169.

Polyamine metabolism as a therapeutic target in hedgehog-driven basal cell carcinoma and medulloblastoma.

Coni S., Magno L.D., Serrao S.M., Kanamori Y., Agostinelli E., Canettieri G.

Cells. 8(2) (no pagination), 2019. Article Number: 150. Date of Publication: February 2019.

[Review]

Publisher

MDPI AG (Postfach, Basel CH-4005, Switzerland. E-mail: indexing@mdpi.com)

➔ Excluded after screening, review

172.

Treatment of inoperable basosquamous carcinoma with hedgehog inhibitors, vismodegib and sonedigib: A case series.

Scott J., DiLorenzo A., Chang S., Harvell J., Jang S., DeSimone J.

Journal of the American Academy of Dermatology. Conference: American Academy of Dermatology 2019 Annual Meeting. District of Columbia United States. 81(4 Supplement 1) (pp AB140), 2019. Date of Publication: October 2019.

[Conference Abstract]

Publisher

Mosby Inc.

→ Excluded after screening, hedgehog pathway inhibitors for aBCC

174.

Clonal replacement of tumor-specific T cells following PD-1 blockade.

Yost K.E., Satpathy A.T., Wells D.K., Qi Y., Wang C., Kageyama R., McNamara K.L., Granja J.M., Sarin K.Y., Brown R.A., Gupta R.K., Curtis C., Bucktrout S.L., Davis M.M., Chang A.L.S., Chang H.Y.

Nature Medicine. 25(8) (pp 1251-1259), 2019. Date of Publication: 01 Aug 2019.

[Article]

Publisher

Nature Publishing Group

➔ Excluded after screening, different treatment

176.

Basal cell carcinoma: A pharmacist's guide.

Harris L.

U.S. Pharmacist. 44(8) (pp 29-35), 2019. Date of Publication: August 2019.

[Article]

Publisher

Jobson Publishing Corporation

➔ Excluded after screening, guideline

178.

Coexistence of Pemphigus Foliaceus and Grover Disease after a Radical Surgery for Basal Cell Carcinoma.

Magdaleno-Tapial J., Valenzuela-Onate C., Martinez-Domenech A., Garcia-Legaz-Martinez M., Carballeira-Brana A., Sanchez-Carazo J.L., Perez-Ferriols A., Alegre-De Miquel V.

American Journal of Dermatopathology. 41(10) (pp 744-746), 2019. Date of Publication: 01 Oct 2019.

[Article]

Publisher

Lippincott Williams and Wilkins (E-mail: kathiest.clai@apta.org)

➔ Excluded after screening, different disease

180.

Vismodegib for the treatment of radiation-induced basal cell carcinoma - a case report and brief literature study.

Laliscia C., Baldaccini D., Antonuzzo A., Paiar F.

Wspolczesna Onkologia. 23(4) (pp 251-253), 2019. Date of Publication: 2019.

➔ Excluded after eligibility assessment, case rerport on patient multiple BCCs and vismodegib, does not report on reoccurence/resistance/dosing regiment/QoL

181.

Not everything is what it seems within geriatric dermato-oncology. Niet alles is wat het lijkt binnen de geriatrische dermato-oncologie <Niet alles is wat het lijkt binnen de geriatrische dermato-oncologie.>

Kerkhof M.A.M., van Winden M.E.C., van Aalst W., Amir A., Hoeben B.A.W., Lubeek S.F.K.

Nederlands Tijdschrift voor Dermatologie en Venereologie. 29(10) (pp 14-17), 2019. Date of Publication: November 2019.

[Article]

Publisher

Stichting Beheer Tijdschriften Dermatologie (E-mail: l.fritschy@nvdv.nl)

➔ Excluded after screening, vismodegib for laBCC

182.

Hedgehog/GLI signaling in tumor immunity - New therapeutic opportunities and clinical implications.

Grund-Groschke S., Stockmaier G., Aberger F.

Cell Communication and Signaling. 17(1) (no pagination), 2019. Article Number: 172. Date of Publication: 26 Dec 2019.

[Review]

Publisher

BioMed Central Ltd. (E-mail: info@biomedcentral.com)

➔ Excluded after screening, review

186.

Complete response of a locally advanced basosquamous carcinoma with vismodegib treatment.

Sahuquillo-Torralba A., Llavador-Ros M., Caballero-Daroqui J., Botella-Estrada R.

Indian Journal of Dermatology, Venereology and Leprology. 85(5) (pp 549-552), 2019. Date of Publication: September-October 2019.

[Letter]

Publisher

Wolters Kluwer Medknow Publications (B9, Kanara Business Centre, off Link Road, Ghatkopar (E), Mumbai 400 075, India)

➔ Excluded after screening, laBCC

188.

Aging and the treatment of basal cell carcinoma.

Sreekantaswamy S., Endo J., Chen A., Butler D., Morrison L., Linos E.

Clinics in Dermatology. 37(4) (pp 373-378), 2019. Date of Publication: July - August 2019.

[Article]

Publisher

Elsevier Inc. (E-mail: usjcs@elsevier.com)

➔ Excluded after screening, opinion/review

190.

Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines.

Peris K., Fargnoli M.C., Garbe C., Kaufmann R., Bastholt L., Seguin N.B., Bataille V., Marmol V.D., Dummer R., Harwood C.A., Hauschild A., Holler C., Haedersdal M., Malvehy J., Middleton M.R., Morton C.A., Nagore E., Stratigos A.J., Szeimies R.-M., Tagliaferri L., Trakatelli M., Zalaudek I., Eggermont A., Grob J.J.

European Journal of Cancer. 118 (pp 10-34), 2019. Date of Publication: September 2019.

[Article]

Publisher

Elsevier Ltd

➔ Excluded after screening, BCC guidelines

191.

Potential molecular mechanisms of the anti-cancer activity of Vitamin D.

Skrajnowska D., Bobrowska-Korczak B.

Anticancer Research. 39(7) (pp 3353-3363), 2019. Date of Publication: 2019.

[Review]

Publisher

International Institute of Anticancer Research (1st km Kapandritiou - Kalamou Rd., P.O. Box 22, Kapandriti, Attica GR-19014, Greece. E-mail: subscriptions@iiar-anticancer.org)

➔ Excluded after screening, review

192.

Hedgehog signaling inhibitors in solid and hematological cancers.

Cortes J.E., Gutzmer R., Kieran M.W., Solomon J.A.

Cancer Treatment Reviews. 76 (pp 41-50), 2019. Date of Publication: June 2019.

[Review]

Publisher

W.B. Saunders Ltd

➔ Excluded after screening, review

193.

Medications Associated with Increased Risk of Keratinocyte Carcinoma.

Crow L.D., Kaizer-Salk K.A., Juszczak H.M., Arron S.T.

Dermatologic Clinics. 37(3) (pp 297-305), 2019. Date of Publication: July 2019.

[Review]

Publisher

W.B. Saunders

➔ Excluded after screening, review different topic

195.

Eruptive epidermoid cysts after imiquimod treatment of recurrent basal cell carcinoma: A case report. Eruptive Epidermoidzysten nach Imiquimod-Therapie eines rezidivierenden Basalzellkarzinoms: Ein Fallbericht <Eruptive Epidermoidzysten nach Imiquimod-Therapie eines rezidivierenden Basalzellkarzinoms: Ein Fallbericht.>

Woltsche N., El-Shabrawi-Caelen L., Deinlein T., Kupsa R., Gschwandtner M., Hofmann-Wellenhof R., Zalaudek I.

Hautarzt. 70(5) (pp 363-366), 2019. Date of Publication: 01 May 2019.

[Article]

Publisher

Springer Verlag (E-mail: service@springer.de)

➔ Excluded after screening, often described adverse event after vismodegib for laBCC

200.

Combination of novel systemic agents and radiotherapy for solid tumors - part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy.

Arcangeli S., Jereczek-Fossa B.A., Alongi F., Aristei C., Becherini C., Belgioia L., Buglione M., Caravatta L., D'Angelillo R.M., Filippi A.R., Fiore M., Genovesi D., Greco C., Livi L., Magrini S.M., Marvaso G., Mazzola R., Meattini I., Merlotti A., Palumbo I., Pergolizzi S., Ramella S., Ricardi U., Russi E., Trovo M., Sindoni A., Valentini V., Corvo R.

Critical Reviews in Oncology/Hematology. 134 (pp 87-103), 2019. Date of Publication: February 2019.

[Review]

Publisher

Elsevier Ireland Ltd

➔ Excluded after screening, review

201.

What's New in Genetic Skin Diseases.

Hill C.R., Theos A.

Dermatologic Clinics. 37(2) (pp 229-239), 2019. Date of Publication: April 2019.

[Review]

Publisher

W.B. Saunders

➔ Excluded after screening, review

202.

Therapeutic implications of cancer epithelial-mesenchymal transition (EMT).

Cho E.S., Kang H.E., Kim N.H., Yook J.I.

Archives of Pharmacal Research. 42(1) (pp 14-24), 2019. Date of Publication: 17 Jan 2019.

[Review]

Publisher

Pharmaceutical Society of Korea (E-mail: pskor@chollian.net)

➔ Excluded after screening, review

203.

Skin adverse events in recently approved targeted therapies in solid malignancies.

Habre M., Salloum A., Habre S.B., Abi Chebl J., Dib R., Kourie H.R.

Future Oncology. 15(3) (pp 331-343), 2019. Date of Publication: January 2019.

[Review]

Publisher

Future Medicine Ltd. (E-mail: info@futuremedicine.com)

➔ Excluded after screening, review

204.

Extensive bony metastases from facial metatypical basal cell carcinoma: a case report.

Pabst A., Klinghuber M., Muller G., Vandersee S., Werkmeister R.

British Journal of Oral and Maxillofacial Surgery. 57(1) (pp 82-84), 2019. Date of Publication: January 2019.

[Article]

Publisher

Churchill Livingstone

➔ Excluded after screening, mBCC

205.

Overexpression of Desmoglein 2 in a Mouse Model of Gorlin Syndrome Enhances Spontaneous Basal Cell Carcinoma Formation through STAT3-Mediated Gli1 Expression.

Brennan-Crispi D.M., Overmiller A.M., Tamayo-Orrego L., Marous M.R., Sahu J., McGuinn K.P., Cooper F., Georgiou I.C., Frankfurter M., Salas-Alanis J.C., Charron F., Millar S.E., Mahoney M.G., Riobo-Del Galdo N.A.

Journal of Investigative Dermatology. 139(2) (pp 300-307), 2019. Date of Publication: February 2019.

[Article]

Publisher

Elsevier B.V.

➔ Excluded after screening, in vitro and in vivo studies on molecular expression

EMBASE VISMODEGIB AND BASAL CELL NEVUS SYNDROME

Database: Embase <1974 to 2021 Week 37>

Search Strategy:

---

1 vismodegib/ (2276)

2 basal cell carcinoma/ (28620)

4 basal cell nevus syndrome/ (2721)

5 1 and 4 (236)

****

Duplicates: 111

1.

Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real-life data.

Gurbuz M., Dogan I., Akkus E., Ermis H., Utkan G., Vatansever S., Tas F.

Dermatologic Therapy. (no pagination), 2021. Date of Publication: 2021.

➔ Excluded after eligibility assessment, only reports on laCC and mBCC

2.

Sonidegib after vismodegib discontinuation in a patient with Gorlin-Goltz syndrome and multiple basal cell carcinomas.

Piccerillo A., Di Stefani A., Costantini A., Peris K.

Dermatologic Therapy. (no pagination), 2021. Date of Publication: 2021.

→ Included after elgibility assessment, reoccurrence of bcc's after vismodegib and consequently treated with sonidegib

4.

A case study on the use of Sonidegib in Basal-nevus syndrome.

Tam L., Ladwa R.

Australasian Journal of Dermatology. Conference: 53rd Annual Scientific Meeting of the Australasian College of Dermatologists, The Art of Dermatology. Virtual. 62(SUPPL 1) (pp 78-79), 2021. Date of Publication: April 2021.

➔ Excluded after eligibility assessment, case report sonidegib for BCNS does not report on reoccurence/resistance/dosing regiment/QoL

5.

Retrospective investigation of hereditary syndromes in patients with medulloblastoma in a single institution.

Wang Y., Wu J., Li W., Li J., Liu R., Yang B., Li C., Jiang T.

Child's Nervous System. 37(2) (pp 411-417), 2021. Date of Publication: February 2021.

[Article]

Publisher

Springer Science and Business Media Deutschland GmbH

➔ Excluded after screening, different disease

9.

Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas in gorlin-goltz syndrome.

Mendes S.R., Brinca A., Vieira R.

Journal of the Dermatology Nurses' Association. Conference: 24th World Congress of Dermatology. Milan Italy. 12(2) (no pagination), 2020. Date of Publication: March-April 2020.

➔ Included after eligibility assessment, case report with mention of reoccurrence and different schedule

10.

Nevoid basal cell carcinoma syndrome: Literature review and case report.

Alifakioti D., Zafiriou E., Gravani A., Gidarokosta P., Roussaki-Schulze A.

Journal of the Dermatology Nurses' Association. Conference: 24th World Congress of Dermatology. Milan Italy. 12(2) (no pagination), 2020. Date of Publication: March-April 2020.

[Conference Abstract]

Publisher

Lippincott Williams and Wilkins

➔ Excluded after screening, review

11.

Targeted treatment for shh+ medulloblastoma in a pediatric patient with gorlin syndrome.

Johnnidis M.

Pediatric Blood and Cancer. Conference: 2020 American Society of Pediatric Hematology/Oncology Conference, ASPHO 2020. Fort Worth, TX United States. 67(SUPPL 2) (no pagination), 2020. Date of Publication: June 2020.

[Conference Abstract]

Publisher

John Wiley and Sons Inc.

➔ Excluded after screening, different disease

12.

Genodermatoses with malignant potential.

Ladd R., Davis M., Dyer J.A.

Clinics in Dermatology. 38(4) (pp 432-454), 2020. Date of Publication: July - August 2020.

[Article]

Publisher

Elsevier Inc. (E-mail: sinfo-f@elsevier.com)

➔ Excluded after screening, genodermatoses in general

19.

Photocarcinogenesis.

Subhadarshani S., Athar M., Elmets C.A.

Current Dermatology Reports. 9(3) (pp 189-199), 2020. Date of Publication: 01 Sep 2020.

[Review]

Publisher

Springer

➔ Excluded after screening, review

22.

Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma.

Gurbuz M., Dogan I., Utkan G., Tas F.

Annals of Oncology. Conference: ESMO Asia Virtual Congress. Virtual, Online. 31(Supplement 6) (pp S1410-S1411), 2020. Date of Publication: November 2020.

[Conference Abstract]

Publisher

Elsevier Ltd

➔ Excluded after screening, vismodegib for aBCC

23.

388 Natural history and management of basal cell nevus syndrome: Updates from the gorlin syndrome registry.

Eng V., Saldanha G., Li S., Bailey-Healy I., Teng J., Tang J.

Journal of Investigative Dermatology. Conference: Society for Investigative Dermatology 2020. Virtual, Online. 140(7 Supplement) (pp S50), 2020. Date of Publication: July 2020.

→ Excluded after eligibility assessment, does not discuss hpi outcomes

26.

Treatment and therapeutic rest with vismodegib in a patient with Gorlin Goltz syndrome. Tratamiento y descanso terapeutico con vismodegib en un paciente con sindrome de Gorlin Goltz <Tratamiento y descanso terapeutico con vismodegib en un paciente con sindrome de Gorlin Goltz.>

Gonzalez Gonzalez M.A., Matilla Fernandez M.B., Ferreras Lopez N., Nieto Mangudo B., Ortiz de Urbina Gonzalez J.J.

Piel. 35(1) (pp 22-24), 2020. Date of Publication: January 2020.

→ Excluded after eligibility assessment, daily dosing for BCNS patient

William's syndrome associated with extensive infiltrative basal cell carcinoma.

Mosca M., Azzam M., Savell A., Hovenic W.

Journal of the American Academy of Dermatology. Conference: American Academy of Dermatology 2019 Annual Meeting. District of Columbia United States. 81(4 Supplement 1) (pp AB298), 2019. Date of Publication: October 2019.

[Conference Abstract]

Publisher

Mosby Inc.

➔ Excluded after screening, different disease

29.

Hereditary Tumor Syndromes with Skin Involvement.

Hamid R.N., Akkurt Z.M.

Dermatologic Clinics. 37(4) (pp 607-613), 2019. Date of Publication: October 2019.

[Review]

Publisher

W.B. Saunders

→ Excluded after screening, review

36.

Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.

Gutzmer R., Solomon J.A.

Targeted Oncology. 14(3) (pp 253-267), 2019. Date of Publication: 01 Jun 2019.

[Review]

Publisher

Springer-Verlag France (22, Rue de Palestro, Paris 75002, France)

➔ Excluded after screening, review

38.

Targeted biological drugs and immune check point inhibitors for locally advanced or metastatic cancers of the conjunctiva, eyelid, and orbit.

Esmaeli B., Sagiv O.

International Ophthalmology Clinics. 59(2) (pp 13-26), 2019. Date of Publication: 01 Mar 2019.

[Article]

Publisher

➔ Excluded after screening, aBCC

0.

Targeting the hedgehog pathway in cancer: Current evidence and future perspectives.

Girardi D., Barrichello A., Fernandes G., Pereira A.

Cells. 8(2) (no pagination), 2019. Article Number: 153. Date of Publication: 2019.

[Review]

Publisher

MDPI AG (Postfach, Basel CH-4005, Switzerland. E-mail: indexing@mdpi.com)

➔ Excluded after screening, review

41.

Hedgehog Pathway Inhibitors and Their Utility in Basal Cell Carcinoma: A Comprehensive Review of Current Evidence.

Tay E.Y.-X., Teoh Y.-L., Yeo M.S.-W.

Dermatology and Therapy. 9(1) (pp 33-49), 2019. Date of Publication: 01 Mar 2019.

[Review]

Publisher

➔ Excluded after screening, review

42.

Nonmelanoma Skin Cancer.

Brandt M.G., Moore C.C.

Facial Plastic Surgery Clinics of North America. 27(1) (pp 1-13), 2019. Date of Publication: February 2019.

[Review]

Publisher

W.B. Saunders

→ excluded after screening, review

43.

Sonidegib in nevoid basal cell carcinoma syndrome.

Canha C., Bajric B., Martinez A.E., Rana F.

Journal of Investigative Medicine. Conference: Southern Regional Meeting 2019. New Orleans, LA United States. 67(2) (pp 433-434), 2019. Date of Publication: February 2019.

➔ Excluded after eligibility assessment, sonidegib for BCNS, does not report on reoccurence/resistance/dosing regiment/QoL

45.

A rare presentation of multiple scrotal basal cell carcinomas secondary to Gorlin's syndrome.

Rohan P., Shilling C., Shah N., Daly P., Cullen I.

Journal of Clinical Urology. (no pagination), 2019. Date of Publication: 2019.

➔ Excluded after eligibility assessment, does not discuss HPI treatment

46.

Advanced basal cell cancer: Concise review of molecular characteristics and novel targeted and immune therapeutics.

Nikanjam M., Cohen P.R., Kato S., Sicklick J.K., Kurzrock R.

Annals of Oncology. 29(11) (pp 2192-2199), 2018. Date of Publication: November 2018.

[Review]

Publisher

Oxford University Press

➔ Excluded after screening, review

47.

Current trends in Hedgehog signaling pathway inhibition by small molecules.

Ghirga F., Mori M., Infante P.

Bioorganic and Medicinal Chemistry Letters. 28(19) (pp 3131-3140), 2018. Date of Publication: 15 October 2018.

[Review]

Publisher

Elsevier Ltd

➔ Excluded after screening, review

49.

Programmed death-1 blockade for multiple basal cell carcinomas: clearing the field systemically?.

Haug V., Schilling B.

British Journal of Dermatology. 179(3) (pp 566-567), 2018. Date of Publication: September 2018.

[Note]

Publisher

Blackwell Publishing Ltd

➔ Excluded after screening, different treatment

50.

Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.

Moreira A., Kirchberger M.C., Toussaint F., Erdmann M., Schuler G., Heinzerling L.

British Journal of Dermatology. 179(3) (pp 747-749), 2018. Date of Publication: September 2018.

[Article]

Publisher

Blackwell Publishing Ltd

➔ Excluded after screening, different treatment

52.

SOX9 Transcriptionally Regulates mTOR-Induced Proliferation of Basal Cell Carcinomas.

Kim A.L., Back J.H., Chaudhary S.C., Zhu Y., Athar M., Bickers D.R.

Journal of Investigative Dermatology. 138(8) (pp 1716-1725), 2018. Date of Publication: August 2018.

[Article]

Publisher

Elsevier B.V.

➔ Excluded after screening, cell research

53.

Illuminating Alternative Strategies to Treat Targeted Chemotherapy-Resistant Sporadic Basal Cell Carcinoma.

Nguyen T.T.L., Atwood S.X.

Journal of Investigative Dermatology. 138(5) (pp 1017-1019), 2018. Date of Publication: May 2018.

→ Excluded after screening, commentary

54.

Vismodegib-resistant basal cell carcinomas in basal cell nevus syndrome: Clinical approach and genetic analysis.

Sinx K.A.E., Roemen G.M.J.M., van Zutven V., Janssen R., Speel E.-J.M., Steijlen P.M., van Geel M., Mosterd K.

JAAD Case Reports. 4(5) (pp 408-411), 2018. Date of Publication: June 2018.

➔ Included after eligibility assessment, vismdoegib for BCNS discusses reoccurence

55.

Novel patched 1 mutations in patients with gorlin-goltz syndrome strategic treated by smoothened inhibitor.

Hsu S.-W., Lin C.-Y., Wang C.-W., Chung W.-H., Yang C.-H., Chang Y.-Y.

Annals of Dermatology. 30(5) (pp 597-601), 2018. Date of Publication: October 2018.

➔ Excluded after eligibility assessment, vismodegib for BCNS family, does not report on reoccurence/resistance/dosing regiment/QoL

56.

Advances in genetic understanding of gorlin syndrome and emerging treatment options.

Shih S., Dai C., Ansari A., Urso B.A., Laughlin A.I., Solomon J.A.

Expert Opinion on Orphan Drugs. 6(7) (pp 413-423), 2018. Date of Publication: 03 Jul 2018.

[Review]

Publisher

Taylor and Francis Ltd (E-mail: healthcare.enquiries@informa.com)

➔ Excluded after screening, review

57.

Gorlin Syndrome. Sindrome de Gorlin <Sindrome de Gorlin.>

Palacios-Alvarez I., Gonzalez-Sarmiento R., Fernandez-Lopez E.

Actas Dermo-Sifiliograficas. 109(3) (pp 207-217), 2018. Date of Publication: April 2018.

➔ Excluded after screening, review

59.

Basal cell nevus syndrome (Gorlin syndrome): genetic insights, diagnostic challenges, and unmet milestones.

Akbari M., Chen H., Guo G., Legan Z., Ghali G.

Pathophysiology. 25(2) (pp 77-82), 2018. Date of Publication: June 2018.

➔ Excluded after eligibility assessment, does not report on treatment with HPIs

60.

Mosaic SMO mutation in a patient with linear basal follicular hamartomas confirms Happle-Tinschert syndrome as a variant of Curry-Jones syndrome.

Lovgren M.-L., Twigg S.R.F., Moss C.

British Journal of Dermatology. Conference: 98th Annual Meeting of the British Association of Dermatologists, BAD 2018. Edinburgh United Kingdom. 179(Supplement 1) (pp 78-79), 2018. Date of Publication: July 2018.

➔ Excluded after eligibility assessment, does not report on treatment with HPIs

61.

Bromodomain-containing proteins BRD7 and BRD9 are novel interacting regulators of BCC resistance.

Kim A.L., Jin G.C., Zhu Y., Bickers D.R.

Journal of Investigative Dermatology. Conference: 2018 Annual Meeting of the International Investigative Dermatology, IID 2018. Orlando, FL United States. 138(5 Supplement 1) (pp S38), 2018. Date of Publication: May 2018.

➔ Excluded after screening, markers for resistance to vismodegib

62.

Confocal microscopy in management of gorlin syndrome.

Zaman S., Ravenscroft J., Flohr C., Craythorne E.

Pediatric Dermatology. Conference: 18th Annual Meeting of the European Society for Pediatric Dermatology, ESPD 2018. London United Kingdom. 35(Supplement 2) (pp S20), 2018. Date of Publication: April 2018.

➔ Excluded after screening, RCM for management of BCCs in gorlin children

63.

Case report: Use of vismodegib in a patient with Gorlin Goltz syndrome.

Gonzalez Gonzalez M.A., Ferreras N., Matilla B., Martinez E., Nieto B., Ruano R.

European Journal of Hospital Pharmacy. Conference: 23rd Congress of the European Association of Hospital Pharmacists, EAHP 2018. Gothenburg Sweden. 25(Supplement 1) (pp A97-A98), 2018. Date of Publication: March 2018.

→ Duplicate

66.

What's new with common genetic skin disorders?.

Ma J.E., Hand J.L.

Minerva Pediatrica. 69(4) (pp 288-297), 2017. Date of Publication: August 2017.

➔ Excluded after screening, review

67.

Spectrum of orocutaneous disease associations: Genodermatoses and inflammatory conditions.

Wilder E.G., Frieder J., Sulhan S., Michel P., Cizenski J.D., Wright J.M., Menter M.A.

Journal of the American Academy of Dermatology. 77(5) (pp 809-830), 2017. Date of Publication: November 2017.

Mosby Inc. (E-mail: customerservice@mosby.com)

➔ Excluded after screening, review

70.

Molecular basis of basal cell carcinoma.

Montagna E., Lopes O.S.

Anais Brasileiros de Dermatologia. 92(4) (pp 517-520), 2017. Date of Publication: July-August 2017.

➔ Excluded after screening, review

71.

Nevoid basal cell carcinoma syndrome (gorlin-goltz syndrome): A patient showing distinctive dermoscopic features: Case report.

Yorulmaz A., Atilan A.U., Yalcin B.

Turkiye Klinikleri Dermatoloji. 27(2) (pp 80-85), 2017. Date of Publication: 2017.

[Article]

Publisher

OrtadogAYu Reklam Tanitim Yayincilik Turizm Egitim Insaat Sanayi ve Ticaret A.S. (Turkocagi Caddesi No. 30, Balgat 06520, Turkey. E-mail: aysea@turkiyeklinikleri.com)

➔ Excluded after screening, not treated with hedgehog pathway inhibitor

72.

18th Annual Scientific Meeting of the NVED 2017.

Anonymous

Nederlands Tijdschrift voor Dermatologie en Venereologie. Conference: 18th Annual Scientific Meeting of the Nederlandse Vereniging voor Experimentele Dermatologie, NVED 2017. Lunteren Netherlands. 27(1) (no pagination), 2017. Date of Publication: January 2017.

[Conference Review]

Publisher

DCHG Partners in Mediscne Communicatie

➔ Excluded after screening, no information

76.

Predicting response to vismodegib before treatment initiation based on baseline characteristics in patients with metastatic basal cell carcinoma in a pooled analysis.

Grob J.-J., Hansson J., Basset-Seguin N., Kunstfeld R., Dreno B., Mortier L., Ascierto P., Licitra L., Hertig C., Dimier N., Fittipaldo A., Hauschild A.

Journal of the European Academy of Dermatology and Venereology. Conference: 13th Congress of the European Association of Dermato-Oncology, EADO 2017. Athens Greece. 31(Supplement 3) (pp 80-81), 2017. Date of Publication: June 2017.

[Conference Abstract]

Publisher

Blackwell Publishing Ltd

- ➔ Excluded after screening, research on mBCC
- ➔

  80.

  Vismodegib treatment in a multidisciplinary team, Aarhus Denmark - One year intention-to-treat cohort analysis and recommendations.
  Lorentzen H.F., Heje M., Als A.B.
  Journal of the European Academy of Dermatology and Venereology. Conference: 13th Congress of the European Association of Dermato-Oncology, EADO 2017. Athens Greece. 31(Supplement 3) (pp 88), 2017. Date of Publication: June 2017.
  [Conference Abstract]
- ➔ Excluded after eligibility assessment, does not discuss outcomes for multiple BCCs

82.

Abstracts of the 13th Congress of the European Association of Dermato-Oncology, EADO 2017.

Anonymous

Journal of the European Academy of Dermatology and Venereology. Conference: 13th Congress of the European Association of Dermato-Oncology, EADO 2017. Athens Greece. 31(Supplement 3) (no pagination), 2017. Date of Publication: June 2017.

[Conference Review]

Publisher

Blackwell Publishing Ltd

➔ Excluded after screening, no information

85.

Basal cell nevus syndrome (Gorlin-Goltz syndrome): Genetic predisposition, clinical picture and treatment.

Witmanowski H., Szychta P., Blochowiak K., Jundzill A., Czajkowski R.

Postepy Dermatologii i Alergologii. 34(4) (pp 381-387), 2017. Date of Publication: August 2017.

[Letter]

Publisher

Termedia Publishing House Ltd. (Kleeberqa St.2, Poznan 61-615, Poland)

➔ Excludded after screening, small review

86.

Implementation of systemic hedgehog inhibitors in daily practice as neoadjuvant therapy.

Tang N., Ratner D.

JNCCN Journal of the National Comprehensive Cancer Network. 15(4) (pp 537-543), 2017. Date of Publication: 01 Apr 2017.

[Review]

Publisher

Harborside Press (37 main Street, Cold Spring Harbor NY 11724, United States)

➔ Excluded after screening, review

88.

Ocular basal cell carcinoma: A brief literature review of clinical diagnosis and treatment.

Shi Y., Jia R., Fan X.

OncoTargets and Therapy. 10 (pp 2483-2489), 2017. Date of Publication: 08 May 2017.

[Article]

Publisher

Dove Medical Press Ltd. (PO Box 300-008, Albany, Auckland, New Zealand)

➔ Excluded after screening, review

90.

Segmental basal cell naevus syndrome caused by an activating mutation in smoothened.

Khamaysi Z., Bochner R., Indelman M., Magal L., Avitan-Hersh E., Sarig O., Sprecher E., Bergman R.

British Journal of Dermatology. (no pagination), 2016. Date of Publication: 2016.

[Article In Press]

Publisher

Blackwell Publishing Ltd (E-mail: customerservices@oxonblackwellpublishing.com)

➔ Excluded after screening, no treatment

91.

Hijacking the hedgehog pathway in cancer therapy.

Laukkanen M.O., Castellone M.D.

Anti-Cancer Agents in Medicinal Chemistry. 16(3) (pp 309-317), 2016. Date of Publication: 01 Mar 2016.

[Article]

Publisher

Bentham Science Publishers (P.O. Box 294, Bussum 1400 AG, Netherlands)

➔ Excluded after screening, review

92.

Hedgehog blockade for basal cell carcinoma coming at a (secondary neoplastic) price.

Rubben A., Hilgers R.-D., Leverkus M.

JAMA Dermatology. 152(5) (pp 521-523), 2016. Date of Publication: May 2016.

[Review]

Publisher

American Medical Association (E-mail: smcleod@itsa.ucsf.edu)

➔ Excluded after screening, review

96.

Recent trends in the treatment of benign odontogenic tumors.

Covello P., Buchbinder D.

Current Opinion in Otolaryngology and Head and Neck Surgery. 24(4) (pp 343-351), 2016. Date of Publication: 01 Aug 2016.

[Review]

Publisher

Lippincott Williams and Wilkins (E-mail: kathiest.clai@apta.org)-

➔ Excluded after screening, review on odontogenic keratocysts

97.

AKT1 activation is obligatory for spontaneous BCC tumor growth in a murine model that mimics some features of basal cell nevus syndrome.

Kim A.L., Back J.H., Zhu Y., Tang X., Yardley N.P., Kim K.J., Athar M., Bickers D.R.

Cancer Prevention Research. 9(10) (pp 794-802), 2016. Date of Publication: October 2016.

[Article]

Publisher

American Association for Cancer Research Inc. (E-mail: helen.atkins@aacr.org)

➔ Excluded after screening, molecular/cell research

98.

Safety and efficacy of vismodegib in patients with basal cell carcinoma nevus syndrome: Pooled analysis of two trials.

Chang A.L.S., Arron S.T., Migden M.R., Solomon J.A., Yoo S., Day B.-M., McKenna E.F., Sekulic A.

Orphanet Journal of Rare Diseases. 11(1) (no pagination), 2016. Article Number: 120. Date of Publication: 01 Sep 2016.

➔ Excluded after eligibility assessment, only results for aBCC

103.

Can hair re-growth be considered an early clinical marker of treatment resistance to Hedgehog inhibitors in patients with advanced basal cell carcinoma? A report of two cases.

Soura E., Plaka M., Dessinioti C., Syrigos K., Stratigos A.J.

Journal of the European Academy of Dermatology and Venereology. 30(10) (pp 1726-1729), 2016. Date of Publication: 01 Oct 2016.

→ Included after eligiblity assessment, resistance and reoccurence in BCCs BCNS patient with vismdeogib

107.

Familial skin cancer syndromes Increased risk of nonmelanotic skin cancers and extracutaneous tumors.

Jaju P.D., Ransohoff K.J., Tang J.Y., Sarin K.Y.

Journal of the American Academy of Dermatology. 74(3) (pp 437-451), 2016. Date of Publication: 01 Mar 2016.

➔ Excluded after screening, review

109.

Basal cell naevus syndrome: An update on genetics and treatment.

John A.M., Schwartz R.A.

British Journal of Dermatology. 174(1) (pp 68-76), 2016. Date of Publication: 01 Jan 2016.

[Article]

Publisher

Blackwell Publishing Ltd (E-mail: customerservices@oxonblackwellpublishing.com)

➔ Excluded after screening, guideline

110.

The burden of illness in patients with basal cell nevus syndrome: United States patient registry experience.

Solis D.C., Kwon G., Ransohoff K.J., Chahal H.S., Lindgren J.A., Li S., Ally M.S., Peters M., Teng J., Burr K., Epstein E., Tang J.

Journal of Investigative Dermatology. Conference: 2016 Annual Meeting of the Society for Investigative Dermatology, SID 2016. Scottsdale, AZ United States. 136(8) (pp B5), 2016. Date of Publication: August 2016.

→ Excluded after eligibility assessment, does not report outcome of QoL during hedgehog pathway inhibitor treatment

113.

Novel SUFU splice mutation in a child with multiple tumors.

Walsh M.F., Harlan M., Kennedy J., Musinsky J., LaQuaglia M., Stadler Z., Gilheeney S., Offit K.

Cancer Research. Conference: AACR Special Conference on Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship 2015. Fort Lauderdale, FL United States. 76(5 Supplement) (no pagination), 2016. Date of Publication: March 2016.

[Conference Abstract]

Publisher

American Association for Cancer Research Inc.

➔ Excluded after screening, not treated with hedgehog pathway inhibitor

115.

Long-term follow-up of two patients with Nevoid basal cell carcinoma syndrome (NBCCS) treated with Vismodegib.

Van Eecke L., Wolter P., Bechter O., Rogiers A., De Smedt J., Garmyn M.

Melanoma Research. Conference: 16th World Congress on Cancers of the Skin 2016. Vienna Austria. 26(Supplement 1) (pp e75-e76), 2016. Date of Publication: August 2016.

[Conference Abstract]

→ included after eligibility assesment, long term vismodegib in bcns with reoccurence

Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms Involved

Meghana Kesireddy , Vincent L. Mendiola , Bagi Jana , Shrestha Patel

→ Included after eligibility assessement

117.

Gorlin syndrome with locally advanced basal cell carcinomas treated with vismodegib.

Abeldano A., Maskin M., Arias M., Gonzalez A., Benedetti A., Lamas C.

Melanoma Research. Conference: 16th World Congress on Cancers of the Skin 2016. Vienna Austria. 26(Supplement 1) (pp e88), 2016. Date of Publication: August 2016.

[Conference Abstract]

Publisher

Lippincott Williams and Wilkins

➔ Excluded after screening, laBCC

119.

Resistances to vismodegibs in a French case series of 207 patients with locally advanced basal cell carcinoma.

Basset-Seguin N., Sharpe H., Poulalhon N., Mortier L., Saiag P., Monestier S., Hou J., Bagot M., Guillot B., Robert C., Meyer N., Khammari A., Grange F., Dutriaux C., Dreno B., De Sauvage F.

Journal of Clinical Oncology. Conference: 2016 Annual Meeting of the American Society of Clinical Oncology, ASCO 2016. Chicago, IL United States. 34(Supplement 15) (no pagination), 2016. Date of Publication: May 2016.

[Conference Abstract]

Publisher

American Society of Clinical Oncology

➔ Excluded after screening, resistance in laBCC

122.

Ingenol Mebutate Treatment in a Patient with Gorlin Syndrome.

Stieger M., Hunger R.E.

Dermatology. 232(1 Supplement 1) (pp 29-31), 2016. Date of Publication: 01 Aug 2016.

[Article]

Publisher

S. Karger AG

→ Excluded after screening, different treatment

125.

Non-melanoma skin cancer - Overview.

Joseph K.

Current Cancer Therapy Reviews. 12(3) (pp 142-151), 2016. Date of Publication: 01 Sep 2016.

[Review]

Publisher

Bentham Science Publishers B.V. (P.O. Box 294, Bussum 1400 AG, Netherlands)

➔ Excluded after screening, review

126.

Diagnosis and management of hereditary basal cell skin cancer.

Shanley S., McCormack C.

Recent Results in Cancer Research. 205 (pp 191-212), 2016. Date of Publication: 2016.

[Article]

Publisher

Springer New York LLC (E-mail: barbara.b.bertram@gsk.com)

➔ Excluded after screening, review/guideline

127.

Not the usual suspect: a case of basal cell naevus syndrome caused by a SMO mutation alone.

Ahn R.S.

British Journal of Dermatology. 175(1) (pp 21-22), 2016. Date of Publication: 01 Jul 2016.

[Note]

Publisher

Blackwell Publishing Ltd (E-mail: customerservices@oxonblackwellpublishing.com)

➔ Excluded after screening, no treatment with hedgehog pathway inhibitor

129.

Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndrome.

Chaudhary S.C., Tang X., Arumugam A., Li C., Srivastava R.K., Weng Z., Xu J., Zhang X., Kim A.L., McKay K., Elmets C.A., Kopelovich L., Bickers D.R., Athar M.

Oncotarget. 6(34) (pp 36789-36814), 2015. Date of Publication: 2015.

[Article]

Publisher

Impact Journals LLC (E-mail: editors@impactaging.com)

➔ Excluded after screening, cell/molecular research

130.

Review of ocular manifestations of nevoid basal cell carcinoma syndrome: What an ophthalmologist needs to know.

Chen J.J., Sartori J., Aakalu V.K., Setabutr P.

Middle East African Journal of Ophthalmology. 22(4) (pp 421-427), 2015. Date of Publication: October-December 2015.

➔ Excluded after screening, review

131.

Usefulness of photodynamic therapy as a possible therapeutic alternative in the treatment of basal cell carcinoma.

Savoia P., Deboli T., Previgliano A., Broganelli P.

International Journal of Molecular Sciences. 16(10) (pp 23300-23317), 2015. Date of Publication: 28 Sep 2015.

➔ Excluded after screening, review

134.

Paediatric dermatology highlights.

Dinulos J.G.

Current Opinion in Pediatrics. 27(4) (pp 453), 2015. Date of Publication: 01 Aug 2015.

➔ Excluded after screening, review

139.

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: Clinical update.

Takebe N., Miele L., Harris P.J., Jeong W., Bando H., Kahn M., Yang S.X., Ivy S.P.

Nature Reviews Clinical Oncology. 12(8) (pp 445-464), 2015. Date of Publication: 30 Aug 2015.

[Review]

Publisher

Nature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom)

➔ Excluded after screening, review

140.

Hedgehog signaling and urological cancers.

Shigemura K., Fujisawa M.

Current Drug Targets. 16(3) (pp 258-271), 2015. Date of Publication: 2015.

[Article]

Publisher

Bentham Science Publishers B.V. (P.O. Box 294, Bussum 1400 AG, Netherlands)

➔ Excluded after screening, different disease

141.

Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations.

Gururangan S., Robinson G., Ellison D.W., Wu G., He X., Lu Q.R., Mclendon R., Grant G., Driscoll T., Neuberg R.

Pediatric Blood and Cancer. 62(10) (pp 1855-1858), 2015. Date of Publication: 01 Oct 2015.

➔ Excluded after screening, different gorlin symptom

142.

Characteristics and outcomes of nonmelanoma skin cancer (NMSC) in children and young adults.

Khosravi H., Schmidt B., Huang J.T.

Journal of the American Academy of Dermatology. 73(5) (pp 785-790), 2015. Date of Publication: November 2015.

[Article]

Publisher

Mosby Inc. (E-mail: customerservice@mosby.com)

➔ Excluded after eligibility assessment, only 1 patient received vismodegib and nothing is mentioned on outcome

144.

Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - Role of smoothened inhibitors.

Fecher L.A., Sharfman W.H.

Biologics: Targets and Therapy. 9 (pp 129-140), 2015. Date of Publication: 06 Nov 2015.

[Review]

Publisher

Dove Medical Press Ltd. (PO Box 300-008, Albany, Auckland, New Zealand)

➔ Excluded after screening, review aBCC

145.

Digging a hole under Hedgehog: Downstream inhibition as an emerging anticancer strategy.

Di Magno L., Coni S., Di Marcotullio L., Canettieri G.

Biochimica et Biophysica Acta - Reviews on Cancer. 1856(1) (pp 62-72), 2015. Date of Publication: August 01, 2015.

➔ Excluded after screening, review

148.

Cooperative integration between HEDGEHOG-GLI signalling and other oncogenic pathways: Implications for cancer therapy.

Pandolfi S., Stecca B.

Expert Reviews in Molecular Medicine. 17 (no pagination), 2015. Article Number: e5. Date of Publication: 30 Jan 2015.

➔ Excluded after screening, review

150.

Basal cell carcinoma: Clinical practice assessment and educational gap analysis.

Herrmann T., Pearce F., Williamson C., Peters P., Weiss G.J.

Journal of the American Academy of Dermatology. Conference: 73rd Annual Meeting of the American Academy of Dermatology. San Francisco, CA United States. Conference Publication: (var.pagings). 72(5 SUPPL. 1) (pp AB181), 2015. Date of Publication: May 2015.

➔ Excluded after screening, lecture

152.

Smoothened (SMO) resistance is driven by PI3K-Akt signaling in a subset of murine ASZ001 BCC cells displaying tumor-initiating cell (TIC)-like characteristics.

Jin G.C., Zhu Y., Kim A., Bickers D.R.

Journal of Investigative Dermatology. Conference: 2015 Annual Meeting of the Society for Investigative Dermatology. Atlanta, GA United States. Conference Publication: (var.pagings). 135(SUPPL. 1) (pp S20), 2015. Date of Publication: May 2015.

➔ Excluded after screening, cell/molecular research

158.

Gorlin syndrome (nevoid basal cell carcinoma syndrome): Update and literature review.

Fujii K., Miyashita T.

Pediatrics International. 56(5) (pp 667-674), 2014. Date of Publication: 01 Oct 2014.

➔ Excluded after screening (review)

163.

The spectrum of oculocutaneous disease: Part II. Neoplastic and drug-related causes of oculocutaneous disease.

Day A., Abramson A.K., Patel M., Warren R.B., Menter M.A.

Journal of the American Academy of Dermatology. 70(5) (pp e1-821), 2014. Date of Publication: 2014.

[Article]

Publisher

Mosby Inc. (E-mail: customerservice@mosby.com)

➔ Excluded after screening, aBCC

165.

Targeted therapy for hereditary cancer syndromes: Neurofibromatosis type 1, neurofibromatosis type 2, and gorlin syndrome.

Agarwal R., Liebe S., Turski M.L., Vidwans S.J., Janku F., Garrido-Laguna I., Munoz J., Schwab R., Rodon J., Kurzrock R., Subbiah V.

Discovery Medicine. 18(101) (pp 323-330), 2014. Date of Publication: 2014.

➔ Excluded after screening, review

167.

Case: Targeted therapy-vismodegib in the management of recurrent basal cell carcinoma in gorlin syndrome.

Kelly W., Kelly C., Hanrahan E.O., Ballot J.

Irish Journal of Medical Science. Conference: RAMI Intern Section Meeting 2014. Dublin Ireland. Conference Publication: (var.pagings). 183(4 SUPPL. 1) (pp S145), 2014. Date of Publication: July 2014.

➔ Excluded after eligibility assessment, does not report outcome in the abstract

170.

Interaction of hedgehog and vitamin D signaling pathways in basal cell carcinomas.

Albert B., Hahn H.

Advances in Experimental Medicine and Biology. 810 (pp 329-341), 2014. Date of Publication: 2014.

➔ Excluded after screening, book chapter

171.

Targeted therapy for advanced basal-cell carcinoma: Vismodegib and beyond.

Cowey C.L.

Dermatology and Therapy. 3(1) (pp 17-31), 2013. Date of Publication: June 2013.

➔ Excluded after screening, review

173.

Inhibition of hedgehog/Gli signaling by botanicals: A review of compounds with potential hedgehog pathway inhibitory activities.

Drenkhahn S.K., Jackson G.A., Slusarz A., Starkey N.J.E., Lubahn D.B.

Current Cancer Drug Targets. 13(5) (pp 580-595), 2013. Date of Publication: 2013.

➔ Excluded after screening, review of compounds with potential hedgehog pathway inhibition

177.

New prospects for drug development: The hedgehog pathway revealed. Focus on hematologic malignancies.

Pimentel A., Velez M., Barahona L.J., Swords R., Lekakis L.

Future Oncology. 9(5) (pp 681-697), 2013. Date of Publication: May 2013.

➔ Excluded after screening, review

178.

Systemic treatment for hereditary cancers: A 2012 update.

Imyanitov E.N., Byrski T.

Hereditary Cancer in Clinical Practice. 11(1) (no pagination), 2013. Article Number: 2. Date of Publication: 01 Apr 2013.

[Review]

Publisher

BioMed Central Ltd. (Floor 6, 236 Gray's Inn Road, London WC1X 8HB, United Kingdom)

➔ Excluded after screening, review

179.

Systemic therapy for inoperable and metastatic basal cell cancer.

Fecher L.A.

Current Treatment Options in Oncology. 14(2) (pp 237-248), 2013. Date of Publication: June 2013.

[Article]

Publisher

Springer New York (233 Spring Street, New York NY 10013-1578, United States)

➔ Excluded after screening, review

180.

Brief S2k guidelines - Basal cell carcinoma of the skin. S2k Kurzleitlinie - Basalzellkarzinom der Haut <S2k Kurzleitlinie - Basalzellkarzinom der Haut.>

Hauschild A., Breuninger H., Kaufmann R., -DieterKortmann R., Klein M., Werner J., Reifenberger J., Dirschka T., Garbe C.

JDDG - Journal of the German Society of Dermatology. 11(SUPPL. 3) (pp 10-15), 2013. Date of Publication: June 2013.

[Article]

Publisher

Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)

➔ Excluded after screening, guidelines BCC

181.

The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy.

Hui M., Cazet A., Nair R., Watkins D.N., O'Toole S.A., Swarbrick A.

Breast Cancer Research. 15(2) (no pagination), 2013. Article Number: 203. Date of Publication: 28 Mar 2013.

[Review]

Publisher

BioMed Central Ltd. (Floor 6, 236 Gray's Inn Road, London WC1X 8HB, United Kingdom)

➔ Excluded after screening, review on different disease

182.

Therapeutic targeting of developmental signaling pathways in medulloblastoma: Hedgehog, Notch, Wnt and Myc.

Raabe E., Eberhart C.G.

Current Signal Transduction Therapy. 8(1) (pp 55-66), 2013. Date of Publication: April 2013.

[Article]

Publisher

Bentham Science Publishers B.V. (P.O. Box 294, Bussum 1400 AG, Netherlands)

➔ Excluded after screening, different disease

184.

Targeting hedgehog signaling in cancer: Research and clinical developments.

Xie J., Bartels C.M., Barton S.W., Gu D.

OncoTargets and Therapy. 6 (pp 1425-1435), 2013. Date of Publication: 2013.

[Review]

Publisher

Dove Medical Press Ltd. (PO Box 300-008, Albany, Auckland, New Zealand)

➔ Excluded after screening, review

186.

Cancer-associated genodermatoses: Skin neoplasms as clues to hereditary tumor syndromes.

Ponti G., Pellacani G., Seidenari S., Pollio A., Muscatello U., Tomasi A.

Critical Reviews in Oncology/Hematology. 85(3) (pp 239-256), 2013. Date of Publication: March 2013.

[Review]

Publisher

Elsevier Ireland Ltd (P.O. Box 85, Limerick, Ireland)

➔ Excluded after screening, review

188.

Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome.

Ally M.S., Wysong A., Tang J.Y., Aasi S.

Dermatologic Surgery. 39(9) (pp 1413-1414), 2013. Date of Publication: September 2013.

[Letter]

Publisher

Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)

➔ Excluded after eligibility assessment, discusses no new cases

189.

Role of the Hedgehog pathway in hepatocellular carcinoma (Review).

Zheng X., Zeng W., Gai X., Xu Q., Li C., Liang Z., Tuo H., Liu Q.

Oncology Reports. 30(5) (pp 2020-2026), 2013. Date of Publication: November 2013.

[Review]

Publisher

Spandidos Publications Ltd. (10 Vriaxidos Street, Athens 11635, Greece)

➔ Excluded after screening, review different disease

190.

Targeted therapies and basal cell carcinoma.

Basset-Seguin N.

Oncologie. 15(2) (pp 101-105), 2013. Date of Publication: January 2013.

[Review]

Publisher

Springer Paris (1 rue Paul Cezanne, Paris 75008, France)

➔ Excluded after screening, review

197.

A better way forward: Targeting hedgehog signaling in liver cancer.

Kappler R., Von Schweinitz D.

Frontiers in Bioscience - Scholar. 4 S(1) (pp 277-286), 2012. Date of Publication: 01 Jan 2012.

[Article]

Publisher

Frontiers in Bioscience

➔ Excluded after screening, different disease

198.

Basal cell carcinoma: Topical therapy versus surgical treatment.

Sharquie K.E., Noaimi A.A.

Journal of the Saudi Society of Dermatology and Dermatologic Surgery. 16(2) (pp 41-51), 2012. Date of Publication: July 2012.

[Review]

Publisher

Elsevier

➔ Excluded after screening, review

200.

Targeting the Hedgehog signaling pathway for cancer therapy.

Li Y., Maitah M.Y., Ahmad A., Kong D., Bao B., Sarkar F.H.

Expert Opinion on Therapeutic Targets. 16(1) (pp 49-66), 2012. Date of Publication: January 2012.

[Review]

Publisher

Informa Healthcare (69-77 Paul Street, London EC2A 4LQ, United Kingdom)

➔ Excluded after screening, review

201.

Adult medulloblastoma, from spongioblastoma cerebelli to the present day: A review of treatment and the integration of molecular markers.

Shonka N., Brandes A., de Groot J.F.

ONCOLOGY (United States). 26(11) (no pagination), 2012. Date of Publication: 2012.

[Review]

Publisher

UBM Medica Healthcare Publications (PO Box 390427, Minneapolis MN 55439, United States)

➔ Excluded after screening, different disease

202.

New systemic treatment options for advanced basal cell carcinoma.

Guminski A.

Cancer Forum. 36(3) (no pagination), 2012. Date of Publication: November 2012.

[Review]

Publisher

Cancer Council Australia (Level 1, 120 chambers street, Surry Hills NSW 2010, Australia)

➔ Excluded after screening, review

203.

Urticaria after methyl aminolevulinate photodynamic therapy in a patient with nevoid basal cell carcinoma syndrome.

Wolfe C.M., Green W.H., Hatfield H.K., Cognetta Jr. A.B.

Journal of Drugs in Dermatology. 11(11) (pp 1364-1365), 2012. Date of Publication: November 2012.

[Article]

Publisher

Journal of Drugs in Dermatology (377 Park Avenue South, New York NY 10016, United States)

➔ Excluded after screening, different treatment

204.

Targeting hedgehog in hematologic malignancy.

Irvine D.A., Copland M.

Blood. 119(10) (pp 2196-2204), 2012. Date of Publication: 08 Mar 2012.

[Review]

Publisher

American Society of Hematology (1900 M Street, Suite 2000, Washington DC 20036, United

→ excluded after screening, different disease

205.

Investigational agents in metastatic basal cell carcinoma: Focus on vismodegib.

Batty N., Kossoff E., Dy G.K.

Journal of Experimental Pharmacology. 4(1) (pp 97-103), 2012. Date of Publication: 2012.

[Review]

Publisher

DOVE Medical Press Ltd. (PO Box 300-008, Albany, Auckland, New Zealand)

➔ Excluded after screening, review

207.

Advances in targeting the Hedgehog signaling pathway in cancer therapy.

Kiesslich T., Neureiter D.

Expert Opinion on Therapeutic Targets. 16(2) (pp 151-156), 2012. Date of Publication: February 2012.

[Review]

Publisher

Informa Healthcare (69-77 Paul Street, London EC2A 4LQ, United Kingdom)

➔ Excluded after screening, review

209.

Metastatic basal cell carcinoma in the era of hedgehog signaling pathway inhibitors.

Weiss G.J., Korn R.L.

Cancer. 118(21) (pp 5310-5319), 2012. Date of Publication: 01 Nov 2012.

[Review]

Publisher

John Wiley and Sons Inc. (P.O.Box 18667, Newark NJ 07191-8667, United States)

➔ Excluded after screening, review

210.

Introduction: Advanced cutaneous malignancies.

Glass L.F., Deconti R.C., Sondak V.K.

Seminars in Oncology. 39(2) (pp 132-133), 2012. Date of Publication: April 2012.

[Editorial]

Publisher

W.B. Saunders (Independence Square West, Philadelphia PA 19106-3399, United States)

→ excluded after screening, editorial

213.

The hedgehog signaling pathway in basal cell carcinoma-from bench to bedside.

Caro I.

Wound Repair and Regeneration. Conference: Conjoint 3rd Australasian Wound and Tissue Repair Society and 9th Australasian Society for Dermatology Research Conference. Sydney Australia. Conference Publication: (var.pagings). 20(5) (pp A55), 2012. Date of Publication: September-October 2012.

[Conference Abstract]

Publisher

Blackwell Publishing Inc.

➔ Excluded after screening, no study in patients

215.

The oral hedgehog inhibitor vismodegib (GDC-0449) in the treatment of locally advanced basal cell carcinoma: Experience of one Australian centre.

Intong L.R.A., Rhodes L.M., Caro I., Murrell D.F.

Australasian Journal of Dermatology. Conference: 45th Annual Scientific Meeting of the Australasian College of Dermatologists. Brisbane, QLD Australia. Conference Publication: (var.pagings). 53(SUPPL. 1) (pp 40), 2012. Date of Publication: May 2012.

[Conference Abstract]

➔ Excluded after screening, treatment of laBCC

216.

Hedgehog pathway as a drug target: Smoothened inhibitors in development.

Lin T.L., Matsui W.

OncoTargets and Therapy. 5 (pp 47-58), 2012. Date of Publication: 2012.

[Review]

Publisher

DOVE Medical Press Ltd. (PO Box 300-008, Albany, Auckland, New Zealand)

-→ excluded after screening, review

219.

Vismodegib is effective in the treatment and prevention of BCC.

Anonymous

Cancer Discovery. 2(8) (pp 661), 2012. Date of Publication: August 2012.

[Article]

Publisher

American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106-3483, United States)

➔ Excluded after screening, no information

220.

Initial assessment of tumor regrowth after vismodegib in advanced basal cell carcinoma.

Chang A.L.S., Oro A.E.

Archives of Dermatology. 148(11) (pp 1324-1325), 2012. Date of Publication: November 2012.

[Article]

Publisher

American Medical Association (515 North State Street, Chicago IL 60654, United States)

➔ Included after eligibility assesment, discusses regrwoth in multiple BCC patients

221.

Expect a miracle.

Burr K.S., Hughes P., LaRosa S.

Journal of the Dermatology Nurses' Association. 4(1) (pp 42-44), 2012. Date of Publication: January-February 2012.

[Conference Paper]

Publisher

Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106-3621, United States)

➔ Excluded after screening, patient story

222.

Emerging trends and treatment approaches in nonmelanoma skin cancer: A Canadian perspective.

Kuzel P., Green J.B., Metelitsa A.I.

Journal of Cutaneous Medicine and Surgery. 15(SUPPL. 1) (pp S365-S370), 2011. Date of Publication: December 2011.

[Review]

Publisher

Decker Intellectual Properties (E-mail: claims@sagepub.com)

➔ Exclued after screening, review

223.

Long-term safety, tolerability, and efficacy of vismodegib in two patients with metastatic basal cell carcinoma and basal cell nevus syndrome.

Weiss G.J., Tibes R., Blaydorn L., Jameson G., Downhour M., White E., Caro I., Von Hoff D.D.

Dermatology Reports. 3(3) (no pagination), 2011. Article Number: e55. Date of Publication: 2011.

[Article]

Publisher

Page Press Publication (via Giuseppe Belli, Pavia 7, 27100, Italy)

➔ Excluded after eligibility assessment, multiple BCCs in BCNS patient, does not report on reoccurence/resistance/dosing regiment/QoL

224.

Conference Essence in Dermatology 2011, Hong Kong.

Tang J.W.S., Lam W.Y.K., Yau E.K.Y.

Hong Kong Journal of Dermatology and Venereology. 19(4) (pp 197-201), 2011. Date of Publication: 2011.

[Conference Paper]

Publisher

Medcom Limited (18 Cheung Lee Street, Chaiwan, Hong Kong)

➔ Excluded after screening, conference overview

225.

Cancer interception.

Blackburn E.H.

Cancer Prevention Research. 4(6) (pp 187-192), 2011. Date of Publication: June 2011.

[Note]

Publisher

American Association for Cancer Research Inc. (615 Chestnut Street, 17th Floor, Philadelphia PA 19106-3483, United States)

➔ Excluded after screening, note

231.

Hereditary tumour syndromes featuring basal cell carcinomas.

Parren L.J.M.T., Frank J.

British Journal of Dermatology. 165(1) (pp 30-34), 2011. Date of Publication: July 2011.

[Review]

Publisher

Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)

➔ Excluded after screening, review

233.

Whole organism based techniques and approaches in early stage oncology drug discovery-patents and trends.

Hampson R.J., Wyatt M.D.

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery. 5(3) (pp 183-191), 2011. Date of Publication: September 2011.

[Article]

Publisher

Bentham Science Publishers B.V. (P.O. Box 294, Bussum 1400 AG, Netherlands)

➔ Excluded after screening, drug discovery paper

234.

Scientific highlights from the 71st annual meeting of the society for investigative dermatology.

Schultz H.Y.

Journal of Investigative Dermatology. 131(10) (pp 1963-1967), 2011. Date of Publication: October 2011.

[Conference Paper]

Publisher

Nature Publishing Group (345 Park Avenue South, New York NY 10010-1707, United States)

➔ Excluded after screening, review on conference

235.

Changing pathology with changing drugs: Skin cancer.

Karpova M.B., Barysch M.J., Zipser M.C., Schonewolf N., French L.E., Dummer R.

Pathobiology. 78(2) (pp 61-75), 2011. Date of Publication: June 2011.

[Review]

Publisher

S. Karger AG (Allschwilerstrasse 10, P.O. Box, Basel CH-4009, Switzerland)

→ Excluded after screening, review

236.

Vismodegib: SMO receptor antagonist hedgehog signaling inhibitor oncolytic.

Haddley K.

Drugs of the Future. 35(5) (pp 379-384), 2010. Date of Publication: May 2010.

[Article]

Publisher

Prous Science (P.O. Box 540, Barcelona 08080, Spain)

➔ Excluded after screening, review

EMBASE SONIDEGIB AND BASAL CELL CARCINOMA

Database: Embase <1974 to 2021 Week 37>

Search Strategy:

---

2 basal cell carcinoma/ (28620)

4 basal cell nevus syndrome/ (2721)

6 multiple basal cell carcinomas.mp. (472)

8 sonidegib/ (873)

9 2 and 8 (350)

****

Duplicate: 217

Excluded after screening: 131

Eligibility assessment: 2
Included: 2

17.

Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas.

Tarantino V., Zavattaro E., Veronese F., Gironi L.C., Savoia P.

Anti-Cancer Drugs. (pp 465-468), 2021. Date of Publication: 2021.

[Article]

Publisher

Lippincott Williams and Wilkins

- ➔ Excluded after eligibility assessment, case report of BCNS patient with multiple BCC treated with sonidegib, does not report on reoccurence/resistance/dosing regiment/QoL

114.

An iatrogenic conundrum: Novel management of multiple facial BCCs years after radiotherapy for acne.

Charlton O., Phan K., Smith S.

Australasian Journal of Dermatology. Conference: 52nd Annual Scientific Meeting of the Australasian College of Dermatologists. Melbourne, VIC Australia. 60(Supplement 1) (pp 24-25), 2019. Date of Publication: May 2019.

- ➔ Excluded after eligibility assessment, case report of BCNS patient with multiple BCC treated with sonidegib, does not report on reoccurence/resistance/dosing regiment/QoL

EMBASE SONIDEGIB AND BASAL CELL NEVUS SYNDROME

Database: Embase <1974 to 2021 Week 37>

Search Strategy:

---

1 basal cell nevus syndrome/ (2721)

2 sonidegib/ (873)

3 1 and 2 (67)

****

Duplicates: 62

Unique: 5

Assessed: 3

Included: 2

2.

26211 Pharmacokinetics of sonidegib in patients with nevoid basal cell carcinoma syndrome.

Lear J., Hauschild A., Squittieri N., Basset-Seguin N., Dummer R.

Journal of the American Academy of Dermatology. Conference: 2021 AAD VMX Vertual Meeting. Virtual, Online. 85(3 Supplement) (pp AB90), 2021. Date of Publication: September 2021.

[Conference Abstract]

Publisher

Mosby Inc.

➔ Excluded after eligibility assessment, only discusses pharmacokinetics

3.

26206 Effect of sonidegib on secondary tumor size endpoints through 12 weeks of treatment in patients with nevoid basal cell carcinoma syndrome.

Lear J., Hauschild A., Squittieri N., Basset-Seguin N., Dummer R.

Journal of the American Academy of Dermatology. Conference: 2021 AAD VMX Vertual Meeting. Virtual, Online. 85(3 Supplement) (pp AB90), 2021. Date of Publication: September 2021.

➔ Included after eligibility assessment, long-term data on sonidegib vs placebo trial

13.

Efficacy and safety of sonidegib in adult patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome): Results from a phase 2, double-blind, randomized trial.

Lear J.T., Hauschild A., Stockfleth E., Squittieri N., Basset-Seguin N., Dummer R.

Clinical, Cosmetic and Investigational Dermatology. 13 (pp 117-121), 2020. Date of Publication: 2020.

➔ Included after eligibility assessment, short-term data on sonidegib vs placebo trial

44.

Canonical and non-canonical hedgehog signaling pathways: Role of G proteins.

Riobo N.A.

Topics in Medicinal Chemistry. 16 (pp 13-42), 2015. Date of Publication: 2015.

➔ Excluded after screening, review

52.

From an orphan disease to a generalized molecular mechanism: PTPN11 loss-of-function mutations in the pathogenesis of metachondromatosis.

Yang W., Neel B.G.

Rare Diseases. 1(OCT) (no pagination), 2013. Article Number: e26657. Date of Publication: 02 Oct 2013.

➔ Excluded after screening, different syndrome

EMBASE ITRACONAZOLE AND BASAL CELL CARCINOMA

Database: Embase <1974 to 2021 Week 37>

Search Strategy:

---

1 basal cell carcinoma/ (28620)

2 itraconazole/ (31765)

3 1 and 2 (165)

****

Duplicates: 85

Excluded after screening: 79

Assessed: 1

Included: 1

31.

Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients with Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas: A Phase 2, Open-Label, Placebo-Controlled Trial.

Sohn G.K., Kwon G.P., Bailey-Healy I., Mirza A., Sarin K., Oro A., Tang J.Y.

JAMA Dermatology. 155(9) (pp 1078-1080), 2019. Date of Publication: September 2019.

➔ Included after eligibility assessment, results topical itraconazole in BCNS/mult BCC

Supplementary Table 1. Risk of bias of included efficacy trials

	Selection bias	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other bias
(Tang, Mackay-Wiggan et al. 2012, Tang, Ally et al. 2016)	+	+	+	?	?	+
(Lear, Hauschild et al. 2020)	?	+	+	?	−	?
(Dreno, Kunstfeld et al. 2017)	+	?	?	+	+	+
(Verkouteren, Wakkee et al. 2021)	+	Not applicable	−	+	+	?
(Sohn, Kwon et al. 2019)	+	?	?	+	+	+
(Epstein, Lear et al. 2018)	+	+	+	?	?	?
(Skvara, Kalthoff et al. 2011)	+	+	+	?	?	+

+ low risk of bias

? unknown risk of bias

− high risk of bias

References

Dreno, B., et al. (2017). "Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial." Lancet Oncol **18**(3): 404-412.

BACKGROUND: Vismodegib, a first-in-class Hedgehog-pathway inhibitor, is approved for use in adults with advanced basal-cell carcinoma. Patients with multiple basal-cell carcinomas, including those with basal-cell nevus (Gorlin) syndrome, need extended treatment. We assessed the safety and activity of two long-term intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas. METHODS: In this randomised, regimen-controlled, double-blind, phase 2 trial, we enrolled adult patients with multiple basal-cell carcinomas, including those with basal-cell nevus syndrome, who had one or more histopathologically confirmed and at least six clinically evident basal-cell carcinomas. From a centralised randomisation schedule accessed via an interactive voice or web-based response system, patients were randomly assigned (1:1) to treatment group A (150 mg oral vismodegib per day for 12 weeks, then three rounds of 8 weeks of placebo daily followed by 12 weeks of 150 mg vismodegib daily) or treatment group B (150 mg oral vismodegib per day for 24 weeks, then three rounds of 8 weeks of placebo daily followed by 8 weeks of 150 mg vismodegib daily). Treatment assignment was stratified by diagnosis of basal-cell nevus syndrome, geographical region, and immunosuppression status. The primary endpoint was percentage reduction from baseline in the number of clinically evident basal-cell carcinomas at week 73. The primary analysis was by intention to treat. The safety population included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01815840, and the study is ongoing. FINDINGS: Between April 30, 2013, and April 9, 2014, 229 patients were randomly assigned treatment, 116 in treatment group A and 113 in treatment group B. The mean number of basal-cell carcinoma lesions at week 73 was reduced from baseline by 62.7% (95% CI 53.0-72.3) in treatment group A and 54.0% (43.6-64.4) in treatment group B. 216 (95%) of 227 patients included in the safety analysis had at least one treatment-emergent adverse event deemed to be related to study treatment (107 [94%] of 114 in treatment group A and 109 [97%] of 113 in treatment group B). The most common grade 3 or worse treatment-related adverse events were muscle spasms (four [4%] patients in treatment group A vs 12 [11%] in treatment group B), increased blood creatine phosphokinase (one [1%] vs four [4%]), and hypophosphataemia (zero vs three [3%]). Serious treatment-emergent events were noted in 22 (19%) patients in treatment group A and 19 (17%) patients in treatment group B. Four (2%) patients died from adverse events; one (pulmonary embolism in treatment group A) was possibly related to treatment. INTERPRETATION: Both intermittent dosing schedules of vismodegib seemed to show good activity in long-term regimens in patients with multiple basal-cell carcinomas. Further study is warranted. FUNDING: F Hoffmann-La Roche.

Epstein, E. H., et al. (2018). "Hedgehog pathway inhibition by topical patidegib to reduce BCC burden in patients with basal cell nevus (Gorlin) syndrome." J Clin Oncol **36**(15).

Lear, J. T., et al. (2020). "Efficacy and Safety of Sonidegib in Adult Patients with Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome): Results from a Phase 2, Double-Blind, Randomized Trial." Clin Cosmet Investig Dermatol **13**: 117-121.

Skvara, H., et al. (2011). "Topical treatment of basal cell carcinomas in nevoid basal cell carcinoma syndrome with a smoothened inhibitor." J Invest Dermatol **131**: 1735-1744.

Sohn, G. K., et al. (2019). "Topical Itraconazole for the Treatment of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome or High-Frequency Basal Cell Carcinomas: A Phase 2, Open-Label, Placebo-Controlled Trial." JAMA Dermatol.

Tang, J. Y., et al. (2016). "Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial." Lancet Oncol **17**(12): 1720-1731.

BACKGROUND: Aberrant hedgehog signalling underlies the development of basal-cell carcinomas. We previously reported the interim analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial in patients with the basal-cell nevus (Gorlin) syndrome indicating that the smoothened inhibitor vismodegib reduces basal-cell carcinoma tumour burden and prevents new basal-cell carcinoma growth in patients with basal-cell nevus syndrome. We report the final results of this 36 month trial. METHODS: In our multicentre, randomised, double-blind, placebo-controlled, phase 2 trial we enrolled patients aged 35-75 years with basal-cell nevus syndrome with at least ten surgically eligible basal-cell carcinomas at the Children's Hospital Oakland, Columbia University outpatient dermatology clinic (NY, USA) and a private practice outpatient dermatology office in Newport Beach (CA, USA). Patients were assigned to vismodegib or placebo (2:1) according to a randomisation sequence generated by computer code. The primary endpoint of the trial of 41 patients was to compare the effect of oral vismodegib (150 mg/day) versus placebo on the incidence of new surgically eligible basal-cell carcinomas after 3 months of treatment. In the subsequent, open-label phase (n=37) patients continued vismodegib at two sites for as long as month 36 (n=25) and at the third site were monitored up to month 36 (n=12). Additional endpoints for this phase were: whether continuous versus interrupted dosing differentially affected tumour burden; time to reach various levels of reduction in tumour burden; reduction in tumour size in patients who took less than 50% of the expected number of vismodegib tablets; reduction in the number of surgical excisions required per year before, during, and after treatment; and the effect of vismodegib on hedgehog target gene expression. We monitored patients at visits every 3 months for up to 36 months. The primary endpoint was analysed on a modified intention-to-treat basis. This trial is registered with ClinicalTrials.gov, number NCT00957229. FINDINGS: Between Sept 22, 2009, and Jan 24, 2011, 41 patients were monitored for a median of 36 months (IQR 36-36). Patients treated with vismodegib (n=26) had a mean reduced rate of new surgically eligible basal-cell carcinomas compared with patients randomly assigned to placebo (n=15; two [SD 0.12] new surgically eligible basal-cell carcinomas per patient per year vs 34 [1.32] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001). In the 11 patients initially assigned to placebo, mean cross over to vismodegib reduced the development of new surgically eligible basal-cell carcinomas compared with placebo (0.4 [SD 0.2] new surgically eligible basal-cell carcinomas per patient per year vs 30.0 [7.8] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001). Only three (17%) of 18 patients tolerated vismodegib continuously for the full 36 months. Fewer new surgically eligible basal-cell carcinomas developed in patients receiving vismodegib continuously than in those who interrupted dosing (mean 0.6 [0.72] new surgically eligible basal-cell carcinomas per patient per year vs 1.7 [1.8] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001). Treatment-related grade 3-4 adverse events included weight loss of 20% or more (n=6) and muscle cramps (n=2). Two patients died during the course of the trial, one each from laryngeal and metastatic prostate cancer, deemed probably unrelated to drug. INTERPRETATION: Vismodegib reduces basal-cell carcinoma tumour burden in patients with basal-cell nevus syndrome. Adverse events associated with vismodegib frequently led to interruption of treatment, which is followed by basal-cell carcinoma recurrence. FUNDING: Genentech investigator-initiated trial funding, Clinical and Translational Science Award from the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Cancer Institute, Damon Runyon Cancer Research Foundation Clinical

Investigator Award, Swim across America Foundation, and Michael J Rainen Family Foundation.

Tang, J. Y., et al. (2012). "Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome." N Engl J Med **366**(23): 2180-2188.

BACKGROUND: Dysregulated hedgehog signaling is the pivotal molecular abnormality underlying basal-cell carcinomas. Vismodegib is a new orally administered hedgehog-pathway inhibitor that produces objective responses in locally advanced and metastatic basal-cell carcinomas. METHODS: We tested the anti-basal-cell carcinoma efficacy of vismodegib in a randomized, double-blind, placebo-controlled trial in patients with the basal-cell nevus syndrome at three clinical centers from September 2009 through January 2011. The primary end point was reduction in the incidence of new basal-cell carcinomas that were eligible for surgical resection (surgically eligible) with vismodegib versus placebo after 3 months; secondary end points included reduction in the size of existing basal-cell carcinomas. RESULTS: In 41 patients followed for a mean of 8 months (range, 1 to 15) after enrollment, the per-patient rate of new surgically eligible basal-cell carcinomas was lower with vismodegib than with placebo (2 vs. 29 cases per group per year, P<0.001), as was the size (percent change from baseline in the sum of the longest diameter) of existing clinically significant basal-cell carcinomas (-65% vs. -11%, P=0.003). In some patients, all basal-cell carcinomas clinically regressed. No tumors progressed during treatment with vismodegib. Patients receiving vismodegib routinely had grade 1 or 2 adverse events of loss of taste, muscle cramps, hair loss, and weight loss. Overall, 54% of patients (14 of 26) receiving vismodegib discontinued drug treatment owing to adverse events. At 1 month, vismodegib use had reduced the hedgehog target-gene expression by basal-cell carcinoma by 90% (P<0.001) and diminished tumor-cell proliferation, but apoptosis was not affected. No residual basal-cell carcinoma was detectable in 83% of biopsy samples taken from sites of clinically regressed basal-cell carcinomas. CONCLUSIONS: Vismodegib reduces the basal-cell carcinoma tumor burden and blocks growth of new basal-cell carcinomas in patients with the basal-cell nevus syndrome. The adverse events associated with treatment led to discontinuation in over half of treated patients. (Funded by Genentech and others; ClinicalTrials.gov number, NCT00957229.).

Verkouteren, B. J. A., et al. (2021). "Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study." Br J Cancer **124**(7): 1199-1206.

BACKGROUND: Vismodegib has been used for the treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC (mBCC) since 2011. Most efficacy and safety data are provided by clinical trials. This study evaluates the effectiveness of vismodegib for the treatment of laBCC, mBCC and basal cell nevus syndrome (BCNS) patients, and the tumour characteristics associated with a higher probability of achieving a complete response in the Netherlands. METHODS: A retrospective cohort study that included all patients >/=18 years with histologically proven basal cell carcinoma that received >/=1 dose of vismodegib between July 2011 and September 2019 in the Netherlands. RESULTS: In total, 48 laBCC, 11 mBCC and 19 BCNS patients were included. Median progression-free survival was 10.3 months (95% confidence interval (CI), 7.5-22.6) for laBCC, 11.7 (95% CI, 5.2-17.5) for mBCC and 19.1 (95% CI, 7.4-20.2) for BCNS. Larger laBCCs were associated with a lower probability of complete response (hazard ratio (HR) 0.77 per increase in cm, p = 0.02). Of all BCNS patients, 63% received >/=2 treatment sequences with vismodegib; all achieved partial responses. CONCLUSIONS: Half of the aBCC patients progress within 1 year after the start of vismodegib treatment. More research is needed to investigate other treatment strategies after vismodegib progression and to evaluate long-term effects of repetitive vismodegib treatment.

Supplementary Table 2. Oxford Center for Evidence-Based Medicine Levels

Level	Therapy / Prevention, Aetiology / Harm	Prognosis	Diagnosis	Differential diagnosis / symptom prevalence study	Economic and decision analyses
1a	SR (with homogeneity*) of RCTs	SR (with homogeneity*) of inception cohort studies; CDR" validated in different populations	SR (with homogeneity*) of Level 1 diagnostic studies; CDR" with 1b studies from different clinical centres	SR (with homogeneity*) of prospective cohort studies	SR (with homogeneity*) of Level 1 economic studies
1b	Individual RCT (with narrow Confidence Interval"¡)	Individual inception cohort study with > 80% follow-up; CDR" validated in a single population	Validating** cohort study with good" " " reference standards; or CDR" tested within one clinical centre	Prospective cohort study with good follow-up****	Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses
1c	All or none§	All or none case-series	Absolute SpPins and SnNouts" "	All or none case-series	Absolute better-value or worse-value analyses " " " "
2a	SR (with homogeneity*) of cohort studies	SR (with homogeneity*) of either retrospective cohort studies or untreated control groups in RCTs	SR (with homogeneity*) of Level >2 diagnostic studies	SR (with homogeneity*) of 2b and better studies	SR (with homogeneity*) of Level >2 economic studies
2b	Individual cohort study (including low quality RCT; e.g., <80% follow-up)	Retrospective cohort study or follow-up of untreated control patients in an RCT; Derivation of CDR" or validated on split-sample§§§ only	Exploratory** cohort study with good" " " reference standards; CDR" after derivation, or validated only on split-sample§§§ or databases	Retrospective cohort study, or poor follow-up	Analysis based on clinically sensible costs or alternatives; limited review(s) of the evidence, or single studies; and including multi-way sensitivity analyses

2c	"Outcomes" Research; Ecological studies	"Outcomes" Research		Ecological studies	Audit or outcomes research
3a	SR (with homogeneity*) of case-control studies		SR (with homogeneity*) of 3b and better studies	SR (with homogeneity*) of 3b and better studies	SR (with homogeneity*) of 3b and better studies
3b	Individual Case-Control Study		Non-consecutive study; or without consistently applied reference standards	Non-consecutive cohort study, or very limited population	Analysis based on limited alternatives or costs, poor quality estimates of data, but including sensitivity analyses incorporating clinically sensible variations.
4	Case-series (and poor quality cohort and case-control studies§§)	Case-series (and poor quality prognostic cohort studies***)	Case-control study, poor or non-independent reference standard	Case-series or superseded reference standards	Analysis with no sensitivity analysis
5	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"	Expert opinion without explicit critical appraisal, or based on physiology, bench research or "first principles"	Expert opinion without explicit critical appraisal, or based on economic theory or "first principles"

Oxford Center for Evidence-Based Medicine Levels